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Parkinson’s disease (PD) is an age-related neurodegenerative disorder affecting more than 1% 
of the population aged over 60 years of age. PD is characterised by the loss of dopaminergic 
(DAergic) neurons from the substantia nigra pars compacta (SNpc), with mitochondrial 
dysfunction believed to be a contributor to this degeneration. The finding that complex I deficits 
can trigger Parkinsonism in the 1980s, has resulted in growing evidence of mitochondrial 
impairment in PD and ageing. Alongside the finding that SNpc neurons exhibit increased mtDNA 
deletion levels, these data suggest mitochondrial defects render them highly vulnerable in PD. 
These large scale mtDNA deletions have also been associated with the DAergic neuronal loss 
seen in normal ageing.  
 
Mitochondria are dynamic organelles, whose distribution is regulated by organelle transport to 
balance the energy needs of neurons. Axonal mitochondria travel long and short distances and 
genetic mutations in the machinery which controls these movements have been identified in 
early onset PD. Fundamental insight into the mitochondrial transport system has arisen from 
yeast and fly models, the effects however of altered mitochondrial movement on neuronal 
function still remain unanswered with a mammalian PD model.  
 
Hence, this study investigated mitochondrial trafficking within neurons via two disease models. 
The first involved the optimisation of a method to observe the movements of fluorescently 
tagged mitochondria within DAergic neurons in ex vivo nigrostriatal brain slices. Young and old 
mice were studied to understand the effects of age on these movements. Changes in these 
movements in the presence of PD pathology were studied in human wild type alpha-synuclein 
expressing mice.  
 
The second study utilised induced pluripotent stem cells (IPSCs) to compare modifications in 
mitochondrial trafficking in SNpc neurons from IPSCs derived from a mitochondrial disease 
patient harbouring a large scale mtDNA deletion. Mitochondrial movement was first observed 
within low and high mtDNA deletion cell lines, to ascertain the effect of mitochondrial 
dysfunction on the movement of these organelles. Following this initial study, the effect of 
mitochondrial Ca2+ extrusion into the cytoplasm was investigated, alongside how this mediated 
mitochondrial motility.  
 
This study successfully managed to obtain videos of mitochondrial motility, from cell body to 
synapse, allowing the observation of speed, directionality and membrane potential of 
mitochondria within neurons of these disease models. These models have collectively provided 
information on the movements and trafficking of mitochondria in both culture and in a mouse 
model, presenting a promising method to comprehend the consequences of mitochondrial 
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1.1 MITOCHONDRIAL ORIGIN 
 
Mitochondria are rod-shaped intracellular organelles that are located within the cytosol of 
nucleated eukaryotic cells. Though their primary function is to produce cellular energy in the 
form of adenosine triphosphate (ATP), mitochondria also partake in a myriad of biological 
processes which include iron-sulphur (Fe-S) cluster formation, sequestering calcium, ROS 
generation and removal, and haem biogenesis.  
Mammalian mitochondria were thought to originate through endosymbiotic relationships 
approximately 2 billion years ago (Sagan, 1967, Gray et al., 1999). The theories surrounding 
mitochondrial origin involve two mechanisms i) the archezoan and ii) the symbiogenesis 
methods (Gray et al., 2012). In the archezoan model, the host of the mitochondrial 
endosymbiont was thought to be a primitive eukaryote, whilst the symbiogenesis model 
describes that alpha-proteobacteria were engulfed by a primordial eukaryotic cell causing 
mitochondrial production (Koonin, 2010). The archezoan scenario describes a typical 
endosymbiotic relationship (Margulis 1970, Doolittle 1980) and the symbiogenesis model is 
referred to as the hydrogen hypothesis (Martin and Müller 1998). The theories differ in 
whether mitochondria and nuclear formation occurred simultaneously (symbiogenesis model) 
or whether the nuclear components of the mitochondria appeared later (archezoan scenario) 
(Martin & Müller 1998, Gray et al., 2001).   
Scientists suggest that it is following these biological phenomena’s that mitochondrion to 
nuclear gene transfer occurred. This reaction was found to trigger a reduction in the eubacterial 
genome, instigating the unique morphology of mitochondria to appear within their host cells 
(Martin and Herrman, 1998, Gray et al., 2001). Importantly, not all mitochondrial genes were 
transferred, as during the nuclear transfer, mitochondrial DNA (mtDNA) could not recombine 
and genetic information was lost. Consequently, many mitochondrion-based genes were 
degraded, leaving them to only exist in the nucleus (Blanchard and Lynch, 2000, Selosse et al., 
2001).  
Mitochondria-related organelles (MROs) have been identified (Embley and Hirt, 1998), 
comprising two double membrane bound organelles, hydrogenosomes and mitosomes,  with 
their prominent  functional divergence being that hydrogenosomes harbour the ability to 




Hydrogenosomes (sighted first within non-mammalian eukaryotes), do not contain their own 
genomic DNA and do not house the sufficient OXPHOS and ETC components. Instead, particular 
enzymes are involved in this anaerobic ATP production, where H2 is produced as an end 
product, hence hydrogenosomes (Whatley et al.,  1979).  Mitosomes however do partake in 
aerobic processes though harbour an evolution that is more reduced than that of 
hydrogenosomes. Iron-sulphur (Fe-S) cluster formation is an important function of this 
organelle (Gray, 2012), a key function which appears consistently conserved within 
mitochondria, mitosomes and hydrogenosomes (Gray, 2012), regarding it as a mitochondrial 





















1.2 THE STRUCTURE AND FUNCTION OF MITOCHONDRIA  
 
1.2.1 Mitochondrial structure  
 
Mitochondria retained structural features that support their origin from a bacterial 
endosymbiotic relationship. These organelles are double membraned and contain their own 
genome, circular in shape and are referred to as mtDNA. Palade (1953) and Sjostrand (1956) 
indicate that the mitochondrial double membrane comprises an inner (IMM) and outer 
mitochondrial membrane (OMM) (Palade, 1953, Sjostrand, 1956). 
 
The first model described by Palade in 1953, indicates that baffles (referred to as cristae) are 
produced by the matrix, where the later Sjostrand model, describes an additional membrane, 
known as the septa which separates the mitochondrial matrix (Palade, 1953, Sjostrand, 1956). 
Research revealed that this was actually IMM invaginations that created a structure called crista 
mitochondriales, commonly referenced to as cristae (Frey and Manella, 2000). 
 
The IMM is less permeable than the OMM encompassing a larger protein to phospholipid ratio 
(Fleischer et al., 1961), due to the increased level of proteins that are required for metabolic 
pathways (Wilkens et al., 2013, Cogliati et al., 2016). The IMM is divided into i) the inner 
boundary membrane (IBM), localised near the OMM and creates cristae junctions and ii) and 
the cristae membrane (CM), which holds relevant proteins for OXPHOS (Perkins and Frey, 
2000). The mitochondrial matrix is the central region for mito-biochemical processes i.e. iron-
sulphur (Fe-S) cluster formation and the tricarboxylic acid (TCA) cycle. MtDNA copies are found 
here, alongside the components required for mtDNA transcription and translation. Nuclear 
encoded proteins with a mitochondrial targeting sequence (MTS) enter the mitochondria via 
the outer (TOM) and inner (TIM) mitochondrial translocases (Herrmann and Neupert, 2000, 
Rehling et al.,  2004). These proteins are directed accordingly towards to the matrix, IMS or 





Figure 1.1. Mitochondrial structure. A) Electron microscopy image of a mitochondrion and B) labelled 





1.2.2 Oxidative phosphorylation (OXPHOS) reactions 
 
Mitochondria contain OXPHOS proteins which generate cellular energy in the form of ATP, 
embedded within the IMM of the mitochondrion. The OXPHOS system is composed of the 
electron transport chain (ETC), which houses Complexes I- IV and ATP synthase (complex V) 
(Sheratt.,1991) (Figure 1.2). The mitochondrial complexes facilitate electron transfer and 
proton movement within the matrix to the IMS, creating a proton motive force which promotes 
ATP synthesis from ADP via complex V (Boyer et al., 1975).  
 
The chemiosmotic theory describes the process of electron transfer from a reduced donor to 
the terminal electron acceptor oxygen and the coupling of these reactions to generate ATP. 
Protons that are translocated across the IMM into the IMS have been shown to create an 
electrochemical gradient (Mitchell, 1961), termed as OXPHOS. This process is described as 
follows: the glycolysis or fatty acid oxidation by-product, pyruvate, is imported into the 
mitochondria via the mitochondrial pyruvate carrier. Pyruvate then undergoes decarboxylation 
into acetyl-coenzyme (CoA), which is then transferred to the tricarboxylic acid (TCA) or the 
Kreb’s cycle (Krebs, 1940). In the TCA cycle, carbon atoms of the acetyl component of CoA are 
oxidised, generating high energy electrons. These electrons are then transferred to electron 
carriers, nicotinamide adenine dinucleotide (NADH) and Flavin adenine dinucleotide (FADH2), 
and are distributed to Complex I and II respectively. From here on, electrons are transferred to 
ubiquinone, a soluble electron carrier found within the IMS. Ubiquinone is reduced to ubiquinol 
by CIII, with electron transfer to cytochrome c, a water-soluble carrier. The final step in this 
reaction, describes Complex IV as a generator of molecular oxygen (O2) and water (H2O), 





Figure 1.2. Oxidative phosphorylation. Respiratory chain complexes I-IV comprise the ETC. Complex V 
couples the oxidation of reduced equivalents with ADP phosphorylation to generate ATP and H2O 
molecules. Electrons enter the ETC via complex I or II and are transferred to complex II and IV before 





1.2.2.1 The OXPHOS system – Glycolysis 
 
Before ATP is produced, anaerobic glycolysis reactions occur that link into the TCA cycle within 
the mitochondrial matrix. Glucose metabolism generates two pyruvates via the glycolytic 
pathway (Berg et al., 2012). In addition to ATP, two NADH molecules are also generated.  
 
Glucose + 2[NAD+] + 2[ADP] + 2[Pi] → 2 [Pyruvate] + 2[NADH] + 2[H+] + 2[ATP] + 2[H2O] 
Equation 1.1. Glycolysis reactions 
 
1.2.2.2 The OXPHOS system – The Links Reaction 
 
Pyruvate dehydrogenase regulates the movement of cytosolic pyruvate to the mitochondrial 
matrix for further metabolism via the oxidative carboxylation of pyruvate to acetyl CoA 
(Henderson et al., 2000).  
Pyruvate + CoA + NAD+ → Acetyl-CoA + NADH + H+ + CO2 
Equation 1.2. The Links Reactions 
 
1.2.2.3 The OXPHOS system – The TCA cycle 
 
The TCA cycle encompasses the formation of ATP, NADH and FAD electron carriers, which are 
transferred into the mitochondrial matrix for the final stages of metabolism in the OXPHOS 
system (Berg et al., 2012). Acetyl-CoA is then converted to citrate catalysed by citrate synthase. 
The TCA cycle generates reduced equivalents in the form of NADH and FADH2, where one cycle 
of the pathway yields four reduced equivalents, one GTP molecule and two CO2 molecules.  
Acetyl-CoA + 3[NAD+ + FAD + ADP + Pi + 2[H2O] → CoA + 3[NADH] + 2[H+] + FADH2 + ATP + 
2[CO2] 
Equation 1.3. The TCA cycle 
 






1.2.2.4 The OXPHOS system – Complex I (NADH: Ubiquinone Oxidoreductase) 
 
Complex 1 is the largest complex (1000kDa) of the respiratory chain (Zhu et al., 2016), 
containing 45 subunits encoded by both nuclear (38 subunits) and mitochondrial (7 subunits) 
genomes. 14 of the 45 subunits (7 nDNA and 7 mtDNA encoded) have been rendered as crucial 
for mitochondrial function and are highly conserved with the remaining 31 being mammalian 
supernumery (Letts et al., 2016). This L-shaped structure comprises a hydrophobic arm 
embedded in the IMM and the other arm extended into the matrix (Sousa et al., 2018) (Figure 
1.3) and houses 3 functional segments. These segments are known as: the N (NADH oxidation), 
Q (quinone reduction) and P-(proximal and distal pumping) modules (Hunte et al., 2010). The 
N module binds NADH and is followed by electron transfer to Flavin mononucleotide (FMN), 
forming FMH2. Electrons are then transferred via the Fe-S clusters in the Q module to the 
quinone pool, following which, the QH2 product is released into the IMS. The P-module, 




















NADH + Q + 5[H+] matrix → NAD+ + QH2 + 4[H+] IMS 




Figure 1.3. Complex I. Electrons are passed from NADH to FMN and through Fe-S clusters (yellow dotted line) to 
the quinone pool. Meanwhile, four protons are pumped from the matrix into the IMS. (Figure adapted from 















1.2.2.5 The OXPHOS system – Complex II (Succinate ubiquinone oxidoreductase) 
 
Complex II is the secondary and last site of electron entry into the ETC. It is a 124kDa structure, 
and its enzymatic module is succinate dehydrogenase or (SDH) and does not partake in proton 
translocation across the IMM (Cecchini et al., 2003). Complex II is made of 4 nuclear encoded 
subunits, and catalyses the conversion of succinate to fumarate, generating an oxidised FADH2. 
This oxidation reaction reduces FAD to FADH2, triggering electron transfer to the quinone pool 
























Succinate +FAD +2[H+] +Q → Fumarate +FADH2 + Q → Fumarate +FAD +QH2 




Figure 1.4. Complex II. The oxidation of succinate to fumarate causes the reduction reactions of FAD to FADH2 
which transfers electrons to the quinone pool via 3 Fe-S clusters (Figure adapted from Kühlbrandt 2015, Stefely 










1.2.2.6 The OXPHOS system – Complex III (Ubiquinol Cytochrome c reductase) 
 
Complex III holds 11 subunits, 10 nuclear and 1 mtDNA (cytochrome b) (Xia et al., 1997).  The 
single mtDNA encoded subunit, Cytochrome b, catalyses electrons transfer from 
ubihydroquinone (QH2) to Cytochrome c through the Q cycle which utilises QH2 (Mitchell, 
1976). Each QH2 entails movement of two protons (to the IMS) and two electrons to 
cytochrome c (via the Rieske Fe-S cluster through cytochrome c1) and cytochrome b 
respectively. In the latter reactions, electrons are transferred through two haem b (protoheme) 
groups: low (bL) and high (bH), affinity prior to the binding ubiquinone and being reduced to 























2[QH2] + Q + 2[Cyt c] ox + 2[H+] matrix → 2 [Q] +QH2 + 2[Cyt c] red +4[H+] cytoplasm 
Equation 1.6. Complex III reaction (Berg et al., 2012b) 
 
 
Figure 1.5. Complex III.  Electrons are transferred from the reduced ubiquinone pool to cytochrome c via the Q 
cycle. The shuttling of electrons is coupled with the translocation of protons from the matrix to the intermembrane 













1.2.2.7 The OXPHOS system – Complex IV (Cytochrome c oxidase) 
 
In the final OXPHOS step, electrons are transferred to complex IV. Of the 13 subunits in this 
complex, 3 subunits (COX I, II, III) are encoded by the mitochondrial genome. The substrate for 
complex IV is Cytochrome c which transfers electrons between complexes III and IV. 
Cytochrome c donates electrons to the binuclear protein prosthetic group CuA, then to haem a 
and finally to the oxygen binding site haem a3-Cu8, generating H2O. Electron transfer is coupled 
with the translocation of 4 protons to the IMS (Tsukihara et al., 1996) (Figure 1.6).   
 
 
4[Cyt c] red + 8[H+] matrix +O2 → 4[Cyt c] ox + 2H2O + 4[H+] cytoplasm 
Equation 1.7 Complex IV reaction (Berg et al., 2012b) 
 
 
Figure 1.6. Complex IV. Electrons from cytochrome c are transferred which allows the binding of molecular oxygen 
and hydrogen atoms to form water. The shuttling of electrons is also coupled to the translocation of 4 H+ from the 















1.2.2.8 The OXPHOS system – Complex V (ATP synthase) 
 
Complex V is the last mitochondrial complex where ATP synthase reactions convert ADP to ATP. 
Complex V is formed from 15 -18 subunits (2 mtDNA and ~ 13 nDNA encoded) and is 
approximately 600kDa in size (Stock et al., 2000).  
The F1 region of this complex is water soluble and is made of three α and β subunits as well as 
the catalytically active δ and ε s polypeptide chains (Figure 1.7a). F1 protrudes into the 
mitochondrial matrix and associates with subunit c ring structure on the F0 region situated on 
the IMM through a stalk structure (Figure 1.7b) (Chaban et al.,  2014).  
In addition to the c-ring like subunit, F0 also contains the 2 mitochondrially encoded subunits:  
a (ATP6) and A6L (ATP8) alongside the e, f and g subunits. Within the central stalk segment the 
remaining oligomycin sensitivity-conferring protein (OSCP), b, d and F6 subunits can be found 
(Wittig and Schagger, 2008). The movement of protons across the membrane occurs through 
a proton motive force resultant of the proton gradient. This transfer is linked to F0 c-ring 
rotation as well as the γ, δ and ε subunits. The trimeric F1 α and β subunits do not rotate and 
therefore conduct ATP synthesis through a conformational change (Gresser and Boyer, 1982). 























Figure 1.7. Complex V. ATP synthase catalyses the final step in ATP synthesis via the electrochemical gradient 
which stimulates the rotation of the F0 rotary ring, which instigates ADP phosphorylation forming ATP.  A) The F0 
unit in the IMM and F1 unit projects into the mitochondrial matrix. B) F0 consists of a c-ring and subunits a, b, d, 
F6, OSCP, as well as subunits e, f, g and A6. Subunits a and A6L are the only mitochondrially encoded subunits.  
The F1 unit consists β and α chains that create a hexameric α3β3 ring structure which catalyses ATP synthesis, the 
δ and γ polypeptides form the central stalk of complex V, joining both regions together. A proton motive force is 
produced as a result of the proton gradient, where the flow of protons through the c-ring is coupled with the 
rotation of the c-ring (F0) and γ, δ and ε subunit. This rotation causes the β subunits to undergo a conformational 
change, whilst being bound to ADP and Pi thus causing the phosphorylation of ADP and releasing ATP (Chaban et 






1.2.2.9 Synthesis of new mitochondria 
 
Mitochondrial biogenesis is the process by which pre-existing mitochondria undergo growth 
and subsequent division (Shiota et al., 2015) giving arise to newly synthesised mitochondria. 
Through this process, mitochondrial mass increases where up to 1,000 proteins are transported 
into the mitochondria via the TOM complex (Chacinska et al., 2009). Found initially within 
brown adipose tissues, peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α) was identified to partake in adipogenesis (Puigserver et al., 1998).  PGC-1α, has been 
shown as a vital regulator of mitochondrial biogenesis in brown adipose and skeletal tissue 
(Lehman et al., 2000).  
 
Very little is actually known about mitochondrial biogenesis in neurons. However, there 
remains a large level of similarities between the regulatory network that execute this process 
within neurons. Mitochondria exhibit a longer half-life in neurons in comparison to other post-
mitotic somatic cells, where their renewal is vital for functional neuronal development (Gross 
et al., 1969, Korr et al., 1998, Miwa et al., 2008, O’Toole et al., 2008). Mitochondrial biogenesis 
occurs as a result of collaboration between both the nuclear and mitochondrial genome. This 
function can cause mitochondrial biogenesis to occur within the soma. Thought to only occur 
within the soma, mitochondrial biogenesis has also recently been identified distally within 
















1.3 OTHER MITOCHONDRIAL FUNCTIONS 
 
1.3.1 Iron sulphur cluster biogenesis  
 
Fe-S cluster biogenesis has been largely explored in Yeast, Saccharomyces cerevisae. 
Mitochondrial iron-sulphur cluster (ISC) assembly is conserved and inherited from 
mitochondrial bacterial ancestors (Johnson et al., 2005, Bandyopadhyay et al., 2008, Py and 
Barras 2010). Over the last decade, experiments conducted in cell culture have strengthened 
evidence for this inheritance within a eukaryotic model (Sheftel et al., 2010, Rouault 2012).   
 
ISC assembly consists of 3 main steps involving 17 mitochondrial components (Muhlenhoff et 
al., 2003). Firstly, a [2Fe-2S] cluster is created on the Isu1 scaffolding protein that associates 
with the sulphur donor: cysteine desulfurase (Nfs1) (Stehling and Lill, 2013). In this step, Fe-S 
cluster formation utilises frataxin, ferredoxin and ferredoxin reductases, housed in the ETC.  
Following this, the Fe-S cluster dissociates from Isu1 and binds Hsp70 (Heat shock) proteins, 
which then binds Fe-S cluster transfer proteins. Finally, Fe-S cluster is directed towards 
particular mitochondrial apoproteins, causing Fe-S cluster polypeptide chains (Stehling and Lill, 
2013).  
 
1.3.2 Mitochondrial Calcium handling 
 
Ca2+ buffering within the cell is regulated by modulating the movement of Ca2+ into and out of 
the mitochondria. Mitochondrial Ca2+ (mCa2+) influx is regulated by the mitochondrial Ca2+ 
uniporter (MCU) in the IMM (Baughman et al., 2011, De Stefani et al., 2011), while mCa2+ efflux  
release is via an ion exchange with Na+ (Palty et al., 2010). Regulating this movement is crucial 









1.3.3 Apoptosis  
 
Mitochondria mediated programmed cell death can be triggered due to the perturbed cristae 
architecture and the opening of the mitochondrial permeability transition pore (mPTP) (Rizzuto 
et al., 2012). Moreover, in response to cellular stress, the intrinsic and extrinsic apoptotic 
pathways have been identified and described.  
 
The intrinsic pathway, (the mitochondrial pathway) entails mitochondrial damage occurring 
through the apoptosis complex, cytochrome c,  and the extrinsic pathway (the alternative 
pathway), which is activated outside the cell through ligation reactions of death receptors 
(Wang and Youle 2016). Both pathways can induce ROS production, calcium overload (Brookes 
et al., 2004), ATP deficiency (Lieberthal et al., 1998) or loss of mitochondrial membrane 
potential (Zhang et al., 2009).   
 
1.3.4 Reactive Oxygen Species  
 
Reactive oxygen species (ROS) can damage both protein and DNA (Cui et al., 2012). The close 
proximity of mitochondrial proteins and mtDNA to the respiratory chain, a major generator of 
ROS, can render mitochondria vulnerable to oxidative damage (Turrens, 2003). Reactive oxygen 
species (ROS) include the superoxide anion radical (O22−), hydroxyl radical (•OH) and hydrogen 
peroxide (H2O2). The superoxide anion, is mainly generated by mitochondrial complexes I and 
III of the ETC, is highly reactive and can cross the IMM, where it can be reduced to H2O2 
(Stefanatos and Sanz, 2017). Superoxide is created as a consequence of electron leak from the 
respiratory chain that provokes electron acceptance directly by molecular oxygen (Turrens, 
2003). The enzyme superoxide dismutase, which resides within the cell, can convert superoxide 
into H2O2 and although rather stable, H2O2   still remains highly toxic, until it can be broken down 










1.4 THE MITOCHONDRIAL GENOME 
 
The mammalian mitochondrial genome is described as being negatively coiled: the DNA helix 
under winds anti clockwise when the two DNA strands combine.  The mitochondrial genome is 
double stranded and spans 16.6 kilo bases (kb) (Figure 1.8). 
 
MtDNA comprises two strands,  heavy (H strand) and light (L-strand), containing guanine and 
cytosine abundant base pairs respectively (Anderson et al., 1981, Taanman, 1999). MtDNA 
contains 37 genes, 13 of which are involved in the coding of OXPHOS proteins, with the 
remainder encoding for the small and large ribosomal units and tRNAs. The mitochondrial 
genome contains no introns, unlike the nuclear genome (Ojala et al., 1981), but does contain a 
non-coding region (NCR), referred to as the displacement loop (D-loop), which spans 1kb 
(positions 16024-576) of the entire structure. It is at this location that heavy strand replication 
(OH) occurs (Anderson et al., 1981) (See Section 1.4.1).  
 
Many copies of mtDNA can be found within one mitochondrion, where a cell can hold hundreds 
of copies of mitochondria (cell energy dependant). In post mortem brain tissue, mtDNA copy 
number increases with age where levels of mtDNA copy number were found to range from 









Figure 1.8. The mitochondrial genome. Proteins encoding mitochondrial complex I (blue), complex III (red), 
complex IV (green) and complex V (yellow) are highlighted. The ribosomal RNA genes and tRNAs are indicated as 
orange and grey respectively. Origins of replication, the heavy strand (OH) and the light strand (OL) (light strand) 
are highlighted with black arrows. Within the displacement-loop (D-loop) structure, the non-coding region (NCR) 
can be found, in addition to the heavy strand promotor (HSP), light strand promotor (LSP) and the OH. (Figure 









1.4.1 The replication of mitochondrial DNA 
 
Mitochondrial replication begins at the H-strand (OH) of the D-loop, and is dependent on the 
following proteins: polymerase gamma ([POLG], which manages mtDNA replication), Twinkle 
([TWNK] an mtDNA helicase), mitochondrial single strand binding protein (mtSSB) ligase and 
POLRMT, an RNA polymerase (Wanrooij and Falkenberg, 201).  
Proposed models of mtDNA replication consists of two commonly studied mechanisms, the 
asynchronous  (Figure 1.9a) or the synchronous (Figure 1.9b) model. The Asynchronous (or 
strand displacement: SDM) model of replication proposes that replication is initiated at OH, 
where following on from two thirds of heavy strand replication, the OL (the origin of light strand 
replication) is exposed and light strand replication is initiated. Following on from this, heavy 
strand replication proceeds in a clockwise direction and light strand replication in a counter-
clockwise direction. Light strand replication lags behind the heavy strand, coining the terms 
lagging and leading strand. Once replication is complete, the mtDNA is circularised, becoming 
supercoiled, and lastly, the D-loop is replicated and serves as a template for its own replication 
(Clayton, 1982).  
The synchronous model (Coupled leading-lagging strand) of replication initially proposed by 
Robberson et al., (1972), and further developed by Holt et al., (2000) indicates that heavy 
strand replication is initiated at the OH, and light strand replication occurs simultaneously 
through short oligonucleotide Okazaki fragments (Holt et al., 2000). In the 2000s, Holt et al., 
identified double stranded replication intermediates that were found to house long stretches 
of RNA and DNA hybrids (Holt et al., 2000). This instigated RNA formation via the lagging strand 
which follows the Ribonucleotides are Incorporated ThroughOut the Lagging Strand (RITOLS) 
model (Holt and Reyes, 2012) (Figure 1.9c). This model hypothesises that the leading H strand 
carries out replication via OH, however lagging strand replication occurs as short RNA segments 
which hybridise with the leading strand and then mature into DNA. This model comprises of 
similarities between that of the strand displacement model where both reactions are initiated 






Figure 1.9. Mitochondrial DNA replication. Three methods of mtDNA replication have been suggested. A) 
The strand displacement or asynchronous model where replication is initiated at two separate locations 
B) The strand coupled or the synchronous model describes that replication begins simultaneously for 
both strands at the same region, where the L lagging strand is replicated using okazaki fragments and 
finally C) The RITOLS model is an extension of the strand coupled theory but suggests that the lagging 
strand is protected by an RNA intermediate species which then undergo DNA hybridisation (Figure 




1.4.2 The transcription of mitochondrial DNA 
 
Mitochondrial transcription is bi-directional and the proteins that control these reactions are 
totally nuclear encoded. This process begins at the HSP1 and HSP2 sites of the D-loop structure 
of mtDNA and the light strand promoter (LSP), which is the origin of L-strand transcription 
(Chang and Clayton, 1984) which creates polycistronic mRNA.   
Mitochondrial RNA polymerase (POLMRT) undertakes mitochondrial transcription, alongside, 
transcriptional factor A (TFAM) and transcription factor B2 (TFB2M) (Falkenberg et al., 2002). 
POLRMT and TFAM attaches to the promotor forming an initiation complex, following which 
POLRMT binds and dissolves the promoter prohibiting DNA interaction (Morozov et al., 2014). 
TFB2M is then recruited creating the pre-initiation complex, where mitochondrial transcribing 
elongation factor (TEFM) attaches the POLRMT and by doing so, initiates transcription (Minczuk 
et al., 2011) 
Transcription initiated at HSP1, then undergoes terminations which is managed by 
mitochondrial termination factor (mTERF), thought to play a role in the recycling of the 


















1.4.3 The translation of mitochondria DNA  
 
The proteins necessary for OXPHOS are encoded for by the mitochondrial genome, where 
mitochondrial ribosomes (mitoribosomes) conduct translation of the required genes 
(Lightowlers et al., 2014).  
Mitoribosomes encode 12s and 16s rRNA proteins that are measured in Svedberg units (s) as a 
measure of their sedimentation rate. The 55s mitoribosome sedimentation coefficient, 
comprises a large subunit (LSU), 39s and a small subunit (SSU), 28s, much smaller in comparison 
to cytoplasmic ribosomes. The 39s and 28s subunits partake in peptidyl-transferase and 
translation initiation reactions respectively, and also house the 28s and 12s rRNA subunits 
(Smits et al., 2010) (Figure 1.10). 
Mitochondrially encoded mRNA transcripts are processed at tRNA sites before translation 
begins and are completed with the mitochondrial poly (A) polymerase (mtPAP) regulating a 
poly-A tail addition reaction (Ojala et al., 1981). Mitochondrial translation can be segregated 
into three steps, initiation, elongation and termination. 
The first, initiation step recruits mt-mRNA to the smaller mitochondrial (28s) ribosomal subunit 
(mt-SSU) disrupting association with the large subunit (mt-LSU), consequently removing 
initiation factor: mtIF3 from mt-SSU. Formylated methionine (fMet), then promotes translation 
via the fMet- tRNAMet complex where the remaining unformylated variant is used to conduct 
elongation. Following this, the fMet- tRNAMet are enlisted to the mt-SSU P-site by mtIF2, where 
GTP hydrolysis reactions release mtIF2 allowing mt-LSU to re-attach to this complex (Smits et 
al., 2010, Mai et al., 2016). 
Aminoacylated mt-tRNA mediates mtDNA transcription-elongation reaction which is regulated 
by the mitochondrial elongation factor Tu (mt-EFTu) and GTP hydrolysis (Valente et al., 2007). 
Mt-EFTu is then released from the complex where peptide bonds are generated at the peptidyl 
transferase centre (PTC) of the mt-LSU. Following this, mitochondrial elongation factor 1 
(mtEFG1) instigates a conformational change, moving the mRNA three codons from the A 
(Aminoacyl) to the E (Exit)-site. The resultant polypeptide is relocated into the matrix to 






The concluding step of the mitochondrial translational triad is termination and is stimulated by 
A-site mitoribosomal stop codon. Stop codons associate with mitochondrial release factor 1a 
(mt-RF1a), which hydrolyses the P-site-tRNA and terminal amino acid ester bond. This reaction 
causes the detachment of the P-site polypeptide from the ribosomal complex and following 
this the vacant ribosomal complex undergoes mitochondrial release factor 1 (mt-RRF1) and 
mitochondrial elongation factor G2 (mt-EFG2) mediated recycling. Mt-SSU and LSU dissociate 

































Figure 1.10. Mitochondrial translation.  MtDNA translation is categorised into 3 main stages, initiation, elongation 













1.4.4 Mitochondrial Repair 
 
As the mitochondrial genome is situated near the ETC it is highly susceptible to mtDNA damage 
as direct consequence of ROS production. MtDNA repair systems must therefore exist to 
counteract these damages, namely short patch base excision repair (SP BER). In this case, 
mtDNA repair is conducted by DNA glycosylases that identify the incorrect base and rectify this 
by hydrolysing the sugar phosphate backbone of the DNA molecule (Zinovkina, 2017). 
Mammalian glycosylases identified include UNG1, UNG2 and MUTYH where MUTYH partakes 
in the removal of the incorrect base on the secondary DNA strand. These mitochondrial 
targeted glycosylases then interact with AP endonucleases, in a mechanism which inserts the 
correct base at the single strand 3’-OH (hydroxyl group) end via DNA polymerase involvement. 
Following this the strand is ligated via DNA ligase III. In cases where the DNA polymerase 
interactions fail, long patch (LP) base excision repair (LPBER) occurs where several bases are 
inserted as opposed to one (Kroeger et al., 2003). 
 
1.4.5 Mitochondrial heteroplasmy and the threshold effect 
 
Individual cells can hold more than one copy of mtDNA. Homoplasmy refers the situation by 
which all mtDNA copies within a cell are identical, whereas heteroplasmy suggests that within 
one cell, some mitochondria may harbour a mutation, and some may not (Taylor and Turnbull, 
2005). MtDNA mutations become harmful to the cell once a particular mutation threshold is 
exceeded. This threshold effect indicates that around 60-80% of mutated mtDNA (though this 
can vary for different mtDNA mutations and within different tissues) must occur to cause 













1.4.6 Clonal expansion  
 
The process by which mtDNA deletions increase to high levels are referred to as clonal 
expansion. So far there exists three theories that explain this phenomenon.  
 
Proposed in 1992, the first theory is termed the ‘survival of the smallest’ describes that deleted 
mtDNA molecules replicate at a faster rate due to their smaller size. mtDNA molecules then 
undergo more frequent replication which may cause an accumulation of deleted mtDNA 
molecules (Wallace et al., 1992). Evidence against this scenario has shown that mtDNA point 
mutations specifically,  (regardless of their genome size) still accumulate to levels that are as 
high as the mtDNA deletions (Taylor et al., 2003).  
 
Following this the ‘survival of the slowest’ theory was suggested by DeGrey (1997). This 
hypothesis suggests that mtDNA deletion can perturb the OXPHOS system thus generating 
large amounts of reactive oxygen species (ROS). Through this method, increased mtDNA 
deletions occur which cannot undergo lysosomal degradation and consequently allowing the 
continuous replication of mutated mtDNA (DeGrey, 1997)  
 
The third is the ‘random genetic drift’ theory, arising in the early 2000s, indicates that mtDNA 
molecules replications containing deletions are completely random and their clonal expansion 















1.5 MITOCHONDRIAL DYNAMICS  
 
Mitochondrial movement and their morphological dynamics were first sighted in 1914 via light 
microscopy studies (Lewis and Lewis, 1914) where over the last 30 years, live imaging dyes been 
utilised to  track of mitochondrial movement (Johnson et al., 1981, Bereiter-Hahn and Voth, 
1994, Rizzuto et al., 1996). These experiments demonstrated that mitochondria are constantly 
undergoing mitochondrial fission and fusion. The balance between these two processes 
determines mitochondrial shape and is a key contributor in determining organelle distribution, 
bioenergetics and mitophagy (Bliek et al., 2013).  
 
1.5.1 Mitochondrial fission  
 
Mitochondria can divide through a process known as mitochondrial fission, where the organelle 
is split into two, or in some cases more than two structures (Scott and Youle, 2016).  
Regulated by dynamin related protein-1: (DRP1), a protein member of the dynamin family of 
large GTPases, Drp1 is localised to the OMM through adaptor proteins, such as Fis1 (Hoppins 
et al., 2007). Fis1 is recruited to the OMM where it interacts with Drp1, creating a ‘collar’ which 
surrounds the mitochondrion (Youle and Bliek, 2012). The tightening of this structure then 
causes constriction and the consequent division of the OMM, leading to mitochondrial fission.   
Moreover, mitochondrial dynamics (MiD) proteins 49 and 51, and Mff have been identified as 
Drp1 recruiters to mammalian mitochondria (Elgass et al., 2012, Youle and Bliek, 2012). Though 
OMM fission is a well described process, the factors mediating IMM mitochondrial fission 











1.5.2 Mitochondrial fusion 
 
Mitochondrial fusing is believed to combat mitochondrial stress and dysfunction through the 
fusing activity of damaged mitochondrial components with a healthier mitochondrion (Youle 
and Bliek, 2012). Similarly, to mitochondrial fission, mitochondrial fusion of the OMM is also 
dynamin GTPase dependant. Mitochondrial fusion is regulated by mitofusin (Mfn) 1 and 2 
proteins in mammals residing on the OMM (Hales and Fuller., 1997, Chen et al., 2003), and 
once mitochondria join these tethered proteins, mitochondrial fusion occurs. In regard to 
mitochondrial fusion of the IMM, more investigation is required, however some reports have 
showed Opa1 (Optic atrophy 1) involvement via its IMS and/or IMM location (Wong et al., 2000, 
























Figure 1.11. Mitochondrial fission and fusion in mammalian cells. A)  Drp1 is located in the cytosol, where it shuttles 
back and forth to the OMM during fission events. Drp1 forms a collar that encircles the mitochondrion, the 
tightening of this collar leads to the splitting of the OMM, inducing mitochondrial fission. B) Mfn proteins are found 
on the OMM, which promote the joining of two mitochondria at the early stages of fusion.  OPA1 localised in the 










1.5.3 Neuronal mitochondrial transport  
 
Mitochondrial distribution is highly regulated by mitochondrial transport to balance the energy 
needs of several cell types, especially within neurons. The pre and post synaptic terminals, 
axonal branches and the nodes of Ranvier, contain more mitochondria than other neuronal 
regions (Bogan and Cabot, 1991, Fabricus et al., 1993, Morris and Hollenback, 1993, Mutsaers 
and Carroll, 1998, Ruther and Hollenbeck, 2003, Li et al., 2004, Zhang et al., 2010). Chapter 3 
will discuss ATP provision within neurons further. 
Time lapse studies have shown that neuronal mitochondria undertake bidirectional transport 
along neuronal processes, and their movement is dynamic and sporadic: showing varied 
directionality, pausing and docking/halting (Morris and Hollenback, 1993, Hollenbeck and 
Saxton, 2005, Miller and Sheetz, 2006, Misgeld et al., 2007, Kang et al., 2008). Furthermore, 
dysfunctional mitochondria supposedly return for degradation by the autophagy-lysosomal 
system (Sheng and Cai, 2012). Given this situation, it can be suggested neurons may contain a 
system which regulates mitochondrial movement from the soma to energy demanding regions 
of the neuron.  
These patterns of mitochondrial movement convey how varied this organelle’s motility can be 
where within in vivo experiments, mitochondrial movement is either stationery or motile. 
Motile mitochondrial can pause and then continue onwards without alterations in their 
directionality whilst stationary mitochondria remain anchored (docking/halted) (Faits et al., 
2016, Lewis et al., 2016, Smit-Rigter et al., 2016). Alterations in mitochondrial trafficking are 
due to mitochondrial attachment to anterograde and retrograde motor proteins. The halting 
of mitochondria occurs via various docking and anchoring systems to microtubules. It has been 
shown that mitochondria attach to these motor proteins directly to allow mitochondrial 
movement and directionality (Sheng and Cai, 2012).  
Mitochondrial movement over long distances i.e. from soma to distal axon/ dendrites, depends 
upon neuronal polarity and microtubule organisation. Microtubules are created from the 
polymerisation of alpha- and beta-tubulin and are arranged in a polarised manner with their 
minus and plus ends (Hirokawa and Tanaka, 2010). Axonal microtubules are arranged so that 
the minus ends are targeted towards the soma and plus ends directed distally. 
Kinesin superfamily (KIFs) and cytoplasmic dynein are the two main microtubule-based motor 




whereas cytoplasmic dynein motors mediate microtubule minus-end directed transport. Both 
motor proteins promote long distance transport of mitochondria (Martin et al., 1999, Hirokawa 
and Tanaka, 2010). In axons, the minus end directed cytoplasmic dynein regulates retrograde 
movement towards the soma whilst the plus end kinesin motors allow anterograde transport 
to distal axonal regions and synaptic terminals (Martin et al., 1999, Hirokawa et al., 2010).  
1.5.3.1 Anterograde mitochondrial motors 
 
Partaking in anterograde mitochondrial transport, KIFs are composed of 3 major groups that 
are dependent on the position of the motor domain within the molecule:  the N-terminal motor 
domain KIFs (N-KIFs), the middle motor domain KIFs (M-KIFs), and the C-terminal motor domain 
KIFs (C-KIFs) (Seog et al., 2004). KIFs comprise two functional domains: a motor domain that 
reversibly binds to the cytoskeleton, and the rest of the molecule (the tail) that interacts with 
cargo directly (Figure 1.13a). Around 45 different KIF motor genes exist and are classified into 
14 families (Aizawa et al., 1992, Lawrence et al., 2004).   
Research indicates that the members of the kinesin-1 family are termed as KIF5 and play a role 
in anterograde transport of neuronal mitochondria (Reviewed in: Tanaka et al., 1998, Gorska-
Andrzejak et al., 2003, Pilling et al., 2006). Each KIF5 heavy chain contains an amino-terminal 
motor domain, while their carboxy terminal regulates kinesin light chain association and/or 
direct interactions with mitochondrial adaptor proteins and hence mitochondria (Pilling et al., 
2006, Hirokawa et al., 2010, MacAskill and Kittler, 2010).  
Mammals have three KIF5 motor isoforms, KIF5A, KIF5B and KIF5C, where only KIF5A and KIF5B 
are expressed within neurons (Kanai et al., 2000). Murine Kif5b mutations have been shown to 
instigate the clustering of mitochondria near the nucleus in undifferentiated extra-embryonic 
cells, however in wild type conditions mitochondria are transported peripherally (Tanaka et al., 
1998).Mutations in the KIF5 homologue in Drosophila melanogaster have been shown to cause 
impaired mitochondrial transport in larval motor axons (Pilling et al., 2006). The overexpression 
of the KIF5 cargo binding domain in hippocampal neurons, disrupts KIF5 and microtubule 
adaptor protein association, dysregulating anterograde mitochondrial transport (Cai et al., 
2005). Though mutations of Khc in D.melanogaster reduces anterograde mitochondrial 




Together these studies detail the role of anterograde kinesin motors indicating how these 
motors regulate mitochondrial transport in neurons and also appear to manage the correct 
distribution of neuronal mitochondria.  
 
1.5.3.2 Motor adaptors 
 
Milton is a motor adaptor protein characterised in D.melanogaster.  Milton is associated with 
KIF5 during mitochondrial transport and connects in an indirect manner to mitochondria via 
interactions with mitochondrial Rho (Miro), a RHO family GTPase on the OMM (Stowers et al., 
2002, Fransson et al., 2003, Frederick et al., 2004, Fransson et al., 2006) (Figure 1.12).  
Miro contains two EF hands, Ca2+ binding motifs and two GTPase domains that form 
connections with Milton, KIF5 and then mitochondria. Milton directly binds the C-terminal 
domain of KHC (Glater et al., 2006), where KIF5 is recruited to the mitochondrial surface by 
Milton and Miro adaptors, via the kinesin light chain.  
Recently, Milton orthologues (TRAK1 and TRAK2)  and MIRO orthologues (MIRO1 and MIRO2) 
have been identified in mammals. TRAK1 and TRAK2 have been shown to interact with KIF5 
(Brickley et al., 2005, Smith et al., 2006). TRAK can also bind the first GTPase domain of MIRO1 
and MIRO2 (Fransson et al., 2006).  
In hippocampal neurons, MIRO functions as a vital mitochondrial acceptor site for TRAK2. This 
creates the MIRO1-TRAK2 complex and has shown to be a key regulator of mitochondrial 
transport (MacAskill et al., 2009). TRAK1 knockdown experiments in hippocampal neurons 
result in a dysfunctional respiratory capacity in axons, further eliciting that endogenous TRAK 
expression mediates mitochondrial movement (Brickley et al., 2011).  
These studies demonstrate that together the KIF5, Milton and Miro triad encompass the 












Figure 1.12. The Miro-Milton kinesin complex. The structural of Miro (Rho1/2) comprises of two GTPase domains 
loosely related small GTPases of the ras superfamily, separated by two Ca2+-binding EF hands. The carboxyl 
terminus of the Miro contains a trans-membrane domain that can anchor Miro in the OMM. Milton can bind both 
Miros and kinesin heavy chain (KIF5), facilitating mitochondrial movement in the anterograde direction. (Figure 












1.5.3.3 Retrograde transport motors  
 
Cytoplasmic dynein regulates retrograde movement of mitochondria within axons to the cell 
body.  Structurally dynein comprises two heavy chains, which binds cargo and is a polypeptide 
dependant reaction. Cytoplasmic dynein associates with a protein complex known as dynactin, 
which is a large 11-subunit complex which binds to cytoplasmic dynein and to microtubules, 
regulating its interactions with cargo (King and Schroer, 2000).  
Only two dynein heavy chains have been identified, cytoplasmic dynein heavy chain 1 
(Dync1h1) and 2 (Dync2h1) (Tanaka et al., 1995, Pfister et al., 2006). Furthermore, dynein 
motors also house, several dynein intermediate chains (DIC), dynein light intermediate chains 
(DLIC) and dynein light chains (DLC) (Sheng and Cai, 2012) (Figure 1.13b).  
It has been suggested that dynein forms contacts with proteins on the mitochondrial 
membrane via their light chains. TCTEX1, a dynein light chain protein is believed to attach to 
the mitochondrial OMM protein, VDAC1 (Schwarzer et al., 2002).  
In context of the mitochondrial transport system, the loss of MIRO was shown to impair kinesin 
and dynein axonal transport (Russo et al., 2009). Though the direct association of MIRO with 
dynein motors has not been shown, it appears that MIRO may not only be an adaptor for KIF5 
but also for dynein mediated retrograde transport. Whether dynein associates with the 














Figure. 1.13. The structure of motor proteins that mediate mitochondrial transport. Motor protein structure plays 
a large role in the way it associates with the microtubule and actin filaments. A) Kinesins are made of four chains: 
two heavy (KHCs) and two light (KLCs).  Main kinesin motor functions are mediated by its heavy chains that are 
attached to the coiled regions of the stalk segment of the protein. These heavy chains comprise an amino-terminal 
motor domain, which partakes in ATPase activity and as a result interact with the microtubule. Additionally, the 
role of the carboxy-terminal is to regulate light chain interactions and to consequently bind adaptor proteins.  
B) Unlike kinesin, dynein only contains two dynein heavy chains (DHCs). The remainder of the protein comprises 
numerous dynein intermediate chains (DICs), dynein light intermediate chains (DLICs) and dynein light chains 
(DLCs). Similarly, to kinesins, dynein motor activity is also regulated by its heavy chain component which manages 
the protein’s interactions with cargoes via polypeptide interactions. C) The energy required for myosin motor 
activity across actin filaments is ATP dependant and so far, 18 types of myosin motor proteins have been identified 






1.5.3.4 Bidirectional mitochondrial transport 
 
Bidirectional mitochondrial transport occurs when both both anterograde and retrograde 
motors are associated with an individual mitochondrion simultaneously.  
Dynein has been shown to localise with bi-directionally moving mitochondria (Hirokawa et al., 
1990), whereby interrupting  kinesin motors does not instigate dynein motor mediated 
retrograde (Saotome et al., 2008, Wang and Schwarz, 2009). This suggests that kinesin and 
dynein motor proteins may coordinate bidirectional transport, rather than opposing one 
another (Ligon et al., 2004, Welte, 2004) (Figure 1.15a).   
D.melanogaster mutants that lack the dynactin complex showed disrupted anterograde and 
retrograde movement, indicative that dynactin may coordinate the activity of the opposing 
motors (Haghnia et al., 2007). Likewise, Pilling et al., 2006 demonstrated that kinesin-1 
inhibition reduces anterograde and retrograde mitochondrial movement and is required for 
dynein–driven retrograde transport. This observation was accompanied by organelle-filled 
axonal swellings, perhaps reflecting autophagocytosis of senescent mitochondria accumulated 
in axons as a consequence of retrograde transport failure. It was suggested that this may be a 
protective process aimed to suppress cell death signals and neurodegeneration (Pilling et al., 
2006).  
How mitochondrial directionality mediates mitochondrial transport is unclear. Further 
investigation is required to understand if mitochondrial movement occurs via a ‘tug of war’ 
mechanism between the motor proteins and how alterations of one motor may affect the other 













1.5.3.5 Short range myosin motors 
 
Shorter range mitochondrial movement is observed within nerve terminals predominantly 
comprised of actin filaments mediated by myosin motors. Mitochondrial trafficking regulated 
by myosin motors have not been observed in axon terminals.  However, myosin XIX is targeted 
to mitochondria via its tail domain, where it may play a role in mitochondrial transport in 
neuronal processes and synaptic terminals (Naisbitt et al., 2000). Myosin V has also been shown 
to form a motor complex with dynein light chains, where this motor complex may regulate 
short and long-distance mitochondrial movements (Naisbitt et al., 2000) (Figure 1.13c).  
Mitochondrial motility is enhanced by actin (Morris and Hollenbeck, 1995) and is essential for 
axonal mitochondrial docking (Chada and Hollenbeck, 2004). Myosin V supposedly competes 
with dynein for organelle binding, displacing them from microtubule tracks to actin filaments 
during retrograde movement and myosin V depletion increases bidirectional mitochondrial 
velocity (Sheng and Cai, 2012) 
What may be occurring is that myosin actually favours actin-based mitochondrial docking to 
transport mitochondria away from their microtubule tracks. These mitochondrial transport 
regulatory systems may illustrate various types of neuronal mitochondrial movement though 




Figure 1.14. Myosin and actin mediated mitochondrial trafficking. The transition from long to short–range 
microtubule based mitochondrial trafficking  is myosin driven, leading to subsequent actin-based movement, 
following which actin based docking may occur through unidentified docking and anchoring proteins (Figure 







1.5.3.6 Microtubule based mitochondrial docking  
 
Maintaining a reliant mitochondrial docking system is necessary to keep the required numbers 
of stationary mitochondria in regions that rely heavily on energy production and an efficient 
Ca2+ buffering capacity. For that reason, stationary mitochondria are required to provide a 
localised source of ATP and are crucial in maintaining Na+/K+ ATPase activity, fast spike 
propagation and synaptic transmission (Billups, 2002). Immobilised mitochondria are either 
dissociated from transport motors or anchored to the cytoskeleton.  
Syntaphillin, has been recently described as neuron specific  ‘static anchor’ for axonal 
mitochondria via its its C-terminal domain  (Kang et al., 2008). Syntaphillin (Snph) deletion in a 
murine model augmented the percentage of mobile axonal mitochondria in comparison to wild 
type neurons (Sheng and Cai, 2012). Co-localisation studies have shown that syntaphilin 
interacts with TOM20 on the OMM of the mitochondria, though the specifics of this interaction 
remain unknown (Caino et al., 2016). Syntaphillin overexpression completely abolishes axonal 
mitochondrial transport.  
The syntaphilin mechanism of action constitutes anchoring mitochondria to microtubules via 
its direct association with kinesin-1 (Hirokawa et al., 1982, Linden et al., 1989, Price et al., 1991, 
Jung et al., 1993). Recently, it has become of great interest to understand the role of syntaphilin 
as a molecular target for delving into the mechanistics of what differentiates stationary and 
motile neuronal mitochondria. It was observed that as mitochondrial motility becomes limited, 
the length of time that mitochondria spend at presynaptic boutons increases (Takihara et al., 
2015, Lewis et al., 2016, Smit-Rigter et al., 2016). Furthermore, this reduction of motility was 
accompanied by an increase in syntaphilin expression with ageing (Zhou et al., 2016) (Figure 










1.5.3.7 The role of Ca2+ in the regulation of the KHC, Miro and Milton complex  
 
Neuronal microtubule based mitochondrial arrest occurs at elevated Ca2+ levels (Rintoul et al., 
2003, Yi et al., 2004, Hollenbeck and Saxton, 2005, Chang et al., 2006, Szabadkai et al., 2006). 
During increased cytosolic Ca2+ levels there may be an inefficient ATP supply which can 
interrupt Ca2+ transfer across the plasma membrane. This may also affect dysfunctional 
mitochondrial buffering capacity through impaired ETC activity. Therefore, the halting of 
mitochondrial movement in the presence of increased Ca2+ appears to increase stationery 
mitochondria, which may be useful in regions that require large supplies of ATP when energy 
resources are limited (Figure 1.15C). 
It has previously been shown that the level of mitochondrial Ca2+ inversely correlates with the 
speed of mitochondrial motility, with no indication as to whether this affects directionality of 
mitochondrial movement (Chang et al., 2011). Conversely, Miro EF hand mutation studies 
revealed a failure to arrest mitochondrial motility during elevated cytoplasmic Ca2+ levels 
(MacAskill et al., 2009, Wang and Schwarz, 2009). It appears that instead of dissociating kinesin-
1 from the mitochondria, Ca2+ binding allows Miro to interact directly with the motor domain 
of kinesin-1, preventing motor and microtubule interactions, altering kinesin-1 from an active 
state (bound to Miro only via Milton), to an inactive state (direct binding to Miro). This was 
found to inhibit its interaction with microtubules (Wang and Schwarz, 2009). 
Chang et al., 2011 discovered that mutations within the EF hand domain of miro1 decreased 
Ca2+ influx into the mitochondria. Thus, it can be suggested that blocking mitochondrial Ca2+ 
influx via miro1 EF-hand mutants, can trigger a lapse in mitochondrial motility within neurons 
(Chang et al., 2011). These studies shed some light on how mitochondrial movement can be 
regulated by intra-cellular Ca2+ levels (Niescier et al., 2018). Intra-mitochondrial Ca2+ may also 
be a key player in mitochondrial transport whereby Ca2+ thresholds may be set to inhibit 







Figure 1.15. The regulation of mitochondrial transport.  A) The Miro–Milton (or Miro–Trak) motor adaptor 
complex, mediates KIF5 anterograde mitochondrial transport. B) Retrograde mitochondrial transport mediated by 
dynein motors. C) Ca2+ regulation of Miro-driven mitochondrial transport occurs as Miro contains Ca2+ binding EF-
hand motifs. The C-terminal cargo binding domain of KIF5 motors bind the Miro–Trak adaptor complex, where, 
Ca2+ binding to Miro’s EF-hands causes a separation of the motor domain with microtubules, preventing 
mitochondrial transport via inhibition of any motor and microtubule contact (Wang and Schwarz, 2009). D-E) 
Mitochondrial docking and its arrest occurs through a syntaphilin-mediated model. A Miro-Ca2+ sensing pathway 
triggers the binding switch of KIF5 motors from the Miro–Trak adaptor complex to anchoring protein syntaphilin, 
which immobilises axonal mitochondria via inhibiting motor ATPase activity. This model is termed the ‘engine 
switch off and brake’ model where syntaphilin turns off the KIF5 motor by sensing increased Ca2+ levels, which 







1.6 MITOPHAGY  
 
1.6.1 Autophagy  
 
Autophagy is the process by which intracytosolic components such as proteins and/or 
organelles are delivered to lysosomes in the soma to be degraded. Autophagic substrates are 
engulfed inside an autophagosome, a double membrane vesicle which contains degradation 
molecules. These fuse with the lysosome, a small single membrane organelle that contains 
within its matrix degradation enzymes (Martinez-Vincent, 2015).  
This process maintains neuronal survival and eliminates damaged components. Basal 
autophagy is essential for neuronal viability where faulty autophagic mechanisms can cause the 
accumulation of protein aggregates and/or damaged organelles, all contributors of neuronal 
death (Hara et al., 2006, Komatsu et al., 2006). During basal autophagy the constant turnover 
of intracellular components provides the necessary cellular metabolites under compromised 
conditions. Furthermore, induced autophagy occurs when the cell experiences stress signals 
and exists to maintain vital amino acids through the elimination of damaged material. This 
process can be provoked mitochondrial damage (Kim et al., 2007, Singh et al., 2009).   
 
1.6.2 Mitophagy  
 
Mitophagy is mitochondria specific autophagy. First observed in mammalian cells, this process 
is responsible for increased mitochondrial sequestration in lysosomes (De Duve and Wattiaux, 
1966). Kim and colleagues, created the term ‘mitophagy’ to define the process of the 
engulfment of mitochondria into vesicles that are coated with the autophagosome marker 
MAP1 light chain 3 (LC3), in a process that occurred within 5 minutes (Kim et al., 2007). LC3 is 
a ubiquitin-like protein that covalently attaches to phosphatidylethanolamine during 
autophagosome biogenesis, allowing its integration into the membrane (Nakatogawa et al., 








1.6.3 Mitophagy - Mitochondrial mediated receptors  
 
OMM proteins including: B-cell lymphoma 2 19 kDa interacting protein 3 (BNIP3), Nix, Bcl-2-
like protein 13 (Bcl2-L-13) and FUN14 domain containing 1 (FUND1) have been identified as 
regulators of mitophagy. They share a similar protein structure: an LC3-interacting region (LIR) 
motif which enables their involvement of the mitochondrion with LC3.  
BNIP3 and Nix (members of the Bcl-2 family of proteins) are pro-apoptotic proteins (Zhang and 
Ney, 2009).  Mitophagic Nix activity can remove mitochondria from the erythrocyte (Schweers 
et al., 2007, Sandoval et al., 2008). It is believed that BNIP3 and NIX function is controlled via 
hypoxia-inducible factor-1 (HIF-1) activity, a transcriptional factor which enhances BNIP3 and 
NIX expression under low oxygen conditions (Zhu et al., 2013).  FUND1 dependant mitophagy 
is also triggered under these conditions (Wu et al., 2016). 
Primary sightings of mitophagy were identified in yeast, which suggested Atg32 as a mitophagy 
receptor. Mammalian studies have since then identified Bcl2-L-13 as its homologue. Not only 
can Bcl2-L-13 conduct mitophagy but can also alter mitochondrial morphology, via creating 
mitochondrial fragmentation (Murakawa et al., 2015).  
1.6.4 Mitophagy – Non - mitochondrial mediated receptors  
 
Mitochondria are recognised by two domains present in these receptors: the ubiquitin binding 
domain (UBD) that binds to polyubiquitinated OMM proteins on the mitochondrial surface, and 
the LIR motif that binds LC3-II present on the autophagosome structure (Wild et al., 2014). In 
this mechanism, two main proteins, Phosphatase and tensin homologue-induced putative 
kinase 1 (PINK1) and a E3 ubiquitin ligase (Parkin) are involved. PINK1/Parkin-mediated 
mitophagy has largely contributed to the understanding of mitophagy in mammalian cells in 
response to mitochondrial depolarisation (Martinez-Vicente, 2017).  
Basally, PINK1 is recruited to the mitochondria from the cytosol. Within the cytosol, TOM and 
TIM complexes regulate PINK1 transport, relocating it from the OMM to the IMM. Here, PINK1 
undergoes cleavage which is regulated by mitochondrial processing peptidase (MPP) and 
presenilin-associated rhomboid-like protease (PARL). The cleaved PINK1 is cytosolically 
exported for degradation purposes managed by the proteasome system (UPS) (Deas et al., 





initiates mitophagy by identifying mitochondrial dysfunction i.e. a depolarised membrane 
potential. PINK1 detects mitochondrial dysfunction and signals Parkin to ubiquinate PINK1-
phosphorylated residues (p-S65-Ub) upon the surface of a damaged mitochondrion (Fiesel & 
Springer, 2015) thus triggering mitophagy. Parkin ubiquitinates these proteins on the 
mitochondrial surface which are then phosphorylated by PINK1, creating a PINK1/Parkin 
mediated positive feedback loop (Pickrell and Youle, 2015) (Figure 1.16).  
In the absence of Parkin, it has been shown that five different autophagy receptors (p62, 
neighbour of BRCA1 gene [NBR1], Optineurin [OPTN], NDP52 and TAX1BP1) are all able to 
recognise polyubiquitinated signals in PINK1/parkin mediated mitophagy. p62, has been shown 
as one of the main markers of autophagy and is widely used as a marker of autophagic flux 
together with LC3-II (Klionsky et al., 2016). However, a recent study which manipulated various 
knockouts of all five receptors, deduced that only OPTN and NPD52 were the primary receptors 
for PINK1/parkin-mediated mitophagy (Lazarou et al., 2015). Proposing that though p62 and 





















Figure 1.16. PINK1/Parkin mitophagy. Mitochondria increase PINK1 expression on their OMM when depolarised. 
This increased PINK1 expression allows phosphorylation reactions to occur to both ubiquitin and Parkin, which 
promotes Parkin activity. Parkin ubiquitinates substrates on the OMM, which then promotes the recruitment of 







1.6.5 Neuronal mitophagy 
 
Neurons, as post-mitotic cells exhibit increased vulnerability to mitochondrial impairment. 
Most studies that discuss PINK1/Parkin-dependent mitophagy have been carried out in non-
neuronal cell models and although they provide valuable insight do not mimic physiological nor 
neuronal mitophagic conditions (Grenier et al., 2013).  
In neuronal mitophagy, the translocation of endogenous Parkin to mitochondria upon 
depolarisation is a controversial concept, as most groups cannot detect this (Sterky et al., 2011, 
Rakovic et al., 2013). Neurons rely upon OXPHOS for ATP production (in comparison to 
glycolysis dependant non neuronal cells) therefore differences in mitochondrial bioenergetics 
between cell lines and neurons may justify their inability to recruit parkin (Van Laar et al., 2011).  
Mitochondrial turnover is essential for neuronal survival. Neuronal mitophagy can be 
quantified by measuring mitochondrial mass in the presence of lysosomal inhibitors. Studies 
have shown that when lysosomal degradation is blocked, a loss of mitochondrial membrane 
potential can function as a signal which is detected under basal or induced (CCCP treatment) 
(Mauro-Lizcano et al., 2015). Low levels of Parkin in neurons can induce mitophagy upon strong 
depolarisation in a PINK1-dependent manner, though the rate of mitochondrial clearance still 
remains slow, due to an exclusion of Parkin amplification (Chu et al., 2013) 
Therefore, studies distinguish between either mitochondrial degradation under basal 
conditions or under increased mitochondrial depolarisation. The well described PINK1/parkin 
dependent pathway might be activated in response to severe mitochondrial damage, however 
occurring sparingly due to the low levels of endogenous parkin within neurons. (Mauro-Lizcano 






Figure 1.17. Axonal mitochondrial transport and mitophagy. Within axons, microtubule plus ends (+) are 
orientated toward axon terminals, where kinesin motors regulate anterograde mitochondrial transport and minus 
ends (-) are directed towards the soma, where dynein motors regulate retrograde mitochondrial movement. 
Motile mitochondria can be recruited into stationary pools via dynamic anchoring interactions between syntaphiln 
and the microtubules, ensuring that neuronal mitochondria are distributed along axons and at synapses, where 
constant energy supply is vital. Damaged mitochondria (harbouring a low mitochondrial membrane potential), 
associate with Parkin on the mitochondria and are then transported to the soma for lysosomal degradation 








1.7 SELECTIVE NEURONAL VULNERABILITY IN NEURODEGENERATION 
 
Within neurodegeneration the main unanswered question remains why particular neurons are 
more susceptible to vulnerability than others, and what determines which neuronal 
populations degenerate at later stages of disease. The mechanisms that surround selective 
neuronal vulnerability, include molecular and cellular factors that determine how and when 
particular neurons succumb to or resist an age-related disease (Morris et al., 1998)  
 
Dopaminergic (DAergic) neurons in the substantia nigra (SNc) are damaged in PD and are long 
projection neurons with extending axons (Smith et al., 1987). These neurons are easily 
rendered dysfunctional during ageing as they require a large level of ATP for survival. In 
Parkinson’s disease (PD), dopamine (DA) adds to the demise of the neurons through oxidative 
stress in presynaptic terminals and synapses (Cookson, 2005); the most vulnerable regions of 
the neuron (Mattson and Magnus, 2006). 
 
1.8 PARKINSON’S DISEASE AND THE BASAL GANGLIA CIRCUITRY 
 
1.8.1 Parkinson’s disease  
 
Parkinson’s disease (PD) is an age-related neurodegenerative disorder affecting more than 1% 
of the population aged over 60 years of age (Dawson & Dawson, 2003).  Identified in the 1800s, 
James Parkinson described this disease as  ‘shaking palsy’ (Bartels & Leenders, 2009) as this 
CNS disorder was shown to affect motor activity. PD patients with long-term 
neurodegeneration demonstrated typical Parkinson symptoms which included motor 
impairments, muscle rigidity and impaired posture and balance (Dawson & Dawson, 2002).  
Neuropathologically, PD is characterised by the loss of DAergic neurons from the SNc that 
project to the striatum , causative of the characteristic PD motor symptoms (Fahn and Sulzr, 
2004, Sulzer and Surmeier, 2013). Most cases of PD are sporadic (idiopathic), but 15% of cases 
are inherited (familial) (Bartels & Leenders, 2009). Inherited genetic factors, chemical agents 
(pesticides), genetic mutations, dysfunctional mitochondrial trafficking and mitophagy and ROS 





Whilst PD aetiology is multifactorial (some of which will be discussed below) it has been shown 
that α-synuclein (SNCA) protein aggregates termed Lewy bodies (LBs) are a central component 
in disease pathogenesis. Mechanisms surrounding SNCA related PD toxicity are still being 
investigated where the involvement of mitochondria have been suggested to be contributors 
to this damage. Chapter 4 will further discuss the effects of SNCA and mitochondrial 
dysfunction.  
 
1.8.2 Autonomous pace-making 
 
DAergic neurons within the SNc of the nigrostriatal pathway are autonomous pacemakers, 
generating 2–4 Hz action potentials (APs) without synaptic inputs (Guzman et al., 2009). This 
pace making activity relies on a mechanism involving calcium influx via L-type Ca2+ channels 
Cav1.3 pore-forming subunit. This allows high concentrations of intracellular Ca2+ that cannot 
be immediately removed from cells and are instead sequestered (Surmeier et al., 2017). Ca2+ 
storage in the endoplasmic reticulum (ER) and mitochondria increases the neuron’s metabolic 
rate, resulting in the production of free radicals and ROS, which are thought to accelerate 
ageing. This can lead to significantly higher rates of neuronal loss in SNpc compared to other 
areas of the brain with advancing age (Guzman et al., 2010).  
Studies that were conducted in cultured primary mesencephalic DAergic neurons have 
demonstrated that the opening of L-type Ca2+ channels can cause an increase in mitochondrial 
oxidative damage in dendrites (Pacelli et al., 2015). SNCA aggregate formation can further 
impair this within the perinuclear and dendritic regions (Caraveo et al., 2014). This Ca2+ 
dyshomeostasis most likely explains the reason why DAergic neurons in the SNpc are so 
susceptible to damage in comparison to other neuronal areas.  
The ventral tegmental area (VTA) neurons, though effected to some extent in PD, are relatively 
spared in comparison to DAergic neurons (Sulzer and Surmeier, 2013) expressing lower levels 
of the L-type calcium channel Cav1.3 (Surmeier et al., 2017). This lower expression occurs as 
VTA neurons do not manifest Ca2+ oscillations and utilise HCN/Na+ channels for pace making 
activity (Neuhoff et al., 2002). Therefore, cytoplasmic DA levels are increased in SNc neurons 
compared to VTA dopaminergic neurons. The constant maintenance of this pace making 









Dopamine (DA) undergoes oxidation forming DA quinones and free radicals. A reaction which 
is catalysed by tyrosinase (Munoz et al., 2012). Monoamine oxidases (MAO) and catechol O-
methyl transferase (COMT) are also involved in DA metabolism, where MAO-A and MAO-B are 
situated on the OMM, degrading any excess cytosolic DA through oxidative deamination 
(Jenner and Langston, 2011). DA levels are modulated through MAO-A oxidative reactions 
(Riederer et al., 1987), however, with ageing and PD, the concentration of MAO-B within glial 
cells increases, taking over the main share of DA metabolism (Saura et al., 1997, Youdim et al., 
2006, Fowler et al., 1997). DA is taken up by astrocytes via Na-dependent mechanisms for 
metabolism (Kimelberg and Katz 1986). The products of MAO-B mediated DA metabolism are 
3,4-dihydroxyphenyl-acetaldehyde (DOPAL), an ammonium molecule and H2O2. H2O2 is 
membrane permeable and enters DAergic neurons within close proximity, which may then 
partake in the Fenton reaction, where H2O2 reacts with Fe2+ to generate hydroxyl radicals 
(Nagatsu and Sawada, 2006). Elevated MAO-B expression has been associated with enhanced 
enzyme activity within astrocytes of adult mice showing selective, progressive loss of DAergic 
neurons (Mallajosyula et al., 2008).  
DA oxidation generates DA quinones, a highly reactive aminochrome, which promotes 
superoxide generation in addition to its reduction to NADPH. Furthermore, DA reuptake into 
nigrostriatal terminals following synaptic release requires a DAergic transporter (DAT), thus any 
alterations in these reactions can affect the concentration of cytoplasmic free DA that is prone 
to oxidation (Hastings, 1995, Graham, 1978).  
1.8.4 Organisation of the basal ganglia 
 
The basal ganglia are a set of subcortical nuclei that are involved in regulating processes such 
as motor, cognitive and mnemonic functions. The ventral region of the basal ganglia consists of 
the ventral striatum and the nucleus accumbens which are associated with limbic functions. 
The dorsal region of the basal ganglia consists of the striatum (STR) (also known as the caudate 
putamen), the globus pallidus (GP), the entopeduncular nucleus (EP), the subthalamic nucleus 





dorsal pars compacta (SNc) where DA nigrostriatal neurons are located and ii) the ventral pars 
reticula (SNr).  
Input to the basal ganglia comes from the cortex, where almost the whole cortical mantle 
projects to the basal ganglia.  The corticostriatal projection conveys information to the striatum 
and other regions of the basal ganglia, forming the basal ganglia circuitry (Albin et al., 1989, 
DeLong, 1990, Smith et al., 1998). Corticostriatal projections are processed within the striatum, 
in addition to other inputs from the amygdala and hippocampus that innervate the striatum, 
and once processed are transmitted to the output nuclei of the basal ganglia, the EP and SNr. 
The flow of cortical information through the basal ganglia occurs via 2 routes, the direct and 
indirect pathways (Albin et al., 1989, DeLong, 1990).  
1.8.5 The direct pathway and indirect pathway 
 
The striatonigral/direct pathway consists of information that is transmitted directly from the 
striatum to the output nuclei (Hersch et al., 1995, Bolam et al., 2000).   
At resting state, output nuclei of the basal ganglia are inhibitive with a reduction in inhibition 
observed during basal ganglia associated behaviour. Neurons that project from the striatum 
are GABAergic and inactive at resting state. The basal ganglia output neurons are also 
GABAergic but have a high discharge rate which inhibits basal ganglia targets. This system is 
activated by the firing of corticostriatal glutamatergic neurons, causing striatal neurons to 
discharge which inhibits the basal output nuclei, the EP and SNr (Bolam et al., 2000). 
D1 and D2 receptors come from a superfamily of G protein-couple receptors which respond to 
inputs from the SN to the striatum. Functionally, these receptors stimulate and inhibit adenylyl 
cyclase (AC) (Kebabian and Calne, 1979, Jackson and Westlind-Danielsson, 1994, Missale et al., 
1998). In the striatum, these receptors are separated into two types of medium spiny neurons: 
the striatonigral/direct and the striatopallidal/indirect pathway neurons (Hersch et al., 1995, 
Surmeier et al., 1996). The latter of which will be discussed further below.  
D1 receptors in the direct pathway partake in AC/PKA signalling. PKA activation promotes PKA 
phosphorylation of the substrate dopamine to cause to alterations in neuronal functions 
(Greengard et al., 1999, Hyman and Malenka, 2001). DA receptors co-express the peptide 
substance P and dynorphin,  and provide a direct inhibitory effect on GPi/SNr neurons. 





basal ganglia and therefore is linked to basal ganglia behaviour (Bolam et al., 2000) (Figure 
1.19).   
Striatal neurons in the indirect pathway transmit corticostriatal information in an indirect 
manner to the output nuclei via synaptic connections in the GP and STN (Shink et al., 1996).   
1.8.6 The role of the indirect pathway in motor symptoms of Parkinson’s disease 
 
The striatum comprises both projection and interneurons (Bolam & Bennett, 1995, Kawaguchi 
et al., 1995, Kawaguchi, 1997), where the major projection neurons are medium size densely 
spiny neurons, accounting for the majority of the total population of the striatal neurons (Kemp 
& Powell, 1971a). These neurons use GABA as their main neurotransmitter. Several feedback 
pathways exist with the basal ganglia circuitry, where the major feed-forward reaction is 
involved the DA neuronal projection from the SNc to the striatum. 
Input from DA terminals that arrive from the SNc (that degenerate in PD), create synaptic 
contacts with the necks of the dendritic spines of these spiny projection neurons (Bouyer et al., 
1984, Freund et al., 1984, Smith et al., 1994, Hanley & Bolam, 1997). The head of the spines 
that receive the DA input, then form synapses via creating contacts with the nigrostriatal 
neurons (Freund et al., 1984). This anatomy facilitates DA released from the nigrostriatal 
terminals, which will act on DA receptors that are within the post synaptic membrane (Yung et 
al., 1995) in order to regulate the excitatory input at the head of the spine.  
Cholinergic and GABAergic inputs are also observed in contact with the necks of the spines, 
displaying a similar anatomy (Bolam et al., 1985, Izzo & Bolam, 1988, Pickel & Chan, 1990). The 
striatopallidal/indirect pathway utilises D2 receptors and the peptide enkephalin (ENK). 
Activation of the indirect pathway arises from increased firing of output neurons, and 
therefore, the increased inhibition of basal ganglia targets, where the indirect pathway 
functions to dismiss basal ganglia associated movement or to subdue unwanted movement 
(Mink & Thach, 1993) (Figure 1.18).   
Nigrostriatal DAergic neurons form highly branched networks within their striatal targets, 
Matsuda et al., 2009, where a single DAergic neuron can innervate up to 5.7% of the striatum, 
whilst adjacent DAergic inputs also demonstrate a large degree of overlapping targets. It was 





DAergic inputs, thus clinical signs of PD only develop after up to 70% of neurons are lost 
(Matusyda et al., 2009) (Figure 1.18). 
The reduced activation of DA receptors, caused by a dopamine (DA) deficiency, results in 
reduced inhibition of neurons of the indirect pathway and decreased excitation of neurons of 
the direct pathway. Reduced inhibition from the indirect pathway leads to over-inhibition of 
the GPe, disinhibition of the STN and increased excitation of GPi/SNr neurons, whereas 
decreased activation from the direct pathway causes a reduction in its inhibitory influence on 
the GPi/SNr. The net result is therefore, an excessive activation of basal ganglia output neurons 
accompanied by excessive inhibition of motor systems, leading to the characteristic 
parkinsonian motor features. Following DAergic lesions, expression of D2 receptor and 
preproenkephalin mRNA increases in striatal neurons of the indirect pathway, whereas 
expression of mRNA encoding the D1 receptor, substance P and dynorphin decreases in 








Figure 1.18. The direct and indirect pathway.   Cortical information that reaches the striatum is conveyed to the 
basal ganglia output structures (SNr}, EP, and the SNpr, via 2 pathways. The first pathway: the direct pathway 
comprises of inhibitory projections from the striatum to the SNr and EP (blue line). This direct pathway houses D1 
receptors that provide a direct inhibitory effect on GPi and SNr neurons. The second:  The indirect pathway, which 
holds the D2 receptors and houses inhibitory projections from the striatum to the GP. From the GP another 
inhibitory projection is observed from the GP to the STN (yellow line).  Excitatory projections are then found from 
the STN to the output nuclei, the SNr and EP. DAergic neurons of the SNc generate a massive feedback projection 






1.9  MITOCHONDRIAL INVOLVEMENT IN PARKINSON’S DISEASE 
 
There is evidence of increased oxidative stress in PD, though it remains unclear whether ROS 
accumulation is a primary event or consequential due to the influence of other cellular 
dysfunctions. Increasing evidence has suggested mitochondrial dysregulation as a key player in 
PD pathogenesis (Mattson and Magnus, 2006).  
 
The first suggestion of a mitochondrial role in PD pathogenesis came from the discovery of the 
opiate 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydrodropyridine (MPTP) which was accidently infused 
by drug addicted young individuals, triggering Parkinsonism. Biologically, MPTP undergoes 
oxidation becoming 1-methyl-4-phenylpyridinuim (MPP+) in glial cells which is a dopaminergic 
transporter (DAT) substrate. It is taken up into DAergic neurons, and can selectively inhibit 
complex I of the ETC which is observed in SN and skeletal muscle of PD patients (Bindoff et al., 
1989, Schapira et al., 1990, Haas et al., 1995, Schapira 2007, Langston et al., 1983, Burns et al., 
1985, Mattson and Magnus, 2006). A complex I defect can initiate cell degeneration in PD 
through ATP synthesis reduction, generating a bioenergetic defect. Catalytic subunits isolated 
complex I from the frontal cortex of PD patients display damage due to oxidative stress, which 
has been associated with disruption of Complex I assembly (Keeney et al., 2006). Complex I 
deficiency has also been observed in the platelets and skeletal muscle of PD patients (Krige et 
al., 1992, Bindoff et al., 1991, Parker et al., 1989). Mitochondrial dysfunction in PD has shown 
to manifest within several biological pathways some of which are described further below.  
 
1.9.1. PINK1 and Parkin function in Parkinson’s disease 
 
 
Parkin (or PARK 2) mutations are the most common cause of autosomal recessive early onset 
PD (Corti et al., 2011, Martin et al., 2011, Kitada et al., 1998). Parkin encodes a 465-amino acid 
E3 ubiquitin ligase which ubiquitinates different lysine linkages (Lutz et al., 2009, Akepati et al., 
2008, Narendra et al., 2010). Over a 100 pathogenic parkin mutations have been reported, 
disrupting its E3 ligase activity via altering protein stability and thus causing  DAergic cell 
death (Corti et al., 2011, Martin et al., 2011, Houlden and Singleton, 2012). Post-mortem PD 
brain sections and mouse models have suggested that parkin is inactivated by post-





Abl, a stress-activated non-receptor tyrosine kinase (TH) triggered in sporadic PD brains and in 
animal models of PD. What promotes parkin activation remains undiscovered though its 
translocation to the mitochondria or association with its substrate, E2 conjugating enzyme may 
be causative factors (Imai et al., 2002, Byrd and Weissman, 2013). 
 
The PINK1 (or PARK6) gene was first associated with PD through studies within consanguineous 
families that presented with early-onset PD (Valente et al., 2004, Corti et al., 2011). PINK1 
mutations have been identified as the second most common cause of PD. PINK1 encodes a 
mitochondrial targeted serine/threonine kinase, where the loss of this kinase function is 
associated with PD development. Mitochondrial-localised PINK1 is located on the OMM, with 
its C terminus and kinase domain facing the cytosol (Zhou et al., 2008) indicating that disease 
relevant PINK1 substrates can be found in the cytosol and/or on the OMM.  
 
The loss of PINK1 or Parkin genes in Drosophila has shown evidence of mitochondrial 
aggregation and cellular degeneration in DAergic neurons, muscle and sperm, causing motor 
impairment and decreased fertility (Yang et al., 2006, Clark et al., 2006, Park et al., 2006). PINK1 
knockout flies exhibited approximately 70 % reduction in ATP levels in comparison to control 
flies as well as demonstrating a smaller mitochondrial morphology (Clark et al., 2006, Yang et 
al., 2006). Parkin overexpression studies have shown rescue of the phenotypes caused by PINK1 
deficiency, though not the other way around (Yang et al., 2006, Clark et al., 2006, Park et al., 
2006). It appears that Parkin activity is independent of PINK1.   
 
Phenotypes that arose as a consequence of PINK1 and Parkin mutations were rescued by 
increased Drp1 activity, and reduced Mitofusin (Mfn) or OPA1 activity (Yang et al., 2008, Deng 
et al., 2008, Poole et al., 2008). Promoting mitochondrial fission was found to suppress flight 
muscle and DAer neurons in Pink1 mutant flies. It was suggested that Fis1 may act in-between 
Pink1 and Drp1 in controlling mitochondrial fission, suggesting a role for Pink1 within the 
mitochondrial fission/fusion paradigm (Yang et al., 2008).  Knocking down the muscle-specific 
Mfn fly homologue (Marf) also caused large mitochondrial fragmentation, with altered cristae 
morphology, where the pink1/parkin pathway was found to trigger mitochondrial fission and 







In rat hippocampal neurons, PINK1 or Parkin overexpression, increased mitochondrial number, 
being smaller in size as well as a reduction in mitochondrial number within neuronal processes, 
all in all describing the possibility that the mitochondrial fission/fusion balanced sways towards 
more fission (Yu et al., 2011). PINK1 knockdown showed evidence of an elongated 
mitochondrial structure, tipping this balance towards mitochondrial fusion. In the same study, 
cultured rat midbrain DAergic neurons were transfected with lentiviral vectors expressing 
PINK1 shRNA, PINK1-WT or Parkin-WT constructs, where PINK1-WT/ Parkin-WT expression 
caused fragmentation of the mitochondria within these neurons (Yu et al., 2008). A study by 
Yang et al., 2008, showed that mitochondrial aggregates were formed in PINK1 mutant flies 
within DAergic neuronal clusters and overexpression of Drp1, inhibited this aggregate 
formation. This abnormal mitochondrial morphology and dynamics have also been observed in 
cultured mammalian neurons can suggest that PINK1 and Parkin may have conserved roles in 
the regulation of neuronal mitochondrial dynamics.  
 
In terms of a mammalian model, the knockout of mammalian PINK1 and Parkin has not 
managed to reproduce the motor deficits that are associated with PD (McWilliams and Muqit, 
2017, Gispert et al., 2009, Kitada et al., 2007, Palacino et al., 2004). However, mitochondria 
from knockouts display mild defects in respiration and sensitivity to oxidative stress (Gispert et 
al., 2009, Palacino et al., 2004, Gautier et al., 2008, Mortiboys et al., 2008). Parkin-deficient 
mice that were crossed with the PolgD257A ‘mutator’ mice, showed that these mice accumulated 
mitochondrial DNA mutations as a consequence of their defective mitochondrial proofreading 
system, where lone Parkin-deficiency did not any PD pathology and double-mutants displayed 
age-dependent DAergic neuron loss and motor dysfunction (Pickrell et al., 2015). This finding 
elicits the contribution of endogenous Parkin to maintain DAergic neuronal integrity in vivo. A 
PINK1 knockout rat model, recently displayed locomotor dysfunction and age-related DAergic 
neuronal loss, where, Parkin KO rats did not exhibit any significant PD pathology, perhaps due 
a to loss in ligase activity (McWilliams and Muqit, 2017) 
 
Recently, pivotal evidence has been provided by Fiesel and Springe, which reveals age-
dependent phospho-ubiquitin accumulation in post-mortem brains, and its absence in SNpc 
regions from a patient with a compound heterozygous PARK6 mutation (Fiesel et al., 2015). 
Furthermore, the investigation of this observation within iPSC derived DAergic neurons from 





neurons demonstrated altered mitochondrial morphology as well as a-synuclein accumulation 
(Chung et al., 2016). 
 
1.9.2 Impaired mitochondrial fission and fusion in Parkinson’s disease  
 
In fibroblasts, it was shown that rotenone may also play a role in regulating mitochondrial 
transport. It was found that rotenone treatment triggered mitochondrial swelling which 
consequently reduced mitochondrial motility (Pham et al., 2004) and similar findings were 
observed in differentiated DAergic SH-SY5Y cells (Borland et al., 2008). Disrupting 
mitochondrial fission via DRP1 may cause synaptic loss and DA neuronal cell death (Berthet et 
al., 2014). Two heterozygous missense mutations in the mitochondrial fusion protein OPA1 
(p.G488R, p.A495V) have shown to affect conserved amino acid positions in the guanosine 
triphosphate domain, found in two Italian families. The patients exhibited symptoms of PD and 
dementia. Fibroblasts of these patients showed lower OPA1 protein expression, normal mRNA 
expression, impaired bioenergetics, mitochondrial fragmentation and increased autophagy 
(Van Laar and Berman, 2010). Mitochondrial morphology studies that have been conducted in 
brain tissue from the SNc of PD patients is limited, and although post -mortem tissues is 
available, the ultrastructural details in these models are not well preserved.  
 
1.9.3 Impaired mitophagy in Parkinson’s disease  
 
The disruption of the mitochondrial membrane potential by CCCP in mammalian cultured cells 
(Valente et al., 2004, Beilina et al., 2005, Clark et al., 2006, Zhou et al., 2008, Jin et al., 2010, 
Becker et al., 2012) or Drosophila showed that Parkin translocates to mitochondria with low 
membrane potential, instigating LC3-mediated autophagy, as a method to eliminate the 
damaged mitochondria (Park et al., 2006). After Parkin translocation, mitochondrial 
accumulation of Lys63-linked poly-ubiquitin and Lys48-linkages (Fischer et al., 2012, Yang et al., 
2006), recruited ubiquitin, p62 (Deng et al., 2008, Poole et al., 2008, Becker et al., 2012) and 
deacetylase HDAC6 (Fischer et al., 2012) to the OMM. Lys63-linked poly-ubiquitination may 
contribute to proteasomal degradation of mitochondrial proteins (Yang et al., 2008) and 
HDAC6- and/or p62-mediated sequestration of mitochondria (Yang et al., 2006, Fischer et al., 
2012). Depolarised mitochondria are then engulfed by autophagosomes, followed by lysosomal 





The translocation of Parkin from the cytosol to the mitochondria, requires intact PINK1 with 
kinase activity (Beilina et al., 2005). Then through the ubiquitin proteasome pathway, Parkin 
ubiquitinates and degrades several proteins localised at the mitochondrial OMM, including Mfn 
(Yu et al., 2011, Akepati et al., 2008, Ziviani et al., 2010), Drp1 (Tondera et al., 2009), VDAC1 
(Becker et al., 2012, Ziviani et al., 2010) and Bcl-2 (Youle and Strasser, 2008). In vivo, the loss of 
PINK1/Parkin enhances perturbed mitochondrial fusion, which was reversed as soon as Mfn 
expression was reduced. It may be the case that mitophagy promotes Mfn degradation, 
triggering the clustering of these mitochondria near the nucleus, which inhibits mitochondrial 
fusion of damaged mitochondria with healthy ones, compromising damaged mitochondrial 
motility (Deng et al., 2008, Yu et al., 2011). In vivo Drosophila studies have demonstrated that 
PINK1 mediated phosphorylation of Miro can protect against DA neuron damage (Rakovic et 
al., 2013).  
These studies suggest that PINK1 and Parkin play important roles in the neuronal mitochondrial 
quality control system and not only mitophagy. PINK1/parkin act together to detect 
mitochondrial depolarisation and to label damaged mitochondria, simultaneously regulating 
various aspects of the mitochondrial quality control system, such as mitochondrial 
fragmentation, the arrest of mitochondrial motility, and the degradation of damaged 
mitochondria by mitophagy. As mitochondrial impairment renders neurons vulnerable to cell 
death, alterations of mitochondrial homeostasis may be a key contributor to PD pathogenesis. 
In mouse models, damage to the mitochondria might not be sufficient to affect neuronal 
viability, or other processes might compensate for the PINK1/parkin loss. In humans, however, 








Figure 1.19. Mitochondrial dysfunction leading to Parkinson’s disease. Summary figure highlighting how 
altered mitochondrial genetics, bioenergetics, dynamics, respiration and cell death pathways are triggered 






1.10 AIMS OF THIS THESIS 
The overarching aim of this project was to investigate mitochondrial trafficking within 
dopaminergic neurons in Parkinson’s disease, using both iPSC and mouse models. Specifically 
delving into how mitochondrial dysfunction and alpha-synuclein pathology impacts 
mitochondrial trafficking within these neurons. This study consisted of four aims:   
 
1. Optimise an ex vivo method to image mitochondrial transport within dopaminergic 
neurons of the nigrostriatal pathway. Nigrostriatal slices were taken from 
Dendra2/DATCreIRES mice, containing mito-Dendra2 fluorescence within DAergic 
neurons. Nigrostriatal slice viability was maintained under an artificial cerebrospinal 
fluid (ACSF) perfusion system where videos of nigrostriatal axonal mitochondria were 
collected by confocal microscopy.  
 
2. Study the effect of ageing and human wild type alpha synuclein (SNCA) on 
mitochondrial transport within dopaminergic neurons of the nigrostriatal pathway. The 
technique optimised from the previous aim was employed in this study to observe 
mitochondrial trafficking within aged and alpha synuclein Dendra2/DATCreIRES mice. 
This study aimed to understand alterations in mitochondrial movement in an ageing 
and PD model. The first cohort comprised aged mice for 6 (young) and 12 (old) months, 
to represent young and old populations, and the second cohort comprised human wild 
type SNCA mice (6 – 10 months of age) to observe the impact of important PD 
pathologies i.e. aggregating synuclein on mitochondrial transport in brain slices. Videos 
of nigrostriatal axonal mitochondrial movement were collected by confocal microscopy 
and analysed via kymographs.  
 
3. Differentiate two iPSc cell lines harbouring two levels of a single, large scale mtDNA 
deletion into dopaminergic neurons. This study confirmed the mitochondrial defect 
within iPSCs harbouring a single, large scale mtDNA deletion via observing 
mitochondrial protein complex expression and alterations in mitochondrial membrane 
potential through TMRM staining. It was also attempted to generate a homogeneous 
dopaminergic neuronal population harbouring an mtDNA deletions, via the addition of 






4. Observe the role Ca2+ plays in regulating mitochondrial trafficking, by investigating the 
effects of mCa2+ efflux on mitochondrial trafficking within these iPSC derived neurons.  
This study first compared modifications in mitochondrial trafficking in iPSC derived 
neurons from mitochondrial disease patients harbouring a large scale mtDNA deletion. 
Mitochondrial movement in a heterogeneous population of neurons differentiated 
from iPSCs harbouring a large scale mtDNA deletion were then investigated. The role 
of Ca2+ in mitochondrial transport was explored by observing how mitochondrial Ca2+ 
(mCa2+) extrusion into the cytoplasm within neurons harbouring an mtDNA deletion can 
affect mitochondrial motility. This study comprised of live cell TMRM and Fluo-4-AM 





















































2.1 CELL CULTURE  
 
2.1.1 Generation of neurons from human iPS cells.  
Human fibroblasts were converted into induced neuronal (iN) cells and via the use of a single 
transcription factor, Ngn2 were converted into functional iN cells. Human induced pluripotent 
stem cells (iPSCs) were generated from patient fibroblasts with a single, large-scale mtDNA 
deletion, spanning 6kb base pairs (m.7777- 13794), which removes the following genes, COXII, 
ATPase 6 and 8, COXIII, ND3, ND4L, ND4, ND5 a part of ND6 and several tRNAs. The deletion 
cell line was sent to Novartis for programming into iNGN2 stem cells (Protocol followed Zhang 
et al., 2013). Once reprogrammed, iPSCs were sent to the Wellcome Centre for Mitochondrial 
Research, and were maintained and grown (seeding density of 5x105) in 6cm matrigel (Corning) 
coated dishes. IPSCs were maintained in Nutristem media (Biological Industries) containing 
0.1mg/ml G418, which allows the antibiotic selection of iPSCs containing the ngn2 DNA 
construct and 10μM Rock inhibitor (Y-2763) (ROCKi) (Millipore).  
2.1.2 Preparation of matrigel 
Thawed cells were plated onto a 6cm matrigel dish. Diluted into X-VivoTM 10 (Lonza) in a 1:5 
ratio. Matrigel dishes were pre-made and stored at 4°C until use. All iPSCs and proliferating 
cells were maintained in matrigel dishes until differentiation. 
2.1.3 Defrosting iPSCs 
IPSCS were suspended in cryotubes in Cryostore serum free freezing media (Stem Cell 
Technologies) containing 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen. 1 x 106 
cells were frozen down per mL of cryostore freezing media. Thawed iPSCs were transferred into 
new Nutristem media and centrifuged at 1200 RPM for 5 minutes to remove DMSO. The 
supernatant was then discarded and the pellet was re-suspended in Nutristem media 
containing 0.1mg/ml G418 and 10μM ROCKi and maintained at 37°C to allow cellular 
attachment to the Matrigel coated plates.   
2.1.4 Passaging iPSCs 
Confluent cells (70% coverage) were passaged after approximately 48 hours. Cells were lightly 
washed with Dulbecco’s Phosphate Buffered Saline (DPBS) and the harvesting of iPSCs was 





Cells were stored at 37°C for 5 minutes during trypsin treatment. The trypsin was then 
neutralised by the addition of Nutristem through protease inhibition activity and centrifuged at 
1200 RPM for 5 minutes. The supernatant was then discarded, the pellet retained and re-
suspended in fresh Nutristem media. Cell count was performed by taking 20µl of the cells and 
mixing with 20μl Trypan blue (Gibco) solution, an indicator of intact cell membranes and thus 
cell viability. Live cell counts were carried on the Nexcelom cell counter.  iPSCs were re-plated 
into a new matrigel coated dish at a density of 5 x 105cells/cm2 in NutriStem containing 10μM 
Rock inhibitor and 0.1mg/ml G418 antibiotic. Cells were kept at 37°C. After 24 hours ROCKi was 
removed and iPSCs were maintained at 37°C. 
2.1.5 Generating neuronal progenitor cells (NPCs) 
IPSCs were passaged via the same protocol as above, however 2x106 cells were seeded per 
matrigel dish for proliferation (Table 2.1 for proliferation reagents). 1μg/ml doxycycline was 
added to the proliferation media, instead of G418, to induce ngn2 gene expression in NPCs, 
alongside 10μM ROCKi. Cells containing proliferation media, doxycycline and ROCKi were kept 
at 37°C for 48 hours. After 48 hours ROCKi was removed and NPCs were maintained in 
proliferation media containing only 1μg/ml doxycycline at 37°C.  
2.1.6 Preparing coverslips 
13 and 22mm glass cover slips (for 24 well and 6 well plates respectively) were etched in 1M 
hydrochloric acid overnight whilst shaking, prior to the differentiation of NPCs, which was 
followed by a thorough wash in distilled water and overnight baking. Coverslips were dried and 
sent for autoclaving. Coverslips were etched and baked in order to allow the efficient 
attachment of neurons.   
2.1.7 Coating coverslips 
 
Etched coverslips were placed in 6 and 24 well plates for immunofluorescence studies. 
coverslips were coated with 0.1mg/ml Poly D Lysine (PDL), a synthetic, positively charged amino 
acid chain, used as a coating substrate to enhance cell attachment and adhesion to plastic and 
glass surfaces. Well plates were incubated with PDL for 30 minutes at room temperature. This 
was followed by 2x DPBS washes, and the addition of  5 μg/ml Laminin, an extracellular matrix 





differentiation. The laminin was left on the well plates until use for experiments. NPCs were 
mounted onto coverslips for differentiation.  
2.1.8 Passaging neuronal progenitor cells (NPCs) into neuronal differentiation 
Neuronal progenitor cells were then passaged, as mentioned above and plated into PDL-
laminin coated plates (Table 2.1 for differentiation reagents). For the purpose of live cell 
imaging, 2.5 x 105 cells were seeded into glass bottom (Ibidi) dishes containing differentiation 
media. For immunofluorescent assays, 3 x 105 cells were seeded onto PDL-laminin glass 
coverslips into their respective plates.  A half media change was carried out every other day for 
7 days, during the neuronal differentiation process. After day 7 the differentiation media was 
completely removed and the cells were prepped for their individual experiments.  
2.1.9 Freezing down cells 
1 x 106 passaged iPSCs were centrifuged and re-suspended in freezing media and aliquoted into 
cryotubes (Thermo Fisher Scientific). Cryotubes were then placed into a freezing container, 
Nalgene Mr FrostyTM   (Thermo Fisher Scientific) at - 80°C, containing isopropyl alcohol which 
permits the gradual cooling of the cells at -1°C per minute, allowing optimum cell preservation. 

























Trypan Blue 20μl Gibco Used to observe cell viability 
during cell count 




10μM Sigma-Aldrich Enhances survival of dissociated 
iPSc after passaging by inhibiting 
apoptosis 
Dulbecco’s Phosphate 
Buffered Saline (DPBS) 
6ml Gibco Wash out matrigel dish 
Matrigel-matrix 3ml in 6cm dish Corning Allows attaching of cells to dish 
X-VIVO 10 Chemically 
defined, Serum free 
Hematopoietic Cell 
Medium 
1:5 ratio Lonza Media used to dilute matrigel 
 
Nutristem hPSC XF Medium 100ml Biological 
Industries 
Media used to maintain iPSCs 
Sodium Pyruvate 1mM Gibco  
Penicillin/streptomycin 
(pen/strep) 
1% Gibco Antibiotic 
Uridine 1ml Sigma-Aldrich  
G418 antibiotic 0.1mg/ml Sigma-Aldrich Selective for iPSCs containing 
DNA construct 






B27 supplement 2%  Gibco Growth and survival of cell  
N2 supplement 1% Gibco Growth and survival of cell  
Human Epidermal Growth 
Factor (hEGF) 
10ng/ml Gibco Promotes cell survival 
Human Fibroblast Growth 
Factor (hFGF) 
10ng/ml Gibco Promotes cell survival 
Penicillin/streptomycin 
(pen/strep) 
1% Gibco Antibiotic 















Dulbecco’s Modified Eagle 
Medium DMEM/F12 media 
100ml Gibco Media used to maintain neuronal 
progenitor cells 
Doxycycline 1μg/ml Sigma-Aldrich Replaces role of G418 – induces 
differentiation by activation if 
INGN2 gene 
Differentiation media 
B27 supplement 2%  Gibco Growth and survival of cell  
Neurobasal media 100ml Gibco Neurobasal media 
N2 supplement 1% Gibco Growth and survival of cell  
Brain Derived Neurotrophic 
factor (BDNF) 
10ng/ml R & D systems Survival and morphological 
differentiation of neurons 
Glial-cell derived 
neurotropic factor (GDNF) 
10ng/ml R & D systems Survival and morphological 
differentiation of neurons  
Human Neurotrophin-3 
(hNT3) 
10ng/ml (R&D) systems Survival and morphological 
differentiation of neurons 
Penicillin/streptomycin 
(Pen/strep) 





Cryostore serum free 
freezing media 
1 x 106 cells/ml Stem Cell 
Technologies 
Preservation of iPSCs at low 
temperature  
Coating plates for neuronal differentiation  
Laminin  Sigma-Aldrich Allows neuronal attachment onto 
coverslips 







Figure 2.1. NGN2 Differentiation. Flow chart of INGN2 differentiation from IPSCs to neurons, with indicative 






2.2 IMMUNOFLUORESCENT ASSAYS 
 
2.2.1 Fixation of neurons 
Differentiated neurons were washed with PBS, and coverslips were 2fixed in 4% 
paraformaldehyde and left to incubate for 10 minutes at room temperature. After incubation, 
cells were then washed 3x PBS and prepared for imaging. 
2.2.2 Immunofluorescence on differentiated neurons 
Fixed neurons were stored in PBS at 4°C until ready to use. When ready, PBS was removed and 
coverslips were left to incubate in 5% normal goat serum (NGS) (Sigma Aldrich) to minimalise 
background fluorescence for 30 minutes at room temperature. Cells were then incubated with 
primary antibodies diluted in 5% NGS, and incubated overnight at 4°C. The next day, coverslips 
were PBS washed 3 x over 5 minutes, and incubated for 30 minutes with relevant secondary 
antibodies (Thermofisher) made up in 5% NGS at a 1:200 dilution. Coverslips were then washed 
in 3x in PBS, and incubated with Hoescht for 10 minutes to stain for nuclei. Coverslips were 
washed once more and mounted using Prolong Gold (Invitrogen). All images were obtained on 


















2.3 GENOTYPING EXPERIMENTAL MICE 
 
2.3.1 DNA extraction 
The Qiagen DNeasy Blood and Tissue kit was used to extract DNA from ear notches collected 
from four week old pups for use in slicing experiments. DNA was extracted as per the 
manufacturer’s instructions as follows, Notched ear samples were placed in 1.5ml centrifuge 
tubes, followed by the addition of 180μl buffer ATL, 20μl proteinase K per notch. Each sample 
was vortexed and incubated at 56°C overnight until completely lysed. After lysis, 200μl buffer 
AL was added to centrifuge tubes, vortexed and incubated at 56 °C for another 10 minutes. The 
mixture was then pipetted into a mini spin column placed in 2ml collection tube. Tubes were 
then spun down at 8,000 RPM for 1 minute. Flow through and collection tube were discarded. 
The spin column was then placed into a new 2ml collection tube, to which 500μl buffer AW1 
was added. Tubes were centrifuged at 8000 RPM for 1 minute, and the flow through and 
collection tube was discarded. The spin column was replaced into a new 2ml collection tube, 
to which 500μl buffer AW2 was added, which were centrifuged at 14,000 RPM for 3 minutes. 
Flow through and collection tube was discarded. The spin column was transferred to a new 
1.5ml centrifuge tube and DNA was elute by adding 200μl buffer AE to the centre of the spin 
column and incubated at room temperature for 1 minute. The DNA was then eluted by 
centrifugation at 8000 rpm for 1 minute.  
2.3.2 Cre primers 
The following primers were used: Cre common [oIMR6625] 5’TGGCTGTTGGTGTAAAGTGG3’, 
Cre Wild type reverse [oIMR6626] 5’GGACAGGGACATGGTTGACT3’, Cre Mutant reverse 
[oIMR8292] 5’CCAAAAGACGGCAATATGGT3’. The Cre wild type PCR product yields a band at 
264bp and the Cre mutant at 152bp.   
2.3.3 Dendra primers 
Dendra2 common [13840] 5’CCAAAGTCGCTCTGAGTTGTTATC3’, Dendra2 Wild type reverse 
[oIMR13841] 5’GAGCGGGAGAAATGGATATG3’, Dendra2 Mutant reverse [oIMR7320] 
5’TCAATGGGCGGGGGTCGTT3’. The Dendra wild type pcr product is 604bp whilst the Dendra2 







2.3.4 PDGF-hα- synuclein primers 
The following primers were used to identify pups which expressed the human α-synuclein 
gene: PDGF-hα-synuclein forward  5’CCAGACGGGTGTGACAGCAGT3’ and PDGF-hα-synuclein 
reverse 5’CCAAGGTTGTTAACTTGTTTATTGCAGC3’. The PDGF-hα-synuclein pcr product yields 
a band at 350 bp.   
Dendra, Cre and PDGF-hα-synuclein primers were all obtained from Eurofins. 
2.3.5 Polymerase chain reaction (PCR) reactions for genotype indentification of Cre and Dendra 
mice 
25 μl PCR mastermix (GoTaq Flexi Kit) was made up for each sample which included: [ 2 mM 
MgCl2, 9.3 μl dH20, 1x  PCR buffer, 0.2 mM deoxynucleotide (dNTPs) solution, 1 μM  Cre 
Forward, Cre Wild type reverse, Cre Mutant reverse primers, 0.2 μl GoTaq Polymerase and 2 μl 
of DNA sample. The same protocol was repeated for Dendra PCR, however mastermix 
contained 10.3 μl dh20, alongside, 0.5 mM Dendra Forward and Dendra mutant reverse 
primers.  
DNA products were amplified by Veriti 96 well plate thermo cycler PCR machine (Applied 
BioSystems). Thermal cycle was programmed for 2 minutes at 95°C (1 cycle) as initial 
denaturation, followed by 30 cycles of 30 sec at 95°C for denaturation, 30 sec at 62°C annealing, 
1 minute at 72°C for extension, and a final extension at 72 °C for 10 min. PCR products were 
observed via gel electrophoresis, 1.5% agarose gels were run at 100V for 60 minutes in a in 1 x 
TAE buffer with 1:10,000 SYBR Safe DNA stain. Norgen PCR ranger 1kb molecular weight marker 
was used. The BioRad ChemiDocTM system and Image Lab software were then used for 
visualising the gel and image analysis respectively.   
2.3.6 PCR reactions for PDGF-hα- synuclein mice 
DNA extraction was completed as mentioned above, alongside the same PCR mastermix (GoTaq 
Flexi Kit). 50 μl PCR mastermix (GoTaq Flexi Kit) was made up for each sample which included: 
[ 2 mM MgCl2, 22μL dh20, 1x  PCR buffer, 0.2 mM deoxynucleotide (dNTPs) solution and 100ng/ 
μl  PDGF-Hα- synuclein forward primer, PDGF-Hα- synuclein reverse primer, 0.2 μl GoTaq 





DNA products were amplified by Veriti 96 well plate thermo cycler (Applied BioSystems) PCR 
machine. The thermal cycle was programmed for 3 minutes at 94°C (1 cycle) as initial 
denaturation, followed by 5 cycles of 30 sec at 94°C for denaturation, 30 sec at 49°C as 
annealing, and 72°C for extension. This was followed by the 25 cycles of 30 seconds at 92°C for 
denaturation, 30 seconds at 49°C as annealing, and 72°C seconds for extension. PCR reaction 
was concluded by a final extension at 72°C for 5 minutes. PCR products were observed via gel 
electrophoresis as above. 
2.3.7 PhAMfloxed  mouse line  
 
The mouse model chosen for this study was the PhAMfloxed line, developed by Pham et al., 2012. 
This mouse line comprises of a mitochondrial localised version of the photo-convertible 
fluorescent protein Dendra2 (mito-Dendra2) targeted ubiquitously to the Rosa26 locus, 
alongside upstream loxP-flanked termination signal. The mitochondrial targeting sequence of 
subunit VIII of cytochrome c oxidase (COX8) was fused to the N-terminus of Dendra2 driving 
the expression of Cre in PhAMfloxed cells resulting in mito-Dendra2 fluorescence.  
The PhAMfloxed line mice were subsequently crossed with Cre mice under a dopaminergic 
transporter (DATIREScre) obtained from The Jackson Laboratory, in order to observe mito-













































3.1.1 Mitochondrial trafficking within neurons 
 
3.1.1.1 ATP provision within neurons 
 
Neurons can extend their axons and dendrites for up to a meter. Thus, the neuron poses a case 
for mitochondrial distribution where the need to supply energy to further cellular regions is 
vital as a consequence of their unique morphology (Hall et al., 2012).  
Patch clamp analysis revealed that electrical signalling within neurons dominates ATP 
consumption within mammalian brains (Alle et al., 2009, Harris and Attwell, 2012, Harris et al., 
2012). OXPHOS, generates around 93% of ATP within neurons (Sokoloff, 1960), with the 
remaining 7% coming from glycolysis. Pre and postsynaptic mechanisms show that 55% of total 
ATP is used for action potential generation (APs), synaptic transmission and resting potential 
maintenance in neurons and glia (Attwell and Laughlin, 2001).   
Within rat cerebral cortex (Attwell and Laughlin, 2001) and human cortex (Lennie, 2003), it was 
demonstrated that synaptic transmission is the largest consumer of ATP (Sengupta et al., 2010, 
Harris and Attwell, 2012). ATP consumption by synaptic signalling mechanisms begins 
presynaptically, where ATP is consumed by 4 types of ATPase. The first is the sodium pump, 
which extrudes Na+ ions, generates action potentials and powers Ca2+ removal by Na+ /Ca2+ 
exchange, secondly, calcium-ATPase in the plasma membrane which lowers intracellular Ca2+ , 
thirdly, vacuolar H+ -ATPase, which energises vesicle transmitter uptake, and finally motor 
proteins (kinesin, dynein, myosin) that aid mitochondrial and vesicle motility around the cell 
(Attwell and Laughlin, 2001).  
With postsynaptic activities, ATP consumption is larger, expended mostly on pumping out ions 
that regulate synaptic currents, and a smaller designation to returning Ca2+ to intracellular 
stores and mitochondrial trafficking (Harris et al., 2012). Increased transmission within 
glutamatergic synapses can increase intracellular neuronal Ca2+, which can depolarise 
mitochondria and reduce their ATP production. In extreme cases this causes cytochrome c 
release and apoptosis initiation. Increasing evidence has shown that these events can 
contribute to the development of neurodegenerative disorders (Attwell and Laughlin, 2001). 
Neuronal mitochondria travel long distances, regulated by kinesin and dynein motors (For 





mitochondrial movement are observed, reflecting two different pools of mitochondrial 
trafficking, the motile mitochondrial pool, which includes mitochondria that may temporarily 
pause but usually continue onwards without alterations in their directionality and the 
stationary pool, which remain anchored (Faits et al.,  2016, Lewis et al.,  2016, Smit-Rigter et 
al.,  2016, Misgeld and Schwarx, 2017). The movements of the motile pool are microtubule 
based and are either, anterograde ([+] along microtubules towards the periphery) or retrograde 
([-] towards cell bodies) movements which are regulated by kinesin and dynein microtubular 
proteins respectively (Hollenbeck et al.,  2005, Chang et al.,  2006). Several studies have 
reported disturbances in mitochondrial trafficking in neurodegeneration (Millecamps and 
Julien, 2013).  
3.1.2 Transgenic mouse models for Parkinson’s disease 
 
The development of transgenic animal models have enhanced understanding of PD through 
tissue-specific expression of genetic mutations within the following systems: vertebrates, 
human-IPSC derived neurons, Drosophila melanogaster, Medake fish, and Caenorhabditis 
elegans (Pallanck and Whitworth, 2007, Wong, 2007, Chesselet et al.,  2008, Lim and Ng, 2009). 
Furthermore, Lewy body (LB) pathology in PD, has enhanced the interest and consequently the 
generation of α-syn mouse models over the last twenty years (Discussed further in Chapter 4).  
3.1.3 In vivo mitochondrial imaging 
 
Live imaging of mitochondria has transformed our understanding of the dynamics of these 
organelles. In culture, axons are around a micrometre in diameter (Chang et al.,  2006). The 
mitochondria therefore move within an easily visualised plane and as long as the cell body of 
the axon can be identified, movements are easy to distinguish from plus-end and minus-end 
directed transport allowing the tracking of up to 100 µm or more (Chang et al.,  2006, Schwarz 
2013). Smaller mitochondria are more frequent in their motion than longer mitochondria, 
where the relationships between the size of mitochondria and motility are still undergoing 
investigation (Misgeld et al.,  2007).  
Determining the fraction of motile mitochondria has given variable results, with 10% – 40% of 
mitochondria moving and 60% – 90% recorded as stationary (Morris and Hollenbeck, 1993, 
Ligon and Steward 2000a, Misgeld et al.,  2007). Of the moving mitochondria, approximately 





into understanding whether the anterograde-moving population comprises healthy 
mitochondria and whether the retrograde moving mitochondria, represent older, damaged 
mitochondria with lower mitochondrial membrane potentials (determined with voltage-
sensing dyes) and whether these mitochondria are targeted towards the soma to undergo 
lysosomal degradation (Schwarz, 2013).  
Mitochondrial fission and fusion events (Chapter 1, section 1.5.1 and 1.5.2) are observed in 
axons and dendrites (Amiri and Hollenbeck, 2008), where even during brief moments of contact 
can involve fusion (also evident in non-neuronal cells) (Liu et al. 2009). Therefore, mitochondria 
that appear to be stationary, at least for the duration of what can be successfully imaged, may 
be refreshed in situ by exchanging proteins with the motile fraction. Consequently, due to these 
factors that go some way to explain the sporadic behaviour of mitochondria, developing a 
system by which in vivo mitochondrial trafficking can be captured in an accurate, 
representative, high-resolution manner, has provided to be one of the biggest challenges in 
understanding mitochondrial dynamics in vivo over the last 15 years.  
Much of the research that is currently occurring only pinpoints a segment of an axon (< 150 
µm) and mitochondrial motility within this region, where it can be argued that this observation 
is not an accurate representation of the organelle’s movement. As stated previously, the typical 
protocol to visualise these organelles is to isolate neurons in culture and to stain with a 
mitochondrial tracker which relies on the membrane potential of the mitochondrion, allowing 
the visualisation of their distribution and dynamics (Johnson et al., 1981, Bereiter-Hahn and 
Voth, 1994, Rizzuto et al., 1996). Though the results of these studies have provided valuable 
insights into the behaviour of neuronal mitochondria, it is important to remember that cultured 
neurons have a different biological geometry to an in vivo model, and although such models 
are largely informative, still lack the normal biological milieu which represents disease. 
Fortunately, over the past decade, the view of mitochondrial dynamics has expanded from 
Drosophila to murine models in order to understand variances of mitochondrial dynamics 
within neurons. Scientists have successfully attempted to image axonal mitochondrial transport 
in mammalian in vivo systems (Misgeld et al.,  2007a, Misgeld et al.,  2007b, Ohno et al.,  2011, 
Pluckinska et al.,  2012, Okashi and Okabe, 2013, Sajic et al.,  2013, Sorbata et al.,  2014, Jackson 
et al.,  2014, Takihara et al.,  2015, Faits et al.,  2016, Lewis et al.,  2016), observing 
mitochondrial dynamics through high resolution imaging, producing novel findings that have 





3.1.4 Quantifying in vivo mitochondrial trafficking in neurons 
 
The first in vivo study which observed neuronal mitochondrial movement was conducted by 
Misgeld et al.,  2007, who surgically exposed the sciatic nerve in two well-established mouse 
models. Neuronal promoters were used to control expression of fluorescence in the thy1-
mitoCFP mito-mouse, which allows cyan fluorescent protein (CFP) expression under the control 
of the mouse thymus cell antigen 1, Thy1, promoter and the neuron-specific enolase (nse)-
promoter model to express yellow fluorescent protein (YFP) in nse-mitoYFP mice. In these 
mouse models CFP and YFP are specifically localised to the mitochondria by a human 
cytochrome c oxidase subunit 8A (ubiquitous) construct, which targets signals fused to the N-
terminus. The mitochondria labelled in this study were imaged via confocal and electron 
microscopy, where it was found that the mitochondria exhibited normal physiological 
structure. Mitochondrial membrane potential sensitive mitochondrial dyes, such as MitoFluor 
Red 589, MitoTracker Red CMXRos and Rhodamine 123 displayed the same distribution and 
intensity in mitoCFP-positive and control synapses indicative of physiologically normal 
mitochondria (Misgeld et al.,  2007).  
In these Mito-Mouse lines, a broad spectrum of neuronal populations showed labelled 
mitochondria, including cortical and hippocampal projection neurons, spinal motor neurons, 
Purkinje cells, retinal ganglion cells and basal ganglia neurons. This in vivo study revealed that 
anterograde mitochondrial transport exceeded retrograde transport throughout the branching 
regions of mature motor axons. The difference between anterograde and retrograde transport 
suggests that some parts of the mitochondrion are degraded by the autophagy machinery 
along the axon or in the synapses (Misgeld et al., 2007). 
Sorbata et al., (2014) then utilised the same paradigm of study as Misgeld et al., to study how 
impaired axonal transport can contribute to axon degeneration in 6-12 week old mice. Multiple 
sclerosis (MS) is a common neuroinflammatory disease characterised by progressive axon 
degeneration. This experiment comprised of in vivo two-photon imaging to assess the transport 
of organelles and the stability of microtubule tracks in individual spinal axons. The mouse model 
of MS, comprised of acute experimental autoimmune encephalomyelitis (EAE), where 
inflammatory lesions develop within the spinal cord of the mouse. The tracking of single 
mitochondria revealed that the stop duration greatly increased in the inflamed spinal cord, 





increased density and content of mitochondria observed in experimental autoimmune 
encephalomyelitis (EAE) axons that suggest that moving mitochondria accumulate in the lesion 
area (Sorbata et al., 2014). 
Glaucoma is the most common neurodegenerative eye disease characterised by axonal 
degeneration and death of retinal ganglion cells (RGCs). The occurrence of glaucoma increases 
with ageing, as observed with neurodegenerative diseases of the CNS including, AD and PD. In 
vivo observation of mitochondrial motility in a glaucoma model conducted via minimally 
invasive multiphoton imaging of mouse RGC, demonstrated that mitochondria were highly 
dynamic in the mammalian CNS. Younger mice (4 months old) showed a reduction in motile 
mitochondria (percentage not stated) prior to cell death, without shortening of the 
mitochondria. Conversely, in older mice (23-25 months old), the duration and distance of 
mitochondrial trafficking were augmented, where it was suggested that a change in 
mitochondrial transport in ageing perhaps may underlie the age-related increase in glaucoma 
(Takihara et al., 2015).  
Most recently, a study in cortical neurons by Lewis et al., observed mitochondrial trafficking in 
cortical neurons in P30/45 awake mice. Their study demonstrated that mitochondrial motility 
is greatly reduced during cortical axon maturation in vitro and that mitochondrial motility is 
very limited in adult cortical axons. It was also shown that axonal mitochondria remain 
immobilized over long time periods in mature neurons. This study demonstrated that 
mitochondrial motility is extremely low in mature cortical axons in vitro and in vivo using two-
photon microscopy. These results suggested that mitochondrial immobilisation and 
presynaptic localisation are highly important hallmarks of mature CNS axons both in vitro and 
in vivo (Lewis et al.,  2016). Table 3.1 summarises these models, and the research that has 
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3.1.5 Imaging mitochondria within SNpc neurons 
 
This study designed a unique method to image mitochondrial movement within the SNpc DA 
neurons of the nigrostriatal pathway, as there is currently no available in vivo model which 
yields insight into understanding mitochondrial transport within SNpc neurons in PD.   
The mouse model chosen for this study was the PhAMfloxed line, developed by Pham et al., 2012. 
This mouse line comprises a mitochondrial localised version of the photo-convertible 
fluorescent protein Dendra2 (mito-Dendra2) which is targeted to the ubiquitously 
expressed Rosa26 locus, along with an upstream loxP-flanked termination signal. The 
mitochondrial targeting sequence of subunit VIII of cytochrome c oxidase (COX8) was fused to 
the N-terminus of Dendra2 driving the expression of Cre in PhAMfloxed cells resulting in mito-
Dendra2 fluorescence, without adverse effects on mitochondrial morphology. When crossed 
with Cre drivers, the PhAMfloxed line expresses mito-Dendra2 in specific cell types, allowing 
mitochondria to be tracked even in tissues that have high cell density. The PhAMfloxed line mice 
were subsequently crossed with Cre mice under a dopaminergic transporter (DATIREScre) 
obtained from The Jackson Laboratory, in order to observe mito-Dendra2 only within DA 
neurons of the mouse brain.  
This photo convertible model has been previously employed within rodent studies of the 
nervous system to investigate neuronal activity-dependent control of mitochondrial trafficking 
using mito-Dendra2 sagittal hippocampal brain slices (Stephen et al., 2015). Further insight to 
the effect of calcium handling within neurons, have been elucidated with mito-Dendra2 
primary hippocampal neurons, in an investigation into the role of mitochondrial calcium 
uniporter with Miro (Niescier et al., 2018).  
Several challenges were overcome to optimise a robust tool, which included difficulties such as 
establishing a perfusion system which maintained nigrostriatal slice viability and the accurate 
detection of axons within the nigrostriatal pathway. Offsetting these technical challenges, this 
study successfully managed to image part of the nigrostriatal pathway and obtain videos of 
mitochondrial motility. This technique was achieved via manipulations in microscopy, 







3.2 AIMS OF THIS STUDY 
 
1. Optimise an ex vivo method to image mitochondrial movements within the dopaminergic 
(DA) neurons of the nigrostriatal pathway in a mito-Dendra2  tagged mouse model 
 
2. Record mitochondrial trafficking within cell bodies, axons and synapses of the nigrostriatal 
pathway  
 
3.3 METHODS & MATERIALS 
3.3.1 Generating transgenic mice with photoactivatable mitochondria 
 
3.3.1.1 Mouse model  
 
Dendra2 is an enhanced version of a green to red photoswitchable fluorescent protein Dendra, 
derived from octocoral Dendronephthya sp. Dendra2 exhibits faster maturation and brighter 
fluorescence both before and after photoswitching when compared to Dendra (Gurskaya et al., 
2006). Dendra2 conducts irreversible photoconversion from a green to a red fluorescent form. 
Dendra2 exists in a monomeric state and is suitable for protein labelling, high contrast 
photoconversion with fluorescence at the red spectral region, has low phototoxic activation 
with 488nm laser (available on common confocal microscopes), high photostability of the 
photoconverted state, and efficient chromophore maturation at 37°C in mammalian cells. This 
combination of advantageous properties renders Dendra2 an ideal tool for the real-time 
tracking of organelle dynamics (Gurskaya et al., 2006, Zhang et al., 2007, Chudakov et al., 2007).  
Developed by Pham et al., 2012, this transgenic mouse model was generated via homologous 
recombination in mouse embryonic stem (ES) cells. A neomycin expression cassette containing 
mito-Dendra2 (a version of Dendra2 targeted to the cytochrome oxidase subunit 8A (COX8) 
subunit in the mitochondrial matrix) was inserted into the ubiquitously expressed Rosa26 locus. 
First identified in the 1990s, Rosa26 is the locus which permits constitutive, ubiquitous gene 
expression in mice (Friedrich and Soriano, 1991). The expression cassette included the CAG 
(cytomegalovirus/β-actin) enhancer-promoter, which has been reported to enhance 
expression several fold compared to the endogenous Rosa26 promoter (Chen et al., 2011).  





cassette was removed to generate the PhAMfloxed line. Mice were maintained as heterozygotes 
or homozygotes without apparent defects in viability or fertility (Pham et al., 2012).  
 
3.3.1.2 Identifying mitochondria within DA neurons 
 
Mito-Dendra2 [PhAMfloxed, Gt(ROSA)26Sortm1(CAG-COX8A/Dendra2)Dcc/J), stock#18385] 
mice were crossed with a DAT-Cre [DATIREScre, B6.SJL-Slc6a3tm1.1(cre)Bkmn/J, stock#006660] 
mouse line. Both mouse lines were obtained from The Jackson Laboratory. Cre mice contained 
a loxP-flanked (floxed) termination sequence upstream of mito-Dendra2. The genotyping for 
these mice were carried out as described in (Methods section). In this model, mito-Dendra2 
expression relies on Cre mediated excision of the termination sequence, restricting ubiquitous 
mitochondrial expression. Cre expression was regulated by the dopaminergic (DAT) transporter 
protein, and therefore its expression was only observed within DA neurons. Mitochondria 
emitted bright green fluorescence at 405 nm emission which co-localized precisely with HSP-
60, a marker of the mitochondrial matrix (Pham et al., 2012).  
 
3.3.2 Mouse dissection 
 
The brains of experimental mice were collected on the day of experiment and all procedures 
were performed according to the requirements of the UK Animals Scientific Procedures Act 
(1986). Mouse brains were collected following Schedule 1 cervical dislocation.  
 
3.3.3 Slicing preparation 
 
3.3.3.1 Obtaining the nigrostriatal pathway 
 
Once removed, the mouse brain was submerged in cold (4–5°C) sucrose solution [250 mM 
sucrose, 3 mM KCL, 1.25 mM NaH2PO4, 24 mM NaHCO3, 2 mM MgSO4, 2 mM CaCl2, and 10 mM 
glucose (Sigma-Aldrich)]. In order to obtain an intact nigrostriatal pathway for imaging, the 
brain was vertically halved into two hemispheres. Each hemisphere was further sliced at a 45° 






3.3.3.2 Slicing the mouse brain 
 
The sliced brain was then mounted onto the vibratome, with the cut side facing downwards 
and midline facing upwards and were fully submerged in ice cold sucrose solution. Slices were 
cut at a thickness of 300 µm. Approximately 6 slices were obtained per animal and transferred 
into a large petri dish with sucrose solution. Slices were then transferred into a holding chamber 
containing artificial CSF (ACSF) [in mM: 126 NaCl, 3 KCL, 1.25 NaH2PO4 , 24 NaHCO3, 1 MgSO4, 
1.2 CaCl2, and 10 glucose] (Dheerender et al., 2018). All salts were obtained from BDH 
chemicals (Poole, UK).   
3.3.3.3 Incubating slices 
 
The holding chamber was maintained at room temperature at the interface between ACSF and 
warm, moist carbogen gas (95% O2/5% CO2). Slices were allowed to equilibrate on the holding 
chamber for 30 minutes before being loaded with TMRM and MitoTracker Deep Red FM, to 
allow the simultaneous imaging of mitochondrial membrane potential within the striatum and 
photo-switched mitochondria within SNpc cell bodies respectively. The use of these two 
separate dyes allows us to overcome an overlap in dye fluorescence.    
3.3.3.4 Preparation of DiD solution 
 
1:33 dilution from a 10 mg/ml stock concentration of DiD (Life Technologies) was diluted into 
1ml 1M potassium acetate. This was then sonicated on a mse soniprep 150 with ultrasonic 
disintegrator at 16 khz for 3 seconds. The solution was stored at – 20°C until use. Alexa 
fluorophore 647 hydrazide (Life Technologies) was used in addition to the DiD to optimise 
intracellular recordings. 
3.3.3.5 NucRed Live probes  
 
Nuclear staining was conducted on nigrostriatal slices in order to access viability of slices after 
3 hours of imaging. This was conducted by adding of 2 drops/mL of NucRed® Live 647 
ReadyProbes® Reagent (ThermoFischer) to the slices that were perfused with ACSF. NucRed 






3.3.4 Imaging mitochondria with the dopaminergic neurons of the nigrostriatal pathway 
 
3.3.4.1 Perfusion system setup 
 
In order to ensure that slices were kept ‘alive’ during inverted confocal imaging (Nikon A1r), a 
perfusion system was created. This system maintained a constant circulation of oxygenated 
ACSF through the slices, throughout the entire imaging session. ACSF was aspirated from the 
glass (Ibidi) bottom dish and circumvented through tubing connected to a vacuum pump. This 
vacuum pump stabilised the level of liquid circulating the system at all times. As slices were 
submerged in ACSF, this flow of liquid can cause movement of the whole slice, which can result 
in severe distortion during time lapse studies. To minimise this movement, slices were stabilised 
with a slice anchor (Warner Instruments) placed on top of the slices, to prevent the slice from 
floating within the ACSF solution. Once the slices were anchored to the bottom of the Ibidi dish, 
no movement was observed during the experiment. Slices were also maintained at 37°C and 
held in a glass (Ibidi) bottom dish in a temperature-controlled chamber. ACSF is saturated with 
O2 and CO2 at room temperature, which comes out of solution in the heated imaging chamber 
and can produce small bubbles during imaging. These bubbles can reduce image quality, 
damaging the slices. To prevent this, we kept the ACSF container inside the chamber saturating 
these gases at 37°C. 
3.3.4.2 Imaging membrane potential within the striatum  
 
Slices were loaded with 125nM Tetramethylrhodamine, methyl ester (TMRM), TMRM and left 
to incubate for 30 minutes prior to imaging, in order to allow dye uptake into the slice. A dye 
with a 561 nm emission wavelength was selected to limit overlap with the 488 nm emission of 
the mito-Dendra2.  
 
3.3.4.3 Imaging mitochondrial membrane potential within cell bodies in the SNpc  
 
Slices were loaded with 125nM MitoTracker Deep Red and left to incubate for 30 minutes prior 
to imaging, in order to allow dye uptake into the slice.  As photo-switching was to be carried 
out within cell bodies (405 excitation and 561 emission), we could not incubate with TMRM, 






3.3.4.4 Imaging Mito-Dendra2 fluorescence  
 
Mito-Dendra2 were imaged in the cell body, axons and striatum of the nigrostriatal pathway, 
using a 488nm laser. Mitochondrial movement was observed via videos captured at 5 
frames/second for 10 minutes at x20 magnification.  
 
3.3.5 CLARITY optimisation in ex vivo slices  
 
CLARITY experiments were conducted to ensure the slicing methods were producing an intact 
nigrostriatal pathway. All CLARITY experiments were conducted on nigrostriatal slices by Dr 




3.4 OPTIMISING SLICE IMAGING 
 
Studying nigrostriatal mitochondrial dynamics in an ex vivo model posed the following 
challenges, i) identifying intact neurons (that are not axotomised by sectioning) to track 
mitochondria motility within the nigrostriatal pathway ii) slicing the mouse brain at the right 
angle to obtain intact neurons along the whole length of the nigrostriatal pathway and iii) 
ensuring slices are kept alive throughout the imaging process. This section provides details of 
the optimisation of this technique and how such issues were combatted.  
3.4.1 Identification of intact DA neurons of the nigrostriatal pathway 
 
In order to identify neurons within the nigrostriatal pathway it was suggested that a method to 
track neurons would be required. Literature indicated that long-chain dialkylcarbocyanines, 
such as (DiA and its analogues) were widely used tools to detect neuronal structures in living 
and fixed cells. It has been shown that DiI labelling does not affect neuronal viability, 
development, or any other basic physiological properties, where instances of DiI-labelled motor 
neurons were found to remain viable for up to four weeks in culture and up to one year in vivo 
(Kuffler, 1990). The dyes permit uniform tracking of neurons via lateral diffusion into the plasma 
membrane at a rate of about 0.2 – 0.6 mm per day in fixed specimens (Godement et al., 1978, 
Gordon et al., 1993). In living tissue, labelling is quicker ( approximately 6 mm per day), due to 
active dye transport processes.  
This study manipulated DiD (D307, D7757), an analogue of DiI with a 647 nm excitation and 
emission spectra, that did not interfere with the 488-emission fluorescence of the mito-
Dendra2. This was carried out to characterise only the DAergic neurons within the nigrostriatal 
pathway. Three different approaches were explored to optimise the most efficient method of 
DiD uptake into neurons following the observations and results presented in other studies. 
These comprised of i) pressing a few DiD crystals directly onto the slice, ii) pipetting a dissolved 
DiD solution directly onto the slice and iii) microinjections of the DiD solution onto the slice. 
The following will describe how these experiments were undertaken and the limitations and 
advantages each method poses.  
Initial optimisation studies of DiD uptake into neurons were carried out on hippocampal slices 
of rat brain without mito-Dendra2 fluorescence, as they were readily available (courtesy of 
Clare Tweedy, PhD student, Institute of Neuroscience). Sections were initially cut on a 
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vibratome at a 450μm thickness, which were then modified to a 300μm thickness, rendering 
the slices thinner, granting easy visualisation of DiD within the slices and also reducing the area 
for DiD penetration. Once in contact with the dye, slices were permitted to equilibrate in ACSF 
for 30 minutes before any recordings commenced.   
3.4.1.1 Direct application of DiD crystals onto hippocampal slice  
 
This technique pressed a few crystals of undissolved DiD onto the 450μm hippocampal brain 
slice. Studies have shown that dye crystals can be applied directly to intact or cut neurons for 
retrograde or anterograde labelling (Godement et al., 1978, Gordon et al., 1993, Thanos and 
Mey, 1995.  In particular cases the direct application of crystals produces more consistent 
labelling than the injection of a dye solution (Thanos and Bonhoeffer, 1987). DiD crystals were 
applied to a micropipette tip for delivery onto the hippocampal site via a gelatin sponge (Thanos 
and Bonhoeffer, 1987), to hold the crystals in place during the time required for DiD transport 
along the neuronal pathway.  
Z-stack analysis identified DiD penetration at 90μm into the slice, however the dye labelled all 
neurons and processes that it came into contact with. Pressing the crystals onto the slice 
inhibited precise identification of individual neurons, as the dye had localised to several cells 
and not just one cell on the tissue. The widespread labelling of many cells, as a consequence of 
the ad-hoc pressing of the crystals, demonstrated that the fluorescent signal on the slice was 
saturated within pressed region. This region of amplified fluorescence, impeded any detection 
of individual cell bodies within the neurons and so it was decided that though this method was 
working, in terms of DiD passing into and through the tissue, the crystals within the dye were 
causing a large visual hindrance and non-specific binding of neurons were sighted where 
transport into processes were also not observed (Figure 3.1A-B) 
3.4.1.2 Microinjecting DiD solution onto hippocampal slice 
 
Whole-cell patch clamp is commonly used to study electrophysiological properties of neurons 
in brain slices (Edwards et al., 1989). Using electrodes filled with fluorescent dyes, the whole-
cell configuration of patch clamp injects dye into neurons by diffusion through the pipette tip 
to neuron. This technique has the advantage that the labelling is rapid and that any neuron in 
the slice can be targeted and therefore visualised. When electrophysiological measurements 
are combined with imaging, a lower concentration of dyes are used and the whole-cell patch 
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clamp is maintained during an experiment (Yuste and Denk, 1995). The microinjection of a small 
volume of the concentrated DiD solution was an alternative to the direct application of the 
crystalline dye for neuronal tracing (Honig and Hume, 1986).  
Applying this technique to our studies, DiD crystals were injected into neurons to observe DiD 
incorporation into the tissue. Extracellular recordings (1-300 Hz) were conducted with ACSF-
filled glass microelectrodes (2-4 MΩ) connected to an extracellular amplifier (EXT-10-2F, npi 
electronic GmbH, Tamm, Germany) (Ehrrmann et al., 2016). Microelectrodes were filled with 
DiD solution. Recordings were conducted within the CA3 sub-field of the hippocampus, and DiD 
contents within electrode were transferred into neurons within the hippocampus. This 
technique involves the rupturing of the cell membrane in order to inject the cell with DiD, which 
may have detrimental effects on the cellular content, and therefore possibly mitochondrial 
health and trafficking.  
Whilst attempting to image these slices, it became apparent that DiD crystals were prohibitive 
in two aspects i) the large crystals within the DiD were not allowing the contents of the injection 
to be transferred to the neuron and ii) crystals within the DiD solution transferred to the neuron 
were proving a visual hindrance, as they formed large clusters on the slices inhibiting clear 
vision of where the dye had penetrated (Figure 3.1D) 
Therefore, it was decided that the crystals had to be removed from the DiD solution, and once 
removed, a known concentration and volume of DiD must be incorporated into the brain slice 
in order to devise a reliable method that can be reproduced.  
As the protocol illustrated by Honig and Hume, 1986 uses a 10 mg/mL (1.0 w/v) solution, the 
dye was further diluted down to a 2.5 mg/mL (0.25% w/v) to optimise dye penetration via 
microinjection. Prior to microinjection, the DiD was sonicated and centrifuged, in order to 
dissolve dye crystals blocking the pipette tip. Via replicating this method, the dye was prepared, 
and cells were injected intracellularly. Initial experiments were conducted in hippocampal 
sections at 2.5 and 10 mg/ml concentrations. Intracellular recordings were then taken from a 
single cell in the hippocampal cortex (CA1, CA2 region) by injecting DiD at a 2.5 and 10 mg/ml 
concentration. Here, it was observed that injecting the dye at 2.5 mg/ml was too low a 
concentration and was not taken up efficiently by neurons in the hippocampus. However, at a 
10 mg/ml concentration, dye was taken up into slice with very little background signal, targeting 
only the neuron injected (Figure 3.1C). 
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There are many limitations to microinjections, where finding and patching onto a cell is time 
consuming and in some instances a neuron may not even be located during electrophysiology. 
Injecting the dye into a neuron was also a very intricate process whereby on a few occasions 
the injection had failed to incorporate the dye into the cell completely, as exchanging of the 
contents of the needle was inefficient, and vice versa where the DiD was not efficiently taken 
up by the injection. Using a 10 mg/ml solution showed some DiD penetration into the neuron, 
where perhaps a larger concentration of the dye incubated over a longer time period would be 
required in order for targeted fluorescence within the nigrostriatal pathway. However, the 
issue of a larger concentration causing a larger background fluorescence on the brain slice was 
identified, in addition to decreased cell viability as a consequence of the extended incubation 
time of the slice. Moreover, slices have to be kept alive when imaging, so confocal microscopy 
will be set in accordance to this, ensuring that slices are constantly pumped with artificial 
cerebrospinal fluid in order to prevent slice death.  
 
 
Figure 3.1.  DiD incorporation on to brain slice. Various methods were used to incorporate DiD into neurons. A, 
B) Direct application of DiD onto the slice via gentle pressing of gelatine crystals and C) Use of microinjections 
filled with 2.5 mg/ml DiD D) Use of microinjections filled with 10.0 mg/ml onto slice. Images taken at x 20 






3.4.1.3 Pipetting DiD solution onto hippocampal slice 
 
Direct pipetting of DiD onto the brain slice was carried out with two volumes, <0.5 and <1.0 µl 
of a 10 mg/ml stock. Slices were left to incubate for 60 minutes at room temperature to allow 
time for absorption, within the ACSF holding chamber. DiD was pipetted straight onto 
hippocampal slices, away from the targeted region to observe the degree of penetration over 
60 minutes. DiD uptake was highly efficient within the slice, where emerging neuronal 
processes and pyramidal cell bodies were observed. It was decided that persisting with 
pipetting the dye onto the slice would be the most reliable option, as dye uptake was 
continuous, however more practise was required in terms of directing the dye and where it 
would be localised (Figure 3.2). 
3.4.1.4 Using transgenic Mito-Dendra2 fluorescence to identify the nigrostriatal pathway  
 
Optimisation of DiD insertion into cell bodies distinctly showed that though the DiD was 
penetrating the slice, this process took over two hours. In cases of culture studies, this would 
be a viable situation, however as brain slices will lose viability within 6 – 10 hours once isolated 
from the rodent, it was not practical to let slices incubate with DiD for 3-4 hours, to optimise 
dye uptake.  
Although it was believed that having a neuronal tracer would be essential for the identification 
and tracking of single neurons, it became apparent that due to the organisation of the 
nigrostriatal pathway the engineered mito-Dendra2 fluorescence was sufficient to allow 
neuronal tracing. Therefore, the additional labelling of slices and neurons with DiD was not 
taken further. Efficient slicing of the pathway enabled visualisation of all structures of the 
pathway, and further eliminated incubating slices with a dye prior to imaging, and therefore 
minimalising the length of time the slice remained isolated from the brain. Therefore, future 








Figure 3.2. Pipetting DiD onto nigrostriatal slices. Pipetting the DiD onto the slice was found to be the most 
robust and efficient method that incorporate DiD into slices.  1.0 µl of a 10 mg/ml of DiD as directly applied to 
slices, where in addition to the mito-Dendra fluorescence at 488 nm, neuronal structures can be observed at 647 













3.4.2 Slicing to obtain the nigrostriatal pathway 
 
Once the ability to trace individual neurons was confirmed, the next obstacle in the 
optimisation of these ex vivo experiments was the slicing of the mouse brain in the correct 
orientation to consistently obtain an intact nigrostriatal pathway.  
3.4.2.1 Angled slicing to obtain the nigrostriatal pathway 
 
Once a brain was harvested and divided into two hemispheres (Figure 3.3A), slicing the brain in 
an orthodox manner (horizontal, sagittal, coronal) would disrupt the desired neuronal 
processes, as projections of the nigrostriatal pathway do not lie in one plane. Thus, to combat 
this problem, the mouse brain would have to have a small section sliced removed from the 
cortex of each hemisphere in order to allow angled slicing to be performed.  
To allow the intact pathway to be imaged, a segment was removed from the brain, by trialling 
three different angles: 40° 45° and 50° to appreciate which angle of slicing permitted an intact 
nigrostriatal pathway (Figure 3.3B). Angled sectioning of the brain was carried out by a metal 
block which contained slicing guides angled at 40° 45° and 50°(Figure 3.3B). Once a segment of 
the brain was removed, both hemispheres of the brain were sectioned at a 300 µm thickness 
on the vibratome (Figure 3.3C).  
 
 
Figure 3.3. Live imaging setup. Imaging of the nigrostriatal sections were initiated with A) halving the 
Dendra2/CRE mouse brain into two hemispheres.  B) Optimisation of the best angle for slicing was then carried 
out by slices the hemispheres at three different angles: 40, 45 and 50° with a blade that sat within the angled 




Of the three angles, 45° showed to be a better provider of an intact nigrostriatal pathway. 
Imaging at 45° provided evidence of the mito-Dendra2 and facilitated the visualisation of the 
nigrostriatal pathway, where individual mitochondria within axons and axon terminals leading 
into the striatum could be identified. On repeating this angled slicing method, it was established 
that cutting the sections at 45° and 50°, reproducibly gave an intact nigrostriatal pathway, for 
each experiment. Surprisingly, this further confirmed that the addition of  DiD to identify 
neurons was not required, as the mito-Dendra2 assisted identification of single neuronal 
processes, as mitochondria were distributed within defined structures through the pathway. 
This allowed their movements to be tracked easily from cell body to striatum.  Experiments 
were thus continued by removing a segment of the brain at 45° and imaging according to mito-
Dendra2.   
Further CLARITY experiments conducted on wildtype mice that were angled at this section, 
demonstrated that at 45°, the nigrostriatal pathway was easily observed via tyrosine 
hydroxylase (TH) staining as an indicator of DAergic neurons. DA neurons were identified at 




Figure 3.4.  Nigrostriatal pathway stained with tyrosine hydroxylase via CLARITY. CLARITY assay on nigrostriatal 
pathway within wild type mouse showing, dopaminergic processes from the substantia nigra to the 
striatum by staining with tyrosine hydroxylase (TH)-positive neurons (green). Staining shows intact 




3.4.3 Imaging the nigrostriatal pathway in Dendra/Cre mice – Slice viability 
 
The aim of this study was to image mitochondrial trafficking within ‘live’ DA neurons of the 
nigrostriatal pathway. The most crucial aspect of this study was to maintain living slices 
throughout the imaging process on the Nikon A1r. In vivo studies have monitored and analysed 
live mitochondrial trafficking for 10 -15 minutes (Misgeld et al., 2007a, Misgeld et al., 2007b, 
Pluckinska et al., 2012, Sajic et al., 2013, Sorbata et al., 2014, Lewis et al., 2016) and so this 
length of imaging was replicated in this model, where all experimental videos were of a 10 
minute duration. 
To counteract tissue death, it was key that a method of maintaining live cells for a long duration, 
whilst imaging on the confocal had to be created. Therefore, a perfusion system was created, 
where slices that were being imaged were always supplied with ACSF, imitating the 
environment in which they are retained in prior to imaging, in the holding chamber. In addition 
to the perfusing ACSF solution, a gas cylinder was also incorporated, which ensured that the 
ASCF was oxygenated. This system allowed imaging of the slices of up to 4 hours, without losing 
slice viability. Slices were maintained under the microscope in a glass (Ibidi) bottom dish 
throughout imaging, where a 1.0 mm slice anchor was positioned on top of slices to disable 
floating whilst imaging from below on an inverted confocal microscope.  
Nigrostriatal slice viability was assessed by incubating slices with 2 drops/mL Nuc Red dye, 
which emits signal at 647 nm, indicating cell death. Images were taken of nigrostriatal slices at 
60 and 120 minutes into imaging (Figure 3.5A-F), where cell death was observed around the 
circumference of the slice, where the edges of the sections appeared to begin to degrade 
during imaging. In relation to how this affects the nigrostriatal pathway, the striatum is located 
at the anterior end of the brain slice, in relation to the posteriorly located SNpc. In all cases of 
imaging the striatum was imaged first, simply due to its easy identification as a structure. 
Imaging within the striatal region of the section was conducted within the first 45 minutes, after 
which point, posteriorly located axons and cell bodies of the SNpc were imaged. By these 
means, the imaging usually lasted around 3 hours, by which the middle of the section was 






Figure 3.5. Assessing slice viability with NucRed staining. NucRed images were taken after A-C) 60 minutes into 
imaging and D-F) 120 minutes into imaging, where slice viability is reduced around the edge and the middle of the 
nigrostriatal slice respectively. G) Z-stack analyses of Nuc red staining shows that after 180 minutes of imaging, 




Furthermore, in order to attain as much data from each animal as possible, a minimum of 9 
videos were recorded per slice. Therefore, the nigrostriatal pathway was divided into 3 parts, 
cell bodies in the SNpc, axons projecting toward the striatum and lastly the striatum, where the 
nigrostriatal pathway terminates. For each region, a minimum of 3 videos were obtained, 
generating 9 videos per slice.  
Each mouse generated a minimum of 4 viable, intact slices that could be retained for imaging. 
However, it was not always the case that all four slices could be used, as this would mean they 
would be kept on the confocal for up to 6 hours after dissection, which undoubtedly may not 
provide an accurate representation of live mitochondrial trafficking. The first few hours of 
recording consisted of videoing the 3 regions throughout the nigrostriatal pathway within the 
cell bodies (Figure 3.6), axons (Figure 3.7), and striatum (Figure 3.8). A maximum of two 
nigrostriatal slices were imaged within each experiment, the remainder of which, if viable, were 






Figure 3.6.  Cell bodies within the SNpc in Mito-Dendra2 labelled Dendra2/DATIRESCre mice. Confocal imaging 
was conducted on 300 µm thick slices of 7 month wild type HetDendra/HetCre mice. Mitochondria were labelled 
with mito-Dendra2 and under a DAT Cre promoter, which ensures DA neuronal fluorescence. Ai-iv) Shows mito-
Dendra2  show evidence of SNc cell bodies and the respective axonal processes where individual mitochondria 
can be observed. A large quantity of cell bodies within the SNpc and their interconnected axonal pathways can be 
seen, where individual mitochondria can be observed within these intricate axonal pathways.  B-C) Further show 






Figure 3.7.  Nigrostriatal projections within in Dendra2/DATIRESCre mice. Confocal imaging was conducted on 
350µm thick slices of 7 month wild type HetDendra/HetCre mice. A-B) Neurons form synapses at their axon 
terminals in the striatum where each neuron can synapse into more than one axonal terminal (white boxes), where 
mitochondrial tracks are less dispersed towards their axon terminals. Cell bodies (white arrows) are also observed. 
C) Axonal terminals, where individual mitochondria can be observed within these processes. Scale bars, 100µm. 





Figure 3.8.  Identification of the striatum in the nigrostriatal pathway in Dendra2/DATIRESCre mice. 
Confocal imaging was conducted on 350 µm thick slices of 7 month wild type HetDendra/HetCre mice.  
A-C) Neurons form synapses at their axon terminals, where neurons can synapse into more than one 
axonal terminal. The identification of Wilson’s pencils were used to identify the striatum within the 
nigrostriatal pathway (white arrows) in the slices, where mitochondria within the striatum are tightly 
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3.5 ANALYSING MITOCHONDRIAL TRAFFICKING IN NEURONS 
 
Many factors render the imaging and analysis of mitochondrial movement an intricate and 
complex task. Firstly, the deviations in mitochondrial morphology render mitochondria difficult 
to segment and identify as individual objects. Secondly, photo bleaching throughout imaging 
may enforce a compromise to occur between the frame rate and duration of tracking time 
(Yang et al., 2010);  (combatted in this study by maintaining a constant low laser power during 
experiments) and lastly, the efficient methods to track and quantify mitochondrial movement 
are yet to be established (Yang, 2012). Mitochondrial trafficking analyses described in this 
section used two softwares to image mitochondrial trafficking, IMARIS 9.2 (IMARIS 9.2, Bitplane 
AG, software available at http://bitplane.com) and FIJI, to generate kymographs. 
 
Movement analysis was optimised for use in the following disease models: 
 
i) Nigrostriatal brain slices, to observe mitochondrial dynamics in the cell bodies, axons 
and striatum of the nigrostriatal pathway 
ii) iPSC cultured neurons to observe mitochondrial dynamics within cell bodies and axons 
 
The recording of mitochondrial trafficking was conducted on the Nikon A1R Inverted Confocal, 
where all videos measured were 10 minutes and at a frame/second. This section will describe 
analysis optimisation in both models and justify our selection of the particular analyses. The 














3.5.1 Observing mitochondrial dynamics - Cell bodies 
 
These studies sought to measure the mitochondrial membrane potential via 
TMRM/MitoTracker Deep red staining within cell bodies of SNpc nigrostriatal slices (Figure 3.9A 
and 3.9B) and cultured neurons harbouring low and high heteroplasmy neurons (Figure 3.9C. 
See Chapter 6).  Nigrostriatal slices were loaded with 5nm TMRM and 125nm Mito tracker dye, 
where cultured neurons were loaded with 5nm TMRM.  During this analyses individual cell 
bodies were selected and measured within both cultured neurons and slices. In the cultured 
neurons, many cell bodies can be observed, whereas in nigrostriatal cell bodies were not found 
in similar numbers. In cultured neurons around 10 cell bodies were measured for each video 
taken per experiment and in slices, all the cell bodies that could be observed were analysed 
(around 5-6 per video). Individual ROIs (boxes) were created for each cell body; the size of 
which would vary dependant on cell body size; with the main objective being to avoid axons 
and/or projections from these cell bodies as intensity values of these mitochondria would be 
included in these measurements.  
 
TMRM staining (Fig 3.9A) within the SNpc cell bodies was very punctate reflecting 
mitochondrial staining, here individual cell bodies were identified allowing the measurement 
of mitochondrial membrane potential via IMARIS. Having repeated TMRM staining in other 
nigrostriatal slices, it was found that punctate TMRM staining was not reproducible. Reasons 
for this being, i) the loading concentration of TMRM may have been too high or too low, ii) not 
enough time was given for TMRM dye uptake onto the slice, (more than 30 minutes for TMRM 
uptake is not advisable due to the risk of reducing slice viability), iii) the dye may have been 
largely concentrated within one region only and did not penetrate other regions and finally iv) 
when TMRM was loaded correctly onto the brain slice, this staining was not punctate.  For these 
reasons stated it was decided to discontinue this analysis.  
MitoTracker Deep Red staining (Figures 3.9B) revealed no individual cell bodies, were stained, 
rather the tissue that surrounded the SN, where no punctate staining that co-localises with the 
mito-Dendra2 were observed and therefore this staining was discontined. Altogether, it was 
decided that observing mitochondrial membrane potential within SNpc cell bodies required 
further optimisation.  
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Within cultured neurons (Figures 3.9C) TMRM was loaded prior to live imaging (See chapter 5 
and 6 for details of the methods) where individual cell bodies can be observed (Fig 3.9Ci-iii). 
Videos were analysed on IMARIS, masking analyses were created around these punctate cell 












Figure 3.9. Assessing mitochondrial function via mitochondrial membrane potential.  Mitochondrial function was 
assessed by loading cells with TMRM (A and C) and MitoTracker Deep Red (B). A) Staining of SNpc cell bodies 
(green) loaded with TMRM (red) in nigrostriatal slices. B) Staining of SNpc cell bodies (green) loaded with 
MitoTracker Deep Red (Purple) in nigrostriatal slices and C)  TMRM (red) staining in axons and cell bodies on 







3.5.2 Observing mitochondrial dynamics - Axons  
 
3.5.2.1 IMARIS time lapse imaging  
IMARIS 9.2 allows the analysis of movements over time and can also generate information 
about surrounding stationary objects. It allows the tracking of mitochondrial motility 
throughout videos through trajectories of Brownian motion, encompassing the size of the 
voxels (individual mitochondria) and therefore producing data on a number of parameters that 
include track speed, duration, length as well as mitochondrial volume and TMRM intensity.  
During optimisation of time-lapse imaging on IMARIS, selected mitochondrial parameters were 
measured throughout the recorded videos. The aim of IMARIS analysis, was to identify 
mitochondria within axons and how they vary in individual parameters in the presence of a 
respiratory chain defect (cultured neurons) or aging/PD pathology (Mouse model). IMARIS 
generated information for the parameters that were selected, and if mitochondria did not 
undergo fusion or fission , would have been an adequate method to analyse this data.  
 
3.5.2.2 IMARIS time lapse parameters  
During the initial surface analysis, within an ROI, each mitochondria within each axon would 
have its own track, where IMARIS would trace mitochondrial displacement from its origin and 
would also track mitochondrial directionality. From these tracks, the following mitochondrial 
properties were observed: 
• Track speed (µms-1) – This measured the instantaneous speed of individual mitochondria 
throughout the track, where data for each mitochondrion throughout each track is 
provided for each time point.  
• Track length (µm) - This measures the total length of displacement within each Track, 
and is indicative of the direction of mitochondrial movement within a track over time.  
• Track Duration (s) – The track duration measures the time each mitochondrion takes 
between the first and last time point within each track, and provides insight into how 
short and/or long the tracks are and how this changes throughout the video.  
• Mitochondrial membrane potential (Arb, U) – Cultured Neurons - IMARIS analysis was 
used to measure the intensity of the TMRM (TRITC) channel. The ‘Intensity mean’ was 
generated as a data point for each mitochondrion at each time point, these values were 
then averaged. The intensity mean indicates the average intensity of each mitochondria 
within a surface.  
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Time lapse imaging analysis conducted on IMARIS in both models, indicated that IMARIS did 
not count for the fission and fusion properties of mitochondria throughout a video, as the 
surfaces created did not amend themselves throughout the imaging time in order to cater for 
these mitochondrial properties, but remained fixed throughout imaging, once set. 
Furthermore, if a mitochondrion was to exit the plane of view, this was not controlled for within 
IMARIS imaging, therefore, we did not continue to measure mitochondrial trafficking via the 
IMARIS software in either model. 
3.5.3 Observing mitochondrial dynamics – Axonal kymographs 
 
After having eliminated the tracking of mitochondria within axons using IMARIS, analyses 
moved onto using kymographs to analyse mitochondrial movement. The generation of 
kymographs from time lapse imaging has become the most common method to image 
mitochondrial transport (e.g., Miller and Sheetz, 2004, Hollenbeck and Saxton, 2005, Wang et 
al., 2011).  
In kymograph analyses, there are 4 types of mitochondrial movement classed as dynamic pause 
(DP), stationary (ST), anterograde (AR) and retrograde (RR) movement (Figure 3.10) (Chen et 
al., 2016). Directionality and speed of mitochondrial trafficking were recorded for cultured 
neurons, and within the nigrostriatal slices, kymographs were generated for both axons and 
axon terminals. 
 
Mitochondrial movement in the cultured neurons were observed to be stationery, anterograde 
and retrograde. Furthermore, they exhibited ‘dynamic pause’ movement and also anterograde 
and retrograde movement was found to occur in several speeds. In contrast, within the slices 
very little mitochondrial movement was observed, whereby movement was observed as a 
mitochondrion generating small shuffles adjacent to its original location.  
 
Due to the dynamic and sporadic  nature of mitochondria not all types of movemements were 
analysed  in this project. Two thresholds were set: Speeds between 0 – 0.005 µm/s moving 




Figure 3.10. Kymograph analysis. A) Axons analysed in TMRM stained cultured neurons from human IPSCs 
harbouring large scale mtDNA deletion. B) Nigrostriatum with projecting axon terminals (i and ii) and axons (iii and 
iv) that will be analysed through kymograph analyses.  C) Directionality of mitochondria movement is shown in the 




















3.5.3.1 Generating kymographs  
 
The kymograph plug in was downloaded and installed, which consists of all four “*.class” files, 
which were moved to the ImageJ Plugins folder. Axonal videos recorded on the confocal are 
created as ‘.Nd2’ files that were opened in the IMAGEJ software for analysis.  
 
Creating segments on IMAGEJ -  Using the line function on IMAGEJ, equivocal lines were created 
(in order to combat subjectivity), outlining axons for measuring. The line function allows the 
altering of the thickness of the line, where this can be altered, by increasing or decreasing the 
thickness to include all mitochondria of interest within the axon and conversely, to exclude 
mitochondria that are not a part of the axon of interest (Figure 3.11A). 
 
Creating kymographs - Once the ROI was selected, the ‘Multiple kymograph’ tool was selected 
on the plugin tab. This generated a kymograph, where white straight lines represent stationary 
mitochondria, while moving mitochondria were indicated by the diagonal direction of these 
lines indicating anterograde or retrograde direction. A diagonal upward movement represents 
retrograde movement and a diagonal downward movement indicates anterograde movement 
(Figure 3.11B-C). 
 
Kymograph statistics - Individual mitochondria were selected and their serial numbers were 
recorded via ROI manager, where each ROI generated its own table of information.  
Mitochondria were analysed individually. The macros plugin allowed the analysis of selected 
ROIs, to extract their velocity data.  Excel sheets were created for each mitochondrion, where 




Figure 3.11. Kymograph generation. Figure shows steps taken to generate kymographs to analyse mitochondrial 
trafficking.  A) Lines were drawn over axons to mark the length of the axon in which mitochondria are measured. 
B) The MultipleKymograph plugin was selected to generate a kymograph.  C) Kymograph was generated where 
velocity and directionality of mitochondria within the selected axon could be observed. D-E) Selecting tracks within 
the kymograph, created more information about each mitochondria and its mode of direction by generating a 
statistics table.  F) Exemplar kymograph with individually labelled mitochondria.
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3.5.4 Observing mitochondrial dynamics – Striatum 
 
Striatal analyses comprised of understanding two parameters of mitochondrial function, i) 
mitochondrial trafficking within the nigrostriatum and ii) membrane potential analyses via 
TMRM staining in order to understand membrane potential deviances within synapses of the 
nigrostriatal pathway. This section will describe 3 different methods housed within the IMARIS 
9.2 software, which include surface, spots and masking analyses to carry out this analysis.  
3.5.5 IMARIS surface analyses – Striatal mitochondrial movement 
 
As kymographs help to understand the movement of an object within a linear projection, this 
method of analysis was not applicable to the neurobiological structure of the striatum, as the 
mitochondria found within this region are organised in a tight compact manner within nerve 
terminals and the striatum. Therefore, the following will describe the ‘Surfaces’ IMARIS 
protocol and how this was conducted in order to understand mitochondrial movement within 
the striatum. Surfaces were created over ROIs over (FITC) channel.  
 
Segmentation – Prior to creating surfaces, the area of interest must first select within each 
video. This is achieved by using the ‘segmenting function’ that helps shape and analyse an 
arbitrarily shaped region of interest (ROI) within the video. Segmenting within the video, 
instead of analysing the video as a whole, limits the level of background that would be produced 
from neighbouring axons and permits more control of which objects within the neurons are 
being tracked. From these manually created segments, a surface object could be generated 
around the mitochondria.   
 
Defining the ROI - The creation of surfaces on IMARIS to detect mitochondria within selected 
axons, is based on staining intensity. In addition, the user can input an expected size of the 
object to be tracked which detects a uniform size of mitochondrion throughout the tracking 
process. The manual tracking requires drawing around the area of interest with the use of the 
‘draw’ tool within the creation wizard. A surface is created over the selected channel. Following 
this one could decide whether or not the smoothing tool was to be used. The smoothing tool 
determines how uniform your surface is and whether the rough surface generation is needed, 
via application of a Gaussian filter. However, the correct detection of these structures was 
crucial for analysis, therefore the smoothing tool was not used, as the smoothing tool supresses 
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noise of the segment homogeneously, which may cause mitochondrial fusing, disregarding 
smaller, individual mitochondrial.  
 
Tracking surfaces over time - The surface creation wizard allows the option of tracking the 
surfaces over time. Time points could be individually selected through the scrolling bar, 
whereby the mitochondria that are being recorded can be tracked through each time point.  
 
Creating surfaces - IMARIS will generate a surface encompassing the ROI, where the sensitivity 
of surface creation can be altered by adjusting the threshold. Thresholds within the image were 
adjusted, in order to avoid creating surfaces on unwanted background fluorescence. The 
threshold was adjusted to ensure the surfaces accurately detected positive signal and that the 
surfaces created were most representative of the fluorescent signal.  
 
Background subtraction – The calculation of background subtraction is intensity based and is 
carried out by taking the smallest diameter of mitochondria measured and then creating a 
surface over this voxel.  Once selected the creation wizard will attempt to identify the diameter 
of an object, by recommending an appropriate size of mitochondria and automatic recognition 
of the objects. However, in these experiments, mitochondrial shape was measured in the ‘slice 
view’ tab, where thresholds of mitochondrial shape were altered by checking the threshold 
level, in order to determine a mitochondrial diameter that allowed accurate tracking of all 
mitochondria within the video. This was further confirmed by manually playing the video and 
observing whether the surfaces created were representative of all mitochondrial shapes. 
Furthermore, surfaces can be removed if it seems that the track that is being created is 
incorrect or does not accurately track the mitochondria for the duration of the video. For our 
analyses, no surfaces were removed.  
 
Adjusting voxels - Following on from this the voxels detected within the ROI were ordered and 
displayed as a histogram, depending on size of voxel. A three-dimensional environment is 
typically represented with the use of volumetric features (not to be mistaken with Z-stacks), 
such as voxels, that characterise the complex character of visibility obstacles. In this step, 
surfaces that were too small removed/did not encompass mitochondrial shape. This ensured 




Tracking algorithms and identifying distance – Finally a tracking algorithm is created for each 
surface. There are four algorithms that are available for motion analysis on IMARIS, these 
include, Brownian motion, autoregressive motion, autoregressive motion expert and 
connected components. Of these, the autoregressive motion was selected for my studies, as it 
is indicative of the random movement observed in biological processes. Once the algorithms 
were defined, the ‘maximum distance’ was established. This parameter defines the maximal 
connection distance between the surface and its predicted position over subsequent time 
points.  The tracking algorithms were displayed as individual lines, where tracks could then be 
filtered on various parameters i.e. track duration, length and speed. However, all tracks were 
measured in this analysis. Following this final step of the analysis, all surfaces (mitochondria) 
and their respective tracks could be observed. This allowed the observation of the movement 
of all selected mitochondria throughout the entire video.  
 
Statistics – Once tracks were determined, measurements were generated for each surface 
created throughout the videos as an excel spreadsheet. Results were tabulated for each 
parameter that was measured for each surface, which included data for track duration, length 
and speed, TMRM intensity (as a measure of mitochondrial membrane potential) and 
mitochondrial volume. Mitochondrial movements were measured in an average of 10 axons 
per video, from which intensity averages (as an indication of mitochondrial membrane 
potential) were compared between experimental cohorts via ANOVA testing with a post 
Dunnett’s correction. However, a few limitations were observed during IMARIS analyses of the 














3.5.6 Limitations of imaging mitochondria in the striatum 
 
Segments of the striatum were used to track mitochondrial movement, where unfortunately, 
as mentioned previously, fission and fusion properties of the mitochondria were discounted.  
Furthermore, IMARIS surface tracking showed that actually not all mitochondria were being 
detected by the software, as the software excluded those objects that were too large or small. 
This then created a bias in the tracking of mitochondrial motility throughout the video, as the 
mitochondria that were recognised by IMARIS were only of a defined size.  
The mitochondrial distribution within the striatum renders the analysis of this movement a 
practical challenge. This is due to the fact that mitochondria within the striatum are in large 
quantities which are organised in a tight, compact manner within the striatal fibres. Due to this 
structure, mitochondria within the striatum were mostly found to be stationery in motion and 
if they did move, only shifted slightly and did not displace much from their point of origin. 
Therefore, when tracking this movement, IMARIS generated several tracks (not representative 
of the true mitochondrial movement of each individual mitochondria), as a consequence of 
striatal mitochondria ‘wobble-like’ movement.  
Therefore, it was decided to exclude this analytical approach from this study and instead 
generate TIFFS from each video, which were then analysed for mitochondrial membrane 
potential only, as still images.  As sections were stained with TMRM (TRITC), the surface analysis 
was used again to select segments, and extract values that could be averaged, obtaining 
mitochondrial membrane potential values.  For reasons to similar the TMRM staining within 
SNpc cell bodies, it was decided that the membrane potential of striatal mitochondria would 
not be measured, as further optimisation was required in this field in order to achieve a 
reproducible TMRM staining within brain slices (Figure 3.12).  
 
Therefore, this study continued to observe mitochondrial membrane potential within the cell 
bodies of TMRM stained cultured neurons only via the masked surface analyses function of 
IMARIS. And kymographs will be generated for the analysis of mitochondrial movement in the 






Figure 3.12. TMRM stained striatum. Figures left to right demonstrate variety in TMRM staining which cannot be 

























3.6 DISCUSSION  
3.6.1 Summary of results 
 
• Successfully sliced Dendra2/DATCre mouse brains at an angle to obtain an intact 
nigrostriatal pathway 
• Established a perfusion system that could maintain nigrostriatal slice viability for up to 
4 hours of confocal imaging 
• Optimised a technique that allows the recording of mitochondrial movement within SNc 
axons of the nigrostriatal pathway 
• Optimise method of analysis to quantify mitochondrial movement in axons 
Acute live slices prepared from the brain have become a standard preparation commonly used 
to study electrophysiological properties of neurons in circuits (Alger et al., 1984) and, more 
recently, imaging (Yuste, 2000b). Most of this work is carried out with slices from mouse 
nigrostriatum, where the relatively high degree of preservation of neuronal networks after 
slicing and the availability of a variety of easy experimental manipulations make acute slices an 
attractive experimental preparation. Generally, acute slices can be maintained in good 
condition for up to 6 – 12 hours (Buskila et al., 2014) and all experiments conducted in this 
study have been in nigrostriatal slices that have been observed for less than 6 hours.   
Observing mitochondrial motility within the nigrostriatal pathway is an intricate procedure. This 
study has developed a method by which mitochondria can be imaged within a mouse model 
that targets the nigrostriatal pathway, the largest neuroanatomical structure affected by 
Parkinson’s disease. Manipulation of the Dendra2/DATIRESCre mouse model has facilitated 
detecting mitochondria solely within the dopaminergic neurons of the mouse brain, a crucial 
feature in these experiments. Optimising this technique has allowed to obtain nigrostriatal 
slices in a reproducible manner, which allows the individual tracking of mitochondria 
throughout the nigrostriatal projections. Creating a perfusion system on a confocal microscope 
has now allowed the visualisation of cell bodies within the SNpc and their axonal projections 
towards the striatum, where axonal terminals can be successfully observed within the 
optimised 300μm angled nigrostriatal slices. This method demonstrates that it can be 
replicated between individual mice, highlighting its potential as a means to study mitochondrial 




3.6.2 Visualising DA neurons in the nigrostriatal pathway 
 
In an attempt to identify dopaminergic neurons whilst imaging, slices were incubated with DiD 
a widely used lipophilic neuronal tracer. It was thought that in addition to observing 
mitochondrial transport, it was key to highlight intact axonal projections in which mitochondria 
were moving within. However, it was found that dye penetration required a large time period 
for incubation, which was not feasible as this meant compromising slice viability. Additionally, 
when trying to incorporate a dye within dopaminergic neurons via patch clamping techniques, 
it proved to be largely time consuming. This then compromised slice viability, displayed 
insufficient, non-uniform dye penetration along axons and was unreliable as the dye would not 
be incorporated into the neuron even after hours of incubation with it. These factors combined, 
lead to the decision to not utilise a neuronal dye within these slices, as the time consumption 
of this, was not representative of live mitochondrial trafficking, where any of these variables 
may have had adverse/bias effects on mitochondrial dynamics. Taken together, this study 
confirms that mito-Dendra2 fluorescence provides as a useful tool to identify and image 
mitochondrial movements within nigrostriatal axons.   
 
This study focussed on establishing a method by which mitochondrial trafficking could be 
successfully observed in a mammalian model. This method allows significant input into 
understanding individual mitochondrial movement within the cell bodies, axons and terminals 
of the nigrostriatal projection. This study provides a novel tool that comprises of an ex vivo 
model that can potentially be manipulated to access the nigrostriatal pathway in all murine 
PD models. The development of the Dendra2/DATIRESCre  transgenic mice provides as a useful 
in vivo model to specifically study the role of neuronal mitochondria within nigrostriatal 
projections. 
 
3.6.3 Observing mitochondrial membrane potential throughput the nigrostriatal pathway 
Dysfunctional and aged mitochondria are directed in a retrograde direction for lysosomal 
degradation via mitophagy in the cell body and healthy mitochondria are directed 
anterogradely (Saxton and Hollenbeck, 2012). In order to explore this concept further, the cell 
body and striatum were stained with dyes that fluoresce upon detection of mitochondrial 
membrane potential.  
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Healthy mitochondrial membranes maintain a difference in electrical potential across their 
inner membrane, referred to as the membrane potential. Due to mito-Dendra2 fluorescence 
at 488nm, the striatum was incubated with Tetramethylrhodamine, methyl ester (TMRM), a 
546nm (TRITC) cell-permeant dye, overcoming an overlap in signals. TMRM staining detects 
active mitochondria with intact membrane potentials, where healthy cells with functioning 
mitochondria display a bright signal and conversely, upon the loss of the mitochondrial 
membrane potential, TMRM accumulation ceases where the signal dims or disappears. 
However, within cell bodies of the SNpc, due to an overlap in the fluorescence brought about 
by the photo switching experiments in the TRITC channel, recording membrane potential in the 
SNpc was instead conducted by incubating the slices with MitoTracker Deep Red FM, 
harbouring an excitation and emission at 644 and 665nm respectively.  
3.6.4 Microscopic challenges  
All mitochondria were videoed over a period of 10 minutes on an inverted confocal microscope, 
where initial experiments were undertaken in slices that were 450µm thick slices. It was found 
that the slices were too thick, and due to the thickness of the sections, axonal projections could 
only be superficially viewed, where their projections were disrupted due to fluctuations of 
focusing on the microscope, caused by the ACSF. This obstructed visualising axonal projections 
and the tracking of mitochondria along the axon, though cell bodies and the striatum could 
easily be viewed at this thickness. In contrast, slicing the brain into thinner sections risked slice 
integrity since it may not have remained intact during the imaging process, which is a necessity 
to observe the direction of mitochondrial motility in this study, and also to retain an intact 
pathway. Therefore, it was decided that slices would be cut at 350µm, withstanding the 
possibility of the slice disassembling throughout imaging but also ensuring that mitochondria 
could be traced and recorded throughout axonal projections.  
The usage of confocal microscopy in brain slices permits the high-resolution sub micrometre 
structural observation of neurons. It allows the accurate tracking of engineered fluorescent 
proteins within neuronal structures of the brain. Initial experiments in this study were 
conducted at x40 magnification, where it was found that a large proportion of the mitochondria 
were bleached after a 10-minute recording, whereby this was drastically decreased at x20 
magnification. 
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3.7 CONCLUSION & FUTURE WORK 
 
This study has designed an ex vivo approach to observe mitochondrial trafficking within brain 
slices, in order to decipher the directionality and parameters of mitochondrial trafficking with 
dopaminergic neurons of the nigrostriatal pathway. This system has allowed novel insight into 
directionality of mitochondrial motility within cell bodies of the SNpc and axons. The following 
chapter will use this technique to observe changes of mitochondrial transport between aged 
and SNCA mice. 
Future work in this study will include: 
• Optimising TMRM/MitoTracker staining on these slices in order to gain more 
information about differences in mitochondrial function with the cell bodies and the 
synapses 
• Photo-switch individual mitochondrial populations within cell bodies of the SNpc and 













Figure 3.13 Photo-switching mitochondria within striatum. Photo conversion was achieved with A) A 
small population of around 10 mitochondria within the striatum. B) Mitochondria were photo 
converted with a 405 nm laser within the nigrostriatal pathway, causing their emission spectra to 
convert from a green 488 nm fluorescence to a red fluorescence at 546 nm.  All videos were obtained 




































4.1 INTRODUCTION  
 
4.1.1 Ageing and mitochondrial trafficking 
 
During ageing, mitochondrial biogenesis, dynamics and turnover by mitophagy are not 
efficiently maintained, contributing to cellular senescence (Seo et al., 2010).  
Dysfunctional mitochondrial dynamics are observed during neurodegeneration in Charcot-
Marie-Tooth Neuropathy Type 2A (CMT2A) (Detmer and Chan, 2007), Alzheimer’s disease (AD) 
(Zhu et al.,  2013), PD (Spillantini et al.,  1998, Kamp et al.,  2008) and Huntington’s disease (HD) 
(Wang et al., 2008). For example, β-amyloid (Aβ)-containing plaques trigger mitochondrial 
damage as well as alterations to mitochondrial structure which contributes to AD pathogenesis, 
while APP overexpression causes mitochondrial fragmentation, via alterations of mitochondrial 
fusion and fission proteins in neurons (Wang et al., 2008). 
 
4.1.2 Alpha – synuclein structure and function  
 
The neuropathology of PD is characterised by the presence of Lewy bodies (LBs). These 
eosinophilic, cytoplasmic inclusions are predominantly composed of aggregated alpha–
synuclein (α–syn) protein (Lewy, 1912, Spillantini et al., 1998). SNCA (PARK1 [Chromosome 
4q22]) encodes α-syn, and mutations within this gene have been associated with cases of 
familial PD (Polymeropoulos et al., 1997 , Devoto and Falzone, 2017).  
 
One percent of total neuronal protein is comprised of α–syn, which is densely enriched 
presynaptically (Iwai et al., 1995). α–syn is widely distributed within neurons, located within 
the cytosol, nucleus, mitochondria and mitochondria associated membranes (MAMs) 
( Guardia-Laguarta et al., 2014). α-syn is a 140 amino acid cytosolic protein consisting of three 
different domains, i) the N-terminal amphipathic domain, ii) the non-amyloidogenic 
component (NAC) hydrophobic mid-region, and iii) the acidic domain in the carboxyl tail. The 
N-terminal region consists of six imperfect KTKEGV repeats forming two α-helical structures 
when the protein interacts with lipids (Ulmer et al., 2005). The middle hydrophobic region of 
α-syn confers the oligomerisation properties that drive LB formation in PD (Giasson et al., 
2001). The negative charges in the C-terminal acidic domain confer chaperone-like properties 
supporting this oligomerisation process (Li et al., 2005) (Figure 4.1).  
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α-syn oligomerisation forms fibrils that spread from cell to cell, becoming the predominant 
driving factor that influences its pathogenic effect (Frost and Diamond, 2010,Winner et al.,  









Figure 4.1. Alpha – synuclein structure.  Α–syn is 140 amino acid cytosolic protein harbouring 3 domains, the N-
terminal amphipathic domain, which contains six imperfect repeats (KTKEGV) forming two α-helix structure on 
lipid interaction, the non-amyloidogenic component (NAC) hydrophobic mid-region, and the acidic domain in the 
carboxyl tail. The middle hydrophobic region of α-syn provides the oligomerisation properties driving Lewy body 
formation in PD, supported by the negative charges in the C-terminal acidic domain which hold chaperone-like 




4.1.3 Alpha – synuclein mutations in Parkinson’s disease 
 
α-syn is prone to various post-translational modifications such as ubiquitination, truncation, 
oxidation, and phosphorylation (Oueslati et al., 2010). Functionally, monomeric α-syn is soluble 
within the cytoplasm of presynaptic terminals. Here, it may be phosphorylated, causing its 
accumulation, and formation into insoluble oligomeric or fibrillary aggregates that cannot be 
processed by quality control pathways. These aggregates can be seen within neurites and/or 
cell bodies (Giasson et al., 1999). Although the exact mechanism behind the conformational 
change in α-syn which leads to its accumulation into LBs in sporadic PD is currently unknown, 
mutations within the gene also change its structure, providing insight into a model for its 
aggregation and spread. SNCA mutations associated with familial PD often occur within the N-
terminal region. Previously described mutations lead to α–syn aggregation and include those 
leading to the following amino acid changes: A30P, A53T, A53E, E46K, H50Q and G51D 
(Polymeropoulos et al., 1997, Pasanen et al., 2014).  
One of the most common familial PD associated SNCA mutations is A53T, identified in 12 
families of Greek, Korean and Swedish origin, which arises from a genomic G51D mutation 
(Polymeropoulos et al. 1997, Athanassiadou et al.,  1999, Spira et al.,  2001, Klein and 
Westenburger, 2012). The onset of PD in these patients ranges between 30–50 years, earlier 
than idiopathic PD which generally occurs over the age of 60 (Pozo Devoto et al.,  2017). The 
A53T mutation disrupts the alpha-helical conformation of the protein (Polymeropoulos et al., 
1997) (which aids beta-sheet formation) proceeding onwards to perturb tertiary protein 
structure.  
The A30P α–syn variant was first observed within a German family and arises from a genomic 
G88C missense mutation (Kruger et al.,  1998). Though the A30P mutation is prone to causing 
self-aggregation at a slower rate than A53T mutated α-syn, it still aggregates faster than wild 
type human α-syn (Giasson et al., 1999,  Conway et al., 2000). The E46K mutation has also been 
shown to give rise to early onset Parkinsonism (Krüger et al., 2001, Zarranz et al., 2004). SNCA 
multiplication, another gene variant, was initially identified as a SNCA triplication in a family 
with autosomal dominant PD. The average disease onset for this mutation was 34 years of age 
(Singleton et al.,  2003). SNCA triplication results in an early onset and more aggressive form 
of, whereby patients harbouring an α–syn triplication have earlier PD onset in comparison to 




4.1.4 The effect of alpha- synuclein on mitochondrial bioenergetics  
 
α-syn has been suggested to directly modulate mitochondrial complex I activity, with some 
researchers suggesting that wild-type, natively unfolded α-syn can be transported inside the 
mitochondrion, where it inhibits complex I activity (Liu et al.,  2009, Luth et al.,  2014), possibly 
through direct association with the protein complex (Devi et al.,  2008).  
 
In mice overexpressing α-syn (harbouring the familial A53T mutation) in DAergic neurons, 
complex I was found to be inhibited (Chinta et al., 2010), further illustrating that α-syn has a 
physiological role in regulating complex I activity (Loeb et al., 2010). 
 
Contrastingly, Banerjee and colleagues found that neither WT nor mutant α-syn has any effect 
on complex I activity (or other respiratory chain complexes), instead finding that WT and 
mutant forms of α-syn triggered a depolarisation of the mitochondrial membrane potential 
(Banerjee et al.,  2010). Reeve et al. (2015) supported these findings showing that α-syn reduces 
mitochondrial membrane potential, though interestingly not within cells already expressing a 
complex I deficit (Reeve et al.,  2015). 
 
4.1.5 Alpha – synuclein favours curved membranes 
The toxic effect of α-syn, particularly within the synapses of dopaminergic neurons, may be 
driven by its preferential interaction with curved membranes, i.e. those of synaptic vesicles and 
mitochondria.  
α-syn is referred to as  a "curvature sensing" protein (Drin et al.,  2010, Pranke et al.,  2011) as 
it becomes involved through electrostatic interactions with phospholipid bilayer head groups 
(Jensen et al.,  2011). The reason why α-syn favours curved membranes such as mitochondria, 
may be due to errors in the packing of protein binding sites of the phospholipid bilayer which 
results in anexposed hydrophobic acyl chain that forms a binding site (Pranke et al.,  2011). As 
the organisation of these is vital in maintaining membrane polarity, changes in this composition 





4.1.6 The role of alpha – synuclein in mitochondrial trafficking 
 
In vivo, in α-syn expressing zebrafish, it was shown that the movement of axonal mitochondria 
was reduced within α-syn expressing axons, and within the population of motile mitochondria, 
there were more retrograde than anterograde movements (O’Donnell et al., 2014).  
 
α-syn overexpression in human-derived neurons has been shown to lead to the development 
of dysfunctional anterograde and retrograde mitochondrial movements (Pozo Devoto et al.,  
2017). It is thought that α-syn perturbs mitochondrial movement by interacting with kinesin-1 
(Utton et al., 2005) and interrupting mitochondrial associations with microtubules (Prots et al., 
2013). Aggregated WT α-syn in Lund Human Mesencephalic cells (LUHMES) was found to 
reduce kinesin-driven microtubule motility (Prots et al., 2013). The number of active motors 
interacting with microtubules is regarded as the overall mechanism dominating how organellar 
transport is controlled (Leidel et al., 2012, Fu and Holzbaur, 2014, Lacovich et al.,  2017). 
Therefore, defects in mitochondrial function in PD may be triggered by excessive levels of α-
syn or by its abnormal aggregation.  
 
4.1.7 Transgenic alpha – synuclein mouse models 
 
4.1.7.1 Knockout mouse models  
The first α-syn knockout mice model showed evidence of reduced striatal DA levels alongside 
motor phenotypes. Reduced locomotor activity in new open-field surroundings were observed 
in α-syn null mice, alongside increased locomotor behaviour on amphetamine administration 
(enhances motor behaviour via increasing DA release), (Abeliovich et al.,  2000). Secondly, in 
individual knockout mice (generated in 2002), these mice were unaffected by both acute and 
chronic MPTP intoxication (complex I inhibitor), though primary neuronal cultures derived from 
the same mice displayed sensitivity to rotenone (Dauer et al., 2002). The authors concluded 
that this MPTP resistance may be due to reduced MPP+ entry via DAT and/or increased storage 
of MPP+ within vesicles. Similarly, a third knockout also model also showed some protection 
against MPTP-induced striatal DAergic loss (Schluter et al., 2003) when the α-syn locus was 
deleted in a subpopulation of C57Bl/6J mice (Specht and Schoepfer, 2001). Of these 3 models, 




understanding of phenotypic alterations in α-syn knockout models. Research by both the Dauer 
et al.,  (2002) and Schluter et al.,  (2003) labs indicate that though MPP+ inhibits complex I, 
perhaps in the absence of α-syn, mitochondrial dysfunction in PD can be perhaps be rescued, 
if not stabilised.  
 
4.1.7.2 Alpha – synuclein over expression mouse models 
Mice overexpressing α-syn have been generated, using different promoters to drive transgene 
expression. All the mice, express WT or mutated forms of the human α-syn protein.  
 
The first human α-syn overexpressing mouse model, expressed α-syn under the control of the 
platelet-derived growth factor– β (PDGF-β) promoter (Masliah et al., 2000). The PDGF-β 
promoter was chosen as it had been successfully used to drive human α-syn mRNA expression 
in the brain of several lines of transgenic mice (Games et al., 1995). In this experiment, mice 
were generated with varying levels of transgene, where mice from ‘line D’ displayed the highest 
levels of human α-synuclein mRNA and protein (Masliah et al., 2000).  
 
The Line D transgenic mice displayed intraneuronal inclusions within synuclein dense regions 
in the deeper layers of the neocortex, CA3 region of the hippocampus, olfactory bulb and 
occasionally the SN (Masliah, 2000) (Figure 4.2). Furthermore, within the neurons of the line D 
mice (2 to 3 months of age) electron-dense deposits were identified associated with the rough 
ER, indicative of α-syn-ER localisation. TH-positive nerve terminals within the striatum were 
significantly reduced in line D mice though cell body degeneration was not observed in the SNc. 
The transgenic mice also had lower striatal TH levels and enzymatic activity suggesting that the 
accumulation of human α-syn may lead to injury of nerve terminals and synapses in the absence 
of overt neuronal loss (Masliah et al., 2000).  
 
As the loss of DAergic neuronal input to the striatum is associated with PD–related motor 
impairments (see Chapter 1, section 1.8.6) rotarod tests were conducted at 12 months (Forster 
et al., 1999). Line D mice showed impaired motor performance compared to the low expression 





Later, Hashimoto et al., demonstrated a 25–50% reduction in striatal DA within mice of 12 
months of age, indicating that functional defects in α-syn expressing mice may be age-
dependant (Hashimoto et al., 2003). The PDGF transgenic mice also demonstrated α-syn 
expression within glial cells (Iwai et al., 1995a,b), where α-syn has been shown to accumulate 
in glial cells in dementia with Lewy bodies (DLB) (Takeda et al.,  2000, Piao et al.,  2000).  
 
The second model generated, expressed A53T α-syn regulated by a murine Thy1 regulatory 
sequence. Early and dramatic decline of motor function was observed in mice < 3 weeks of age, 
where a harsher motor phenotype was observed in a male mouse that died at 5 weeks (van der 
Putten et al., 2000). Neuropathologically, α-syn and ubiquitin-positive inclusions were only 
identified, within the spinal cord during motor neuron degeneration (Sommer et al., 2000, van 
der Putten et al., 2000). The overall lack of nigral pathology could possibly be due to insufficient 
transgene expression within the nigrostriatal pathway.  
Mouse lines expressing wild-type or A30P α-syn under the control of the Thy-1 promoter 
displayed A30P α-syn accumulation in the cerebellum, SNc, neocortex, and brainstem but no 
motor phenotype (Kahle et al., 2000). Mice expressing WT, A30P or A53T α-syn under the 
control of the rat TH promoter, presented high levels of expression in the SNc but did not 
display changes in the levels of striatal dopamine regardless of α-syn accumulation within 
DAergic neurons (Matsuoka et al.,  2001). Mice expressing wild-type or α-syn with a double 
A30P and A53T mutation under the rat TH promoter, demonstrated increased DAergic 
transporter (DAT) density and increased MPTP vulnerability (Richfield et al.,  2002). Reduced 
DA striatal levels were found in addition to decreased locomotor activity and coordination 
















Figure 4.2. Alpha–synuclein neuropathology in human α-synuclein expressing transgenic mice. Human α-syn 
immunoreactivity (black arrows) observed in the cytoplasm of SNpc neurons in transgenic mice (Figure taken from 
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4.1.8 Selecting an alpha-synuclein mouse model in which to observe mitochondrial trafficking 
 
To allow the study of the effect of α-syn pathology on mitochondrial movement within the 
nigrostriatal pathway, it was imperative to select a model that accurately reflected PD 
associated α-syn pathology. 
 
The above mouse models were all compared to understand which model would be best suited 
for this study. Of all the models, it was noted that the PDGF-β transgenic mice demonstrated 
higher, more widespread transgene expression. This is beneficial as transgene expression was 
reported within neuronal and glial cells in cortical and subcortical brain regions (Rockenstein et 
al., 2002) unlike the Thy-1 promoter. Human α-syn under the control of the PDGF-β promoter 
also showed α-syn accumulation in synapses of the neocortex, limbic system, and olfactory 
regions in addition to the generation of inclusion bodies within neurons in the deeper layers of 
the neocortex. Additionally, Masliah et al., (2000) showed that in Line D PDGF-β transgenic mice   
decreased TH striatal activity and DAergic loss were observed. Motor impairments were also 
observed at 12 months of age, altogether suggesting that this transgenic mouse model largely 
represented a PD phenotype and was therefore selected as model to use in this current study 
to generate human wild type α-syn expressing Dendra2/DATCre mice.  
 
4.2 AIMS OF THIS STUDY 
 
This study involved observing mitochondrial trafficking within i) a control group to observe the 
effects of ageing on mitochondrial trafficking and ii) and an α-syn expressing cohort,. Using the 
ex vivo slicing method described previously in Chapter 3, this study observed patterns of 
mitochondrial trafficking within nigrostriatal slices expressing mito-Dendra2. To interrogate 
these aspects this study fulfilled the following aims, 
• To record mitochondrial trafficking in mito-Dendra2 within the DAergic neurons of the 
nigrostriatal pathway within aged and human α-syn expressing mice (Masliah et al., 
2000). 
• To quantify directionality of mitochondrial movement through kymograph analyses 




4.3 METHOD & MATERIALS 
4.3.1 Identifying mitochondria within dopaminergic neurons 
 
4.3.1.1 Ageing studies 
Mito-Dendra2 mice were crossed with a DAT-Cre mouse line obtained from The Jackson 
Laboratory. Cre expression, regulated by the dopaminergic (DAT) transporter ensured Dendra2 
expression was only observed within DA neurons. In Mito-Dendra2 mice, mitochondria are 
labelled and emit bright green fluorescence at 488nm (Pham et al., 2012). Mice were aged for 
experiments (Table 4.2).  
 
4.3.1.2 Alpha-synuclein studies 
The Mito-Dendra2/DATCre mice were then crossed with human wild type α-syn mice (provided 
by Dr. Chris Morris, Newcastle University) under the PDGF promoter (Masliah et al., 2000) and 
were aged for experiments (Table 4.2). The initial study design included the analysis of 
mitochondrial movement in young and aged SNCA mice, however this then had to be altered. 
Unfortunately, the ageing SNCA mice had to be prematurely culled as a precaution after Mouse 
Parvovirus was detected by a sentinel animal, within the animal house. Therefore, these mice 
could not be aged for an equivalent time period as those in the wild-type aged cohort.  
4.3.2 Genotyping mice  
Genotyping protocol of the Dendra, Cre and α-syn expressing mice is described in Chapter 2, 
section 2.3. 
4.3.3 Mouse dissection  
The brains of experimental mice were collected on the day of experiment and all procedures 
were performed according to the requirements of the UK Animals Scientific Procedures Act 
(1986). Mouse brains were collected following Schedule 1 cervical dislocation. This study aimed 
to understand mitochondrial trafficking within old vs young control animals and then in human 
α-syn over-expressing animals. Table 4.2 describes the genotypes of the mice used within this 
study. Power calculations were performed as part of the experimental design. To be able to 
detect a predicted 20-30% reduction in mitochondrial motility, a minimum of 4 animals per 
cohort were required for experiments. This calculation assumed a standard deviation of 20, 
with a power of 0.8 and significance level (alpha) of 0.05. Thus, in order to be able to compare 
mitochondrial movements with sufficient power to detect differences in the data an N=5 was 





Table 4.2. Details of mice used in this experiment 




FEMALE HetCre/HomDendra 24.08.15  
 
Old control 












FEMALE HomCre/HetDendra 06.08.15 21 months 
FEMALE HetCre/HomDendra 07.11.15 19 months 
FEMALE HetCre/HomDendra 06.11.15 19 months 
FEMALE HetCre/HomDendra 06.11.15 19 months 
 





MALE HomCre/Hom Dendra   21.09.16 10 months 
FEMALE HetCre/HetDend 04.11.16 8 months 
FEMALE HetCre/HomDend 04.11.16 8 months 
MALE HetCre/HetDend 04.11.16 8 months 
 










FEMALE HomCre/HetDend/ SNCA 04.11.16 10 months 
MALE HomDendra/HetCre/ 
SNCA   
02.02.17 9 months 
MALE  HomCre/Hom Dendra/ 
SNCA 
02.02.17 9 months 
FEMALE  HetDendra/HetCre/ SNCA 06.03.17 9 months 
FEMALE HetDendra/ HetCre/ SNCA 14.09.17 7 months 
MALE HetCre/HetDendra/ SNCA 18.10.17 6 months 
MALE HetCre/HetDendra/ SNCA 18.10.17 6 months 
MALE HetCre/HetDendra/ SNCA 18.10.17 6 months 










4.3.4 Ex vivo imaging of the nigrostriatal pathway 
 
Chapter 3 describes the protocol which was followed for the imaging of the nigrostriatal 
pathway in this study. The methodology is summarised below.  
 
Once removed, the mouse brain was submerged in cold (4–5°C) sucrose solution, then sliced 
to obtain to obtain the nigrostriatal pathway and mounted onto the vibratome to generate 
300µm thick sections.  Slices were then transferred into holding chamber containing artificial 
cerebrospinal fluid (ACSF), maintained at room temperature between ACSF and warm, moist 
carbogen gas (95% O2/5% CO2). Slices were allowed to equilibrate on the holding chamber for 
30 minutes. An ACSF perfusion system was created on the Inverted confocal system throughout 
the entire imaging session. Nigrostriatal slice movement within ACSF solution was stabilised 
with a slice anchor (Warner Instruments) and maintained at 37°C. All videos were taken at 1 
frame/second for 10 minutes.  
  
4.3.5 Imaging mitochondria in the nigrostriatal pathway  
Mito-Dendra2 positive fluorescent mitochondria were imaged in the axons of the nigrostriatal 
pathway, using a 488 nm laser. Mitochondrial movements were observed via videos captured 
at 1 frames/second for 10 minutes at x20 magnification. Around 3-10 axons were analysed per 
video. 
4.3.6 Nigrostriatal axonal kymographs 
Kymograph analyses was conducted to analyse mitochondrial movement within nigrostriatal 
axons, methods for which are described in Chapter 3.  For this thesis mitochondrial movements 
was classified into ‘stationary’ and ‘moving’.  
 
4.3.7 Justification of statistical analyses of ex vivo mitochondrial movement 
A mixed-effect regression model was undertaken by Dr Alasdair Blain (Wellcome Centre for 
Mitochondrial Research) to model the effect of ageing/α–syn on mitochondrial speed and distance 
whilst accounting for any variation between mice by including them as a random effect within the 
model. The data was decided to be plotted as logged values for visual aid only, due to the range in 
mitochondrial movement. Given the outliers found in the data, logging values would distort the 
normal data plots. All data is presented as box and whisker plots that show the distribution of 
mitochondrial speed and distance values for moving mitochondria for all individual mice, in control 




as travelling above 0.005 µm/s and further than 0.01 µm/s. Calculating a linear regression for these 
experiments does not account for variation between the mice in each group. Therefore, a mixed-
effect model was applied to understand significant differences between mice groups. Table 4.3 is an 
exemplar mixed model effects statistical table which assays mitochondrial movement in all mice 




Akaike Information Criterion (AIC) (yellow highlight) is used to compare model performance 
with a lower AIC value for the mixed-effect model (from 13023 for a linear regression model to 
12817 for the mixed model) indicating an improved model fit.  
The Bayesian information criterion (BIC) allows model selection between more than two 
models. During model selection, the goodness of fit will indicate how well it fits a given set of 
data. For this, the BIC value is calculated for each model where the lower the BIC value, the 
better the fit. During the process of fitting these models, AIC and BIC are utilised to ensure that 
‘overfitting’ (a model containing more parameters that what the data can justify) does not 
occur via a penalty term for the number of parameters in the model. This BIC value must be 
greater than the AIC value.  
The maximum likelihood function allows the estimation of how within a statistical model the 
observed data is most likely to occur. This is easier to conduct via the negative of the natural 
logarithm of the likelihood function, Loglik. Here, maximising the likelihood is converted to 
finding the minimised negative log-likelihood value, where smaller values of the negative log-
likelihood signify a better fit. Lastly, the degrees of freedom (DF) indicate that when fitting a 







4.4.1 Generating kymographs in nigrostriatal slices 
 
To observe the movements of Mito-Dendra2 labelled mitochondria, time lapse imaging was 
conducted at (1 frame/second) on DAergic neurons of the nigrostriatal pathway within ex vivo 
brain slices. Since this is the first time that mitochondrial movements have been recorded 
within nigrostriatal slices, it was important to ensure that the videos taken generated 
representative kymographs when analysed. To further ensure that kymograph analysis 
accurately measured mitochondrial movements within the experimental setup steps were 
taken to ensure that false ‘movements’ from background pixels or slice drift were removed.  
 
Kymographs were generated for the duration of each of the 10-minute videos, thus providing 
a measure of speed for each individual mitochondrion, within single nigrostriatal axons (Figure 
4.3). Figure 4.3B and 4.3C show representative kymographs generated from a nigrostriatal slice. 
While the kymographs were able to track the movements of individual mitochondria, no large 
movements in either direction were observed, instead it was found that the mitochondria 
exhibited an ‘arrested’ movement state (remaining stationary throughout live imaging) (Chen 
et al.,  2016).  
 
To ensure that background was not being detected in these videos, and that accurate tracking 
of mitochondria within axons was achieved, areas without the mito-Dendra2 fluorescence were 
also measured to be sure that nonspecific kymographs based on ‘background noise’ pixels, 
were not created (Figure 4.3D). As slices within the glass bottom dish are retained in ACSF, 
drifting may occur throughout the video, whereby the slice may drift away from the region of 
its origin (though this is minimised by the use of the slice anchor), therefore kymographs were 
also generated for these videos. Kymographs based on these videos were then used to ensure 
that experimental data was only collected from videos with no drift. From this analysis, videos 
that exhibited nigrostriatal drifting were excluded due to incorrect kymograph generation 







Figure 4.3. Kymograph creation within nigrostriatal slices. The kymographs were measured within videos which 
were obtained at 1 frame/second over 10 minutes. A) Videos generated from highlighted regions (white boxes i-
iv) in videos. B-C) Kymographs demonstrate mostly stationary mitochondria within nigrostriatal axons. D) No 
kymograph is generated within a region of the video that does not contain mito-Dendra2 fluorescence.  E) 










4.4.2 Effect of ageing on mitochondrial movement with nigrostriatal slices 
 
The primary risk factor for PD is advancing age (Collier et al., 2012). The impairment of 
mitochondrial movement in neurons with advancing age might impact not only neuronal 
function but also survival. Thus, in order to understand the effect of ageing on mitochondrial 
motility, mitochondrial movements within the nigrostriatal pathway were recorded and 
analysed and compared between young (8-10 months) and old (19-21 months) wild-type mice 
(Table 4.2) (Figure 4.4). 
 
Using kymograph analysis, the movements of 2120 mitochondria from 10 mice were 
characterised, where most mitochondrial movements within dopaminergic neurons of ex vivo 
slices occurred at speeds between 0 – 0.005μm/s.  Based on previous experiments (Misgeld et 
al.,  2007, Ohno et al.,  2011, Takihara et al.,  2015), mitochondria with speeds below 0.005μm/s 
were defined as ‘stationary’, while any which moved with a speed greater than this were 
described as ‘moving’ (Figure 4.5). 
 
In young mice, 14.82% of the total mitochondrial population were classed as moving and 
exhibited a mean speed of 0.008 μm/s (mean of moving mitochondria only), while in old mice 
23.15% of nigrostriatal mitochondria were defined as moving with mean speed of 0.042 μm/s. 
The average speed of moving mitochondria did not significantly differ between young and old 
mice (p=0.15). Furthermore, the mean distance travelled of moving mitochondria in young 
mice was 1.906 μm, (with a standard deviation of 2.109) versus 1.901 μm (standard deviation 
3.232) in old mice, with no significant changes were detected between young and old 
nigrostriatal slices by mixed effect statistical modelling (Figure 4.4 and 4.5).  
 
The range of mitochondrial speed for the aged wild type mice ranged from 0 - 0.251 μm/s. 
indicative of large variation of mitochondrial speed within the moving mitochondrial 
population, which could be due to i) young cohort mice 1, 3 and 5 demonstrating higher speeds 
or ii( old cohort - old mouse number 5, which shows increased speed compared to the 
remaining 4 mice. Large intra-animal variability was observed within this experiment and was 
expected due to the nature of ex vivo experiments (See Chapter 3), this variability was taken 










Figure 4.4. Box and whisker distribution plot of the speed and distance travelled of mitochondria in young vs 
old mice. Values are logged to aid visualisation. A) Speed of moving mitochondrial movement for young mice. 
14.82% of these mitochondria were classed as moving and exhibited a mean speed of 0.008 μm/s. B) Speed 
of moving mitochondrial movement for old mice. 23.15% of these mitochondria were classed as moving and 
exhibit a mean speed of 0.042 μm/s. C) Mean distance travelled of moving mitochondria in young mice = 
1.906 µm, SD 2.109 versus. D) Mean distance travelled of moving mitochondria in old mice = 1.90 µm, SD 
3.232. Mixed effect statistics model shows no significant changes in the mitochondrial speed or distance 






























Figure 4.5. Proportion of mitochondrial movements in young vs old mice. A) Statistics table for each mouse (2-3 
slices) used in this study comparing: number of mitochondria (N) observed within each experiment, number of 
moving mitochondria of the total mitochondria and their mean speed, and lastly the number of stationary 
mitochondria. B) Proportion of mitochondria that are moving versus stationary within individual young and old 






















4.4.3 Effect of alpha-synuclein on mitochondrial movement with nigrostriatal slices 
 
The characteristic pathological hallmark of PD is the presence of Lewy bodies (Spillantini et al., 
1998). Previous research has suggested that α–syn may interact with mitochondria and disrupt 
their movements (Prots et al., 2013). Thus, having characterised mitochondrial movement in 
aged nigrostriatal slices it was important to explore the effects of PD pathology on 
mitochondrial movement within these slices.  
 
Following the ageing study, mitochondrial movements were characterised in nigrostriatal ex 
vivo brain slices from α–syn over-expressing animals (aged 6-10 months). The speed of 2117 
individual mitochondria were measured in ten experimental animals, again the observation was 
made that the majority of mitochondria were stationary (88.6%), with only 11.40% of the total 
















Figure 4.6. Box and whisker distribution plot of the speed and distance of mitochondrial movement in alpha 
synuclein mice.  Values are logged to aid visualisation A) Speed of moving mitochondria for α–syn mice. 11.40% of 
these mitochondria were classed as moving and exhibited a mean speed of 0.015 μm/s. B) Mean distance travelled 
of moving mitochondria of α–syn mice = 1.593, SD 2.041. Mixed effect statistics model shows no significant 
changes in the mitochondrial speed or distance travelled within α–syn mice.   C) Statistics table for each mouse 
used in this study comparing: number of mitochondria (N) observed within each experiment, number of moving 
mitochondria of the total mitochondria and their mean speed, and lastly the number of stationary mitochondria 






4.4.4 The effects of ageing and PD pathology on mitochondrial movement 
 
Having characterised mitochondrial movements in both cohorts of mice, the final aim of this 
study was to understand how mitochondrial movement was affected by the involvement of 
two PD risk factors i) ageing and ii) alpha synuclein.  
Having compared the effect of ageing on wild type mice and having characterised 
mitochondrial movements in α–syn mice, it was important to compare both groups of mice to 
understand how these important PD related changes impact mitochondrial movement.  
 
4.4.4.1 Mitochondrial distance travelled   
 
When the distance travelled by mitochondria was compared between all wild-type (young and 
old), and α–syn expressing mice, no significant changes were observed. Though it appears that 
the expression of human α–syn compromises the distance covered by mitochondria when 
compared to only the aged mice (reducing mitochondrial movements by approximately 0.5 
µm), though these changes were not significant (Figure 4.7).  
 
4.4.4.2 Mitochondrial speed 
 
When the speed of moving mitochondria was compared, it was found that the number of 
moving mitochondria was higher in young mice 14.82% versus age-matched α–syn mice 
(11.40%). Moving mitochondria were observed in both groups of mice although the mean 
speed in young wild-type mice was lower (0.008 μm/s) than in age-matched α–syn mice (0.015 
μm/s), however neither of these changes were significant (Figure 4.8).    
When comparing the number of moving mitochondria in old wild-type mice (23.15%) versus α–
syn mice (11.40%). Fewer mitochondria were found to be motile in α–syn mice and those which 
did move displayed a decreased mean speed (0.015 μm/s) compared to the aged wild-type 
mice. Although these differences were significant (p<0.0001: mixed effects model testing), 
these mice were not age-matched and therefore experiments must be repeated with aged-









Figure 4.7. Box and whisker distribution plot of the distance travelled of mitochondria in aged and alpha synuclein 
mice.  Values are logged to aid visualisation. A) Mean distance travelled of moving mitochondria in young mice = 
1.906 µm, SD 2.109 versus B) Mean distance travelled of moving mitochondria in old mice = 1.90 µm, SD 3.232.  
No significant changes were observed between how far mitochondria move in young and old mice. Mean distance 
travelled for all aged mice = 2.137 µm, SD 3.162 C) Mean distance travelled of moving mitochondria of α–syn mice 
= 1.593, SD 2.041.  D) Mixed model table shows intercept that represents the aged mice and indicates that 








Figure 4.8. Box and whisker distribution plot of the speed of mitochondrial movement in aged and alpha synuclein 
mice.  Values are logged to aid visualisation. A) Speed of moving mitochondrial movement for young mice. 14.82% 
of these mitochondria were classed as moving and exhibited a mean speed of 0.008μm/s. B) Speed of moving 
mitochondrial movement for old mice. 23.15% of these mitochondria were classed as moving and exhibit a mean 
speed of 0.042 μm/s. C) Speed of moving mitochondria for α–syn mice. 11.40% of these mitochondria were classed 
as moving and exhibited a mean speed of 0.015 μm/s. A mixed effect statistic model was carried out to show 
significant changes in the speed of moving mitochondria in old aged mice versus α–syn mice (p<0.0001). D) The 
model intercept represents the aged mice. The results of the mixed-effect model suggest that α–syn mice move 









4.5 DISCUSSION  
 
4.5.1 Summary of results 
 
• Considerable variation exists in mitochondrial movements between individual mice 
• No differences were observed in mitochondrial movements in young versus old aged 
mice within nigrostriatal axons  
• Mitochondria within mice overexpressing human wild-type alpha-synuclein are not 
significantly different to age matched wild-type mice (young) in terms of their 
movements. 
• Young alpha-synuclein mice are significantly different from old wild-type mice, 
highlighting the need for further studies with appropriately aged alpha-synuclein mice.  
 
4.5.2 Variability in mitochondrial movement observed between mice in this study 
 
It must be understand that due to the nature of ex vivo experiments and also the pattern of 
mitochondrial movement; large variability in movement is observed both within mice and 
between mice. Instances of the latter were observed in the movement of mitochondria in 
young and old mice. For example, within the ageing experiment in the young cohort, the 
mitochondrial speeds of mouse 1 and 3 were very different in comparison to mice 2,4 and 5. 
Similarly,  in the old cohort, old mouse 5 demonstrated different results in comparison to the 
remaining 4 mice, suggesting variability in mitochondrial movement between the mice. These 
differences will have an effect on the results of this chapter.  
 
4.5.3 Understanding mitochondrial motility in ex vivo nigrostriatal axons 
  
Various previous studies have provided insight into the movement of mitochondria within 
DAergic neurons (PI et al., 2014, Fang et al., 2016, Dukes et al., 2017), however this is the first 
study to provide information regarding mitochondrial trafficking within mammalian DAergic 
neurons within nigrostriatal slices. Individual DAergic nigrostriatal axons were imaged to 
observe and quantify mitochondrial movements and how these altered with ageing and in a PD 
model. Results from these experiments demonstrated that within both young and old mice, 





Several studies have observed live mitochondrial movement in the peripheral and central 
nervous system (CNS). These studies have documented only the details of the percentage of 
stationary mitochondria, where investigation into other attributes such as mitochondrial speed 
and distance have only been briefly described (Table 4.3). Only one in vivo study has analysed 
mitochondrial movements in the CNS, and described 93% of mitochondria as being stationary 
within cortical neurons of mice (Lewis et al.,  2016), the speed and distance travelled of these 
mitochondria were not documented. A further three studies that were conducted in CNS rat 
and mouse explants showed that 60-100% of mitochondria remained stationary within 
hippocampal and retinal ganglion cells respectively (Jackson et al.,  2014, Faits et al. ,2016).  The 
mean speed of moving mitochondria was 0.132 ± 0.067μm/s (n = 66 mitochondria) and the 
Jackson et al.,  (2014) study showed that over 15 minutes the  average mitochondria speed was 
0.15μm/s, with a maximum distance travelled of 5μm.  Mitochondria are known to be held at 
discrete sites within neurons to provide localised ATP for a number of processes and protein 
interactions, this is particularly important for synaptic transmission and maintenance of ionic 
gradients within the axon. Thus, it makes sense that the majority of the mitochondrial 
population within these neurons would be stationary (Morris and Hollenbeck, 1993, Miller and 
Sheetz, 2004, Hollenbeck and Saxton, 2006). (Also see Table 4.4 for references for in vivo 
mitochondrial movement in mouse models). 
 
Several factors affect mitochondrial localisation within neurons, some of which include the size 
of the neurons, neuronal metabolic activity and ageing. Interestingly, the size of stationary sites 
and the speed of mitochondrial transport are significantly increased following demyelination of 
axons (Kiryu-Seo et al., 2010), which may play an important role within the poorly myelinated 
DA neurons of the nigrostriatal pathway (Braak et al., 2004). Extended neuronal processes in 
the periphery present a challenge, in terms of mitochondrial distribution to the required sites, 
particularly since an inability to preserve mitochondrial dynamics within neurons can have 
detrimental effects on neuronal function and physiology (Schon and Przedborski, 2011). In this 
case, it is vital for neurons to sustain mitochondrial networks that are reliable and are capable 
of providing ATP to distant synapses, whilst adapting to changes in energy demand.  
The study described here, attempted to provide information into how mitochondria move 
within CNS DAergic neurons via ex vivo imaging. This experiment was the first in which imaging 




mitochondrial dynamics in PD.  This experiment revealed that in young, old and α–syn mice 
(aged 6-21 months) around 76 -100% of mitochondria remain stationary, with the mean speed 
of this movement ranging between 0.008 – 0.042 μm/s, though this speed is lower than what 
is described in the literature for over 10 minutes of imaging. The variations between these 
results and previously published data, may depend on several aspects of the experiment, 
including the length of the axon measured, number of frames taken during the video and the 
length of the video. Frame rate have shown to vary across in vivo studies i.e in the Faits and 
Jackson study the frame rate ranges from 0.6 to 6 frames per second. This study carried out 
imaging for 10 minutes and obtained videos mostly at 1 frame per second. In any slice study 
variability is bound to occur due the nature of the slice and maintaining its viability throughout 
imaging. Though differences in movement parameters were observed, together this data 
suggests that that neuronal mitochondria remain mostly stationary in vivo, which supports 
current literature observations (Jackson et al.,  2014, Faits et al. ,2016, Lewis et al.,  2016).  
 
Mitochondria that appeared to be stationary in this study (at least for the duration of what can 
be successfully imaged), were thought to perhaps be refreshed in situ by exchanging proteins 
with the motile fraction. Mitochondrial fission and fusion events (Chapter 1, section 1.5.1 and 
1.5.2) are often observed in axons and dendrites allowing the exchange of materials between 
mitochondria (Amiri and Hollenbeck, 2008), where even brief moments of contact can involve 
fusion and the exchange of proteins in each compartment of the mitochondrion, which is also 
evident in non-neuronal cells (Liu et al. 2009). Consequently, due to these factors that go some 
way to explain the sporadic behaviour of mitochondria, developing a system by which in vivo 
mitochondrial trafficking can be captured in an accurate, representative, high-resolution 
manner, has provided to be one of the biggest challenges in understanding mitochondrial 










4.5.4 Ageing does not impact mitochondrial movements within dopaminergic neurons of 
wild-type mice 
 
Though more mitochondrial movement was observed in old mice nigrostriatal axons compared 
to young mice, no significant changes were observed in their mitochondrial speed and distance 
(Figures 4.6 and 4.8).  
 
There are a few possibilities for this occurrence that could be down experimental setup. This 
experiment observed mitochondrial movement in young and old mice, whereby firstly,  the 
ages of these mice were not all exactly the same i.e. not all mice were from a specific age and 
instead were taken from a range of ages young mice (8-10 months) and old mice (19-21 
months). Secondly, these mice were all of mixed genders i.e young mice used were both male 
and female and old mice used were all female. Though not investigated the above two factors 
might affect mitochondrial movement. Thirdly, perhaps the sample size of N=5 was not enough  
to gauge an accurate indication to mitochondrial movement defects with ageing and lastly , 
maybe the mice were in fact healthy and therefore did not display any specific ageing 
phenotypes, (alterations in mtDNA, motor impairment etc) though these were not measured,  
to instigate any alterations in mitochondrial movement. 
 
Biologically, it may be that there exists is a compensatory method allowing efficient 
mitochondrial transport to occur during ageing. Mitochondrial dysfunction occurs within 




of this, which may increase ROS production (Zhang et al., 2010, Suramaniam and Chesselet , 
2014). Oxidative stress has been previously shown to cause decreased mitochondrial transport 
both in vitro and in vivo following paraquat treatment (Liao et al., 2017). Perhaps in this study, 
oxidative stress can lead to or be a consequence of mitochondrial dysfunction. It may be that a 
mechanism exists by which ageing mitochondrial transport defects are regulated within 
nigrostriatal axons.  
 
Direct fibroblast-to-induced neuron (iN) converted cells have been recently manipulated as an 
ageing model (Kim et al., 2019). This model has demonstrated that iNs from older donors show 
evidence of reduced OXPHOS gene expression, reduced mitochondrial density, increased 
mitochondrial fragmentation and reduced mitochondrial coverage (Kim et al., 2019). Thus, it is 
important that future investigations of mitochondrial function and morphology within the aged 
and alpha synuclein mice should focus on whether mitochondrial volume and size affects how 
far mitochondria move. For example, by calculating the mitochondrial sphericity and branching 
via aspect ratio and form factor analyses, it will add valuable insight into whether it is the small 
or larger mitochondria that are being moved and whether harbouring an oxidative defect 
impacts these movements and their mitochondrial distribution.  
 
4.5.5 Alpha-synuclein reduces mitochondrial movement in nigrostriatal axons 
 
This study revealed that between the aged-matched mice number of moving mitochondria was 
higher, at a lower mean speed in young wild type mice when compared to the age-matched α–
syn mice, though these changes were not significant.    
Following this, the effects of ageing and α–syn on mitochondrial movement were analysed.  
This study demonstrated a significant decrease in mitochondrial speed between aged wild-type 
and α–syn overexpressing mice (p<0.0001), with a corresponding decrease in the proportion 
of moving mitochondria within α–syn mice when compared to aged wild-type mice cohort. 
However, to validate these findings, experiments will need to be repeated with aged-matched 
α–syn mice to confirm this.  
A recently, well explored hypothesis is that α–syn mediates changes in mitochondrial transport. 
The mitochondrial transport machinery comprising the Miro/Milton/KHC motor adaptor 




roles for α–syn in this pathway have also been identified. Utton et al., (2005) revealed through 
co-immunoprecipitation studies that α–syn interacts with kinesin-1 (Utton et al., 2005). Also, 
when α-syn oligomerises it has been shown to interrupt kinesin-1 motor interactions with 
microtubules (Prots et al., 2013). As motor association with microtubules regulates 
mitochondrial movement (Lacovich et al., 2017), in the presence of α-syn oligomers, 
microtubule velocity was decreases across kinesin-coated surfaces (Prots et al., 2013). 
Therefore, if α–syn is overexpressed it may cause the dissociation of the kinesins from their 
microtubules decreasing their trafficking properties and thus reducing mitochondrial 
movement parameters (Figure 4.9).  
Furthermore, Parkinson's disease-linked α-syn variants have shown to induce tubulin 
aggregation as opposed to microtubule polymerisation, indicating that α–syn may be a novel, 
foldable, microtubule-dynamase, affecting the organisation of the microtubule network and 
thus inhabiting microtubule based mitochondrial transport (Cartelli et al., 2016).  
Maybe these findings suggest mitochondrial transport defects in PD occur with α–syn 
pathology, but to consolidate these results i) experiments must be repeated in aged-matched 
α–syn overexpressing animals and ii) SNCA levels need to be measured in these mice both 
basally and when over expressing to observe whether wild type SNCA does actually effect 
mitochondrial movement. 
4.5.6 Statistical analyses and graphical representation 
 
Over the course of this study, several statistical tests and various graphical manipulations were 
conducted to ensure that data was being presented in the most accurate  manner. During this 
optimisation several methods were used to firstly quantify mitochondrial movement, which 
were followed by the data being shown as various graphs. As thresholds for the speed and 
distance  of moving and stationary mitochondria  were set , it was observed that these data 
values displayed a very large spread.   To  ensure that visually  this could be depicted in  the 
most representative manner, the values were logged and displayed as box and whisker plots .  
As this was a suitable  method to demonstrate the  results, having perhaps a frequency 
histogram  for these  speed and distance values  of aged versus SNCA mice might  have also 
been a useful way to compare movement data across the cohorts.  This way,  the frequency of 
mitochondria moving at a particular speed/distance could have been directly observed 




Furthermore, this study measured the speed of mitochondrial movement as opposed to their 
velocity. The advantage of measuring velocities over speed are that velocity measures the 
speed with a direction , unlike speed measurements. It will therefore be important to include 
the velocities values so that a measurement of mitochondrial movement and speed can be  
taken simultaneously 
Statistical comparisons were undertaken  between old versus young, and old versus young 
SNCA mice. However, for future work it may be more beneficial to compare all control mice 
(n=10) versus the old (n=5) and young (n=5)  SNCA mice. This is because the ages of the control 
mice match the both ages of the SNCA cohort mice and therefore can be  statistically compared.  
 
4.6 LIMITATIONS OF THE MODEL 
 
• α-syn overexpression has recently been shown to bind curved membraned structures 
as well as to lead to dysfunctional mitochondrial movements (Prots et al., 2013, Pozo 
Devoto et al.,  2017). This study wanted to observe whether α-syn alone can affect 
mitochondrial transport, before delving into whether α-syn mutations could further 
cause mitochondrial movement alterations. For these reasons, this study selected the 
human wild type SNCA PDGF-β transgenic mouse model as the original paper indicated 
widespread transgene expression including neuronal and glial cells in cortical and 
subcortical brain regions (Rockenstein et al., 2002),  α-syn accumulation in synapses/ as 
inclusion bodies within neurons in the deeper layers of the neocortex and in relation to 
dopaminergic neurons and decreased TH striatal activity. Also, motor impairments were 
also observed at 12 months of age, suggesting that this transgenic mouse could 
potentially duplicate a PD model rendering  this wild type  SNCA overexpressor mouse 
model a useful paradigm.  
• Unfortunately, this study did not observe the motor impairments reported at 12 months 
of ages, ( Masliah et al., (2000) and therefore could not associate α-syn pathology with 
motor impairments found within PD.  
• Furthermore, this study did not measure SNCA levels within experimental mice, which 
is a crucial limiting factor to understand whether mice expressed alpha synuclein. 
However, as the original study shows evidence of human α-syn immunoreactivity within 




these α-syn inclusions affect mitochondrial movement, Quantification of SNCA levels 
will be carried out in the future works of this study.  
• The initial project plan included understanding mitochondrial movement in young vs 
old SNCA mice. This study was later eliminated due to the unmatched ages of the mice 
for these experiments as a consequence of the mice being culled as a precaution after 
testing positive for Mouse Parvovirus, detected by a sentinel mouse  
• All mice (both SNCA and control) were of the same mouse strain; C57BL/6. Being from 
similar genetic backgrounds, this strain may have had a role on influencing results 
observed in this study 
 
 
4.7 CONCLUSIONS & FUTURE  WORK 
 
This study explored the effects of ageing and PD pathology within nigrostriatal slices. It was 
found that in aged mice mitochondrial movement is faster in comparison to young mice, and 
in aged SNCA mice mitochondria motility is faster when compared to younger mice. 
Interestingly, it was found that in mice overexpressing human wild type α–syn, mitochondrial 
movement was significantly reduced in comparison to old aged mice, however this was not an 
aged-matched finding and therefore must be repeated to confirm this outcome. This indicates 
that SNCA pathology perturbs mitochondrial movement perhaps more so than ageing. 
Future work in this study will include: 
 
• Analysing mitochondrial morphology within aged and SNCA mice, to understand 
whether α-syn effects their structure and therefore the speed and distance of 
mitochondrial movement  
• Carry out TMRM staining to observe whether α-syn pathology affects mitochondrial 
health within DAergic neurons, and whether this alters mitochondrial directionality in 
PD 
• Quantify α-syn expression within the SNpc in SNCA mice via immunofluorescence to 




































5.1.1 Mitochondrial mutations  
 
Large-scale mtDNA deletions contribute significantly to mitochondrial diseases, ageing and 
neurodegeneration. Pathogenic mtDNA deletions were first discovered in 1988 (Holt et al., 
1988, Wallace et al., 1988). Since this discovery, hundreds of mtDNA mutations have been 
identified in association with mitochondrial disease (http://www.mitomap.org), causing 
defects within the brain and skeletal muscle (Chan, 2006). Different mtDNA 
deletions/duplications have been reported in the development of mitochondrial diseases, 
including Kearns–Sayre syndrome (Zeviani et al., 1988, Shoffner et al., 1989, Moraes et al., 
1989), myopathies (Manfredi et al., 1997, Wong et al., 2003), progressive external 
ophthalmoplegia (Moraes et al., 1989, Wong et al., 2003) and diabetes (Ballinger et al., 1992). 
Around 20% of patients suffering from mitochondrial disease harbour a single large-scale 
mtDNA deletion causative of respiratory deficiency in the mentioned post-mitotic tissues (Tawil 
and Griggs, 2002, Oldfors et al., 2006, Whittaker et al., 2015). Most reported mtDNA deletions 
occur within the major arc of mtDNA (Oldfors et al., 2006), though research in aged muscle 
tissue has identified deletions also within the minor arc (Rygiel et al., 2016). Large-scale mtDNA 
deletions are heteroplasmic and are prone to clonal expansion (Rygiel et al., 2016). 
 
5.1.2 MtDNA deletions in SNpc neurons  
 
Several studies have correlated high mtDNA deletion load within individual SNpc neurons with 
COX deficiency (Bender et al., 2006, Kraytsberg et al., 2006, Reeve et al., 2008 and Dolle et al., 
2016). Furthermore, research has shown an age-related increase in COX-deficient cells in the 
human brain (Cottrell et al., 2001). Bender et al., (2006) showed that COX-deficiency was 
observed within the SNpc of individuals with PD and aged individuals (Kraytsberg et al., 2006, 
Bender et al., 2006).  Further investigation into mtDNA defects within individual SNpc neurons 
leading to COX deficiency described the absence of pathogenic mtDNA point mutations within 
these neurons, where the level of mtDNA deletion was increased in aged controls and 
individuals with PD (Reeve et al., 2008). A real-time PCR assay developed by He et al., (2002), 
calculated a deletion level between 55–60% for these neurons. SNpc neurons with normal COX 




mtDNA, 52% in individuals with PD and 43% in aged controls. The level of mtDNA deletion 
showed a significant correlation with age. Furthermore, the level of mtDNA deletion was 
significantly greater in the COX-deficient neurons than in neurons with normal COX activity, 
confirming that COX deficiency is observed with high levels of deleted mtDNA (Bender et al., 
2006). 
Most recently, Dolle et al., investigated mtDNA deletions, alongside copy-number alterations 
in single SNpc neurons. This study showed that mtDNA copy number increases with age in these 
neurons, consequently maintaining the level of wild-type mtDNA despite deletion 
accumulation. These findings indicate that ageing SNpc neurons upregulate mtDNA copy 
number. This proposes a neuroprotective mechanism within these neurons, which allows 
neurons to maintain wild-type mtDNA molecules, regardless of age-dependent accumulation 
of deletions. However, this upregulation was not observed in individuals with PD, resulting in 
the depletion of the wild-type mtDNA population (Dolle et al., 2016).  
 
5.1.3 Generating dopaminergic neurons from IPSCs   
 
IPSCs can be directly differentiated into midbrain DAergic neurons providing as a useful PD 
model, where pathological studies can be conducted in live neurons (Xiao et al., 2016). Until 
recently, several protocols have attempted to generate these DAergic neurons from 
pluripotent stem cells, which were unsuccessful until researchers began to delve into the 
biology of floor plate tissue. The floor plate of the midbrain is crucial in the development of the 
nervous system within vertebrates, giving rise to nigral DAergic neurons. Here, the ventral 
neural tube degenerates in the spinal cord and hindbrain, whilst survives in the midbrain, thus 
generating midbrain DAergic neurons (Ono et al., 2007).  
Human floor plate cells differentiated from human embryonic stem cells (hESCs) into 
engraftable midbrain DAergic neurons requires the activation of the sonic hedgehog (SHH) 
pathway (Fasano et al., 2010). With the addition of GSK3b inhibitor, CHIR99021 (CHIR), and the 
further activation of the WNT signalling pathway, midbrain floor plates were created (Kriks et 
al., 2011) and differentiated into midbrain DAergic neurons. These neurons cultured in vitro, 
were found to express SNpc markers, such as GIRK2, and exhibit in vivo electrophysiological 
properties observed in SNpc neurons, such as slow spiking (Kriks et al., 2011). On grafting 




viable and functional neurons were identified, where the DA deficiency was rescued in these 
animals (Kriks et al., 2011). Adjusting and optimising the various growth factors supplemented 
to facilitate midbrain DAergic neuron development is critical to producing the desired neuronal 
cell type. Consequently, these protocols have been optimised with either one or two cell lines, 
however the transference of this protocol to other cell lines, would require further optimisation 
and in some cases may not be reproducible (Boulting et al., 2011, Devine et al., 2011). This can 
be controlled for by quantifying neuronal subtypes in differentiated neurons (Dolt et al., 2017). 
5.1.4 Single transcription factor induced functional neurons 
 
The generation of neurons from IPSCs proves a powerful tool to understand neurodegenerative 
mechanisms, although two major limitations have been identified. The first limitation describes 
functional characteristic differences between pluripotent cell lines (Osafune et al., 2008, Hu et 
al., 2009, Bock et al., 2011), where neurons derived from the same protocol from two different 
cell lines can display different properties (Wu et al., 2007). IPSC lines can also exhibit changes 
over time in culture (Mekhoubad et al., 2012). The second limitation comes down to the time-
consuming protocols, as some differentiation protocols can continue for over a month, 
therefore causing a prolonged time to conduct studies (Johnson et al., 2007).  
Zhang et al., 2013 demonstrated that neurogenin-2 (NGN2) overexpression can rapidly convert 
IPSCs into neuronal cells. The forced NGN2 expression converted IPSCs into neuron-like cells, 
in less than one week, which exhibited mature neuronal morphology in less than two weeks, 
quicker than any other available method for generating neurons from human IPSCs. 
Furthermore, almost 100% of surviving IPSCs were converted into neurons, indicating that 
forced expression of a single transcription factor, NGN2 can successfully induce neuronal 
differentiation with high yield. This robust method renders itself highly efficient in comparison 
to the Kriks protocol which comprises of the use of four transcription factors for neuronal 
conversion, under the SMAD (similar to the products of the drosophila MAD genes and the c. 
elegans SMA genes)  inhibition protocol, which spans a 30 day time period (Kriks et al., 2011). 
Moreover, neuronal NGN2 cells can form synapses (Zhang et al., 2013) and could be used 
successfully to observe neuronal plasticity, conduct Ca2+ imaging, as well as be manipulated to 





5.1.5 IPSCs harbouring a large scale mtDNA deletion 
 
Recently, Russell et al., (2018) delved into the methodology of clonal expansion utilising 
reprogrammed single, large scale mtDNA deletion NGN2-IPSCs.  The study described below 
utilised two reprogrammed iPSC lines from Patient ‘A’, a female child with Pearson’s syndrome 
caused by a ~6.0 kb single, large-scale mtDNA deletion spanning m.7777- 13794 removing the 
following genes, COXII, ATPase 6 and 8, COXIII, ND3, ND4L, ND4, ND5, part of ND6 and several 
tRNAs (MT-TK, MT-TG, MT-TR, MT-TH, MT-TS2, MT-TL2). Reprogramming of fibroblasts from 
patient A was conducted using a sendai virus (a single stranded cytoplasmic RNA vector 
[Tokusumi et al., 2002]) and Cyto-Tune-iPS reprogramming kit, yielding 2 clones with of < 10% 
and 40% mtDNA deletion respectively (Russell et al., 2018).  
The long-term culture of these IPSCs showed a consistent increase in mtDNA deletion levels 
over time, where mtDNA heteroplasmy (60%) correlated with an increased respiratory 
deficiency (Russell et al., 2018). In this current study, mitochondrial respiratory complex protein 
expression as well as mitochondrial function was assessed between two cell lines harbouring 
varying levels of mtDNA deletion to confirm the presence of a mitochondrial defect.  
 
5.2 AIMS OF THIS STUDY 
 
1. Confirm presence of the mitochondrial defect reported by Russell et al. in cells used for this 
project through mitochondrial protein complex expression and alterations in mitochondrial 
membrane potential by TMRM staining  
 
2. Differentiate iPSC lines harbouring two levels of large scale mtDNA deletion into 
dopaminergic neurons and quantify the efficiency of this differentiation and whether this 









5.3 METHODS & MATERIALS 
 
Generation of iPSCs from patient fibroblasts harbouring a large scale mtDNA deletion, as well 
their differentiation into neurons are described in detail within (Methods and Materials, 
section 2.1).  
5.3.1 Characterisation of mitochondrial function in low and high heteroplasmy IPSc 
 
5.3.1.1 Cell lysis for western blot 
 
IPSCs were washed with PBS before being scraped off with cell scrapers, followed by 
centrifugation at 350g at 4°C for 10 minutes in ice cold PBS to pellet the cells. The supernatant 
was removed again and the pellet was re-suspended in cell lysis buffer (Table 5.1A), which was 
followed by a 30 second vortex and subsequent 10 min incubation on ice. Lysed cells were then 
centrifuged at 560g at 4°C for 2 minutes, where the supernatant containing cell proteins was 
retained eliminating the cytoskeleton of the cell, snap frozen on dry ice, and stored at -80°C 
until use. Two technical repeats were conducted for western blot experiments. 
5.3.1.2 Bradford assay 
 
Bovine serum albumin (BSA) was used to prepare a standard curve by diluting a gradient of 
volumes (0, 2, 5, 10, 15 and 20μl) of 1μg/μl BSA into 800μL H20. Following this, 1μL of unknown 
sample was also added to 800μl H20, alongside 200μl Bradford reagent. Proteins combine with 
the Coomassie blue under the acidic conditions, triggering a brown to blue colour change, due 
a shift in absorption maximum from 465 to 595 nm, allowing measurement of amino acid 
residues such as arginine, lysine and histidine (Bradford, 1976). Unknown sample protein 
concentrations were determined from values generated from the standard curve. The standard 
curve and samples were placed into an optical bottom plate and wavelengths were observed 
on SpectraMax M3 plate reader. Varying concentrations of BSA, created a standard curve, with 
concentration were plotted on the x-axis and absorbance plotted on the y-axis. The equation 
of the line was re-arranged to calculate the absorbance and therefore concentration of the 






5.3.1.3 Sample preparation and gel electrophoresis 
20μg of low and high heteroplasmy IPSC protein lysates were loaded and separated via gel 
electrophoresis. Lysates were prepared with sample buffer (Table 5.1A) and 10% dithiothreitol 
(DTT) in 200μL PCR tubes. Proteins were denatured by heating samples at 37°C for 30 minutes 
(to observe Complex IV) in order for the efficient transfer of proteins through the gel matrix. 
This was followed by centrifugation at 14,000 RPM for 10 minutes. The SpectraTM multicolour 
broad range protein ladder (ThermoFisher) and protein samples were loaded into 12% Mini-
PROTEAN TGX (Bio-Radx precast gels (Table 5.1B) and run for 60 minutes at 120 Volts in Tris-
glycine running buffer.  
5.3.1.4 Protein transfer 
After 60 minutes, the gel was moved and placed in between two ion reservoir stacks and the 
blotting membrane of the Trans-Blot Turbo Transfer system Transfer Pack. This membrane 
sandwich was then placed into a cassette and inserted into the Trans-Blot Turbo Transfer 
system (Bio-Rad). This turbo transfer system allowed rapid and efficient transfer at <25V for 3 
minutes at 2.5 A.  
5.3.1.5 Detecting mitochondrial protein expression via immunoblotting 
The membrane was transferred into blocking buffer (Table 5.1A) and placed on a roller for 
60 minutes at room temperature to eliminate non-specific antibody binding. Primary 
antibodies (Table 5.1C) were also diluted in blocking buffer and placed on a membrane and 
incubated overnight at 4°C on a rotator. This membrane underwent 3x 10 minute TBST 
washes, which was followed by secondary antibody incubation for 60 minutes at room 
temperature.  
5.3.1.6 Membrane development 
After secondary antibody incubation, the membrane was washed 3x in TBST for 10 minutes. 
Image development was carried out through the AmershamTM ECLTM prime reagent kit, 
which comprises of luminol and peroxide solutions These solutions are utilised by the 
horseradish peroxidase enzyme conjugated on the secondary antibody and which catalyses 
these reagents to produce detectable light. The membrane was incubated in a 1:1 ratio of 
both solutions for 5 minutes, followed by ChemiDoc system imaging and densitometry 








5.3.2 Quantifying mtDNA deletion in neurons 
 
5.3.2.1 Freezing cells for PCR 
 
A pellet of 1x105 cells/mL were frozen at -80 °C until ready for DNA extraction. 
5.3.2.2 DNA extraction and single cell lysis 
 
DNA extraction from 1x105 cells/mL IPSCs was conducted using single cell lysis buffer [50 mM 
Tris HCl (pH 8.5), 0.1% Tween 20, 0.2mg/ml proteinase K (ThermoFisher). Cells were incubated 
in buffer at 2 hours at 56°C, followed by a 10 minute 95°C Proteinase K denaturing step, to 
prevent proteinase K interfering with the Taqman mastermix during the PCR reaction. 
5.3.2.3 Real Time PCR primers 
 
The real time PCR protocol was followed as described by Rygiel et al., 2015. PCR primers for 
these reactions and fluorogenic probes for these regions were designed by (He et al., 2002). 
The following primers were synthesised: ND1 - forward primer (L3485-3504), ND1 reverse 
primer (H3532-355), ND1 probe (L3506-3529) and MT-ND1 VIC-5ʹ-
CCATCACCCTCTACATCACCGCCC-3ʹ-MGB (np 3506-3529). ND4 - forward primer (L12087-
12109), ND4 reverse primer (H12140-12170), ND4 probe (L12111-12138) and MT-ND4 FAM-
5ʹ-CCGACATCATTACCGGGTTTTCCTCTTG-3ʹ-MGB (np 12111-12138) (Table 5.2).  
5.3.2.4 Real Time PCR assay 
 
Taqman chemistry was used to perform real-time PCR. All PCR amplification was carried out in 
20μL reactions, 5μL of the standard curve and DNA samples and 15μL PCR master mix. All 
samples were run in triplicate in a Veriti 96 well (Applied BioSystems) PCR plate. Each plate 
contained serial 1:10 dilutions of a 7D1-B2M plasmid construct containing ND1 and ND4 genes 
in dH2O to generate a standard curve (Rygiel et al., 2015). Plates were sealed, and vortexed to 
mix all the reagents with the DNA samples and spun down. mtDNA deletion levels were 
quantified in low and high heteroplasmy IPSCs on a StepOne Plus (Applied Biosystems) real-
time PCR machine, protocol as follows, 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 





5.3.2.5 Real Time PCR analysis 
 
MtDNA deletion levels were analysed where the trend line of the standard curve was assessed 
for efficiency of the PCR reaction and determining the level of each probe indicative of the 
presence of the gene. The gradient of the standard curve for every reaction needed to fall 
within the range of -3.25 to -3.45, with -3.33 being the optimal value.  MTND1 is preserved in 
both WT and mutant mtDNA in this cell line, therefore acted as reference for mtDNA as, ND4 
is deleted. The ratios of MT-ND1/D-Loop, MT-ND4/D-Loop and MT-ND4/MT-ND1 were 
calculated using standard curves.  
For the cell line harbouring a higher mtDNA deletion a range of 40-48% mtDNA deletion was 
observed and for the second, lower cell line mtDNA deletion was observed as <10%. Any sample 
with measured heteroplasmy of 0–10% was classed as <1Ct. During experiments, the level of 













Taqman Universal PCR master mix - 10 1x Applied 
Biosystems 
MTND1 forward primer   L3485-3504 0.6 10 µM Eurofins MWG 
MTND1 reverse primer H3532-355 0.6 10 µM Eurofins MWG 
MTND4 forward primer  L12087-12109 0.6 10 µM Eurofins MWG 
MTND4 reverse primer  H12140-1217 0.6 10 µM Eurofins MWG 
MTND1 probe VIC  L3506-3529 0.4 5 µM Life Technologies 
MTND4 probe FAM  L12111-12138 0.4 5 µM Life Technologies 
dH20 - 1.8 - - 




5.3.3 Neuronal imaging 
 
5.3.3.1 Fixing cells, immunofluorescence and live imaging experiments 
 
Conducted as highlighted in (Methods and Materials, section 2.3). Primary and secondary 
antibodies used in experiments are highlighted in (Table 5.3). 
 





Primary Antibodies Dilution Detection Type Manufacturer 
Tyrosine Hydroxylase (TH) 1:200 DAergic neurons Rabbit/IgG1 Sigma 
γ-aminobutyric acid (GABA) 1:1000 Inhibitory (GABA) 
neurons 
Rabbit Sigma 
Vglut 1:500 Glutamatergic 
neurons 
IgG2a Synaptic systems 
MTCO1 (COX IV) 1:200 Mitochondrial mass 
marker 
IgG2a Abcam 





1:200 Neuronal marker Rabbit Abcam 
Hoechst 1:500 Nuclear marker  Sigma 
Secondary Antibodies     






ThermoFisher Alexa Fluor 546 nm  
Alexa Fluor 647 nm  






5.4.1 Immunoblotting showing a reduction in mitochondrial protein expression in IPSCs 
harbouring a large-scale mtDNA deletion  
 
Russell et al., (2018) reported a reduction in mitochondrial oxygen comsumption rate (OCR) 
within IPSCs harbouring a higher level of mtDNA deletion. This study aimed to quantify 
mitochondrial protein complex expression within these two lines to confirm alterations in the 
mitochondrial oxidative capacity within IPSCs used for experiments and their differentiated 
neuronal phenotype in the presence of a large-scale mtDNA deletion.  
 
The mtDNA deletion in this line spans 6kb (m.7777- 13794) of the mitochondrial genome. 
Therefore, mitochondrial protein expression was assessed to detect alterations between the 
two IPSC lines. Lysates were obtained from low and high heteroplasmy IPSCs, followed by 
western blot to observe protein levels of mitochondrial complex subunits. The following 
mitochondrial complex subunits were analysed: Complex I (NDUFB8), complex II (SDHA), 
complex IV (MTCO1) and complex V (ATP50) (Figure 5.1) (N=2). These results demonstrated 
that IPSCs containing 42% heteroplasmy (mtDNA deletion) displayed a decrease in Complex I 











Figure 5.1. Respiratory chain protein expression in iPSCs. Western blot analyses of Complex I, II, IV and V of the 
respiratory chain via staining with NDUFB8, SDHA, MTCO1, and ATP50 antibodies. The downregulation of Complex 
1 (NDUFB8) and Complex IV (MTCO1) can be observed within iPSC harbouring large scale mtDNA deletion (A.2 
~42% mtDNA deletion). All quantification was normalised to alpha-tubulin loading control. Decrease in protein 

















5.4.2 Mitochondrial membrane potential analyses in large scale mtDNA deletion IPSCs vs 
neurons 
 
The development of membrane potential reliant fluorescent stains has become a robust 
method to assess ΔΨm. TMRM, a fluorescent lipophilic cationic dye is efficient for this purpose 
(Tehrani et al., 2018).  
 
To observe alterations in mitochondrial membrane potential between both cell lines, and to 
confirm whether a decrease in these values were observed in these cell lines, Russell et al., 
(2018) quantified the level of mitochondrial membrane potential within the IPSCs and neurons 
(Figure 5.2A and B). These findings demonstrated that TMRM fluorescence was slightly higher 
within IPSCs  with ~53% mtDNA deletion level,  ~10% mtDNA deletion level cell line  although 
these changes were not significant.  
 
This current study repeated the TMRM intensity analysis within IPSCs and differentiated 
neurons (8 days maturation) of these cell lines. It was also found that TMRM fluorescence 
within NGN2 derived neurons expressing a decreased TMRM fluorescence in observed within 
patients harbouring ~53% mtDNA deletion compared to cell line with lower mtDNA deletion 
(grey bar) (not significant, p<0.05) (Figure 5.2D). When repeated in this current study TMRM 
intensity was decreased in the axons of high heteroplasmy cell lines with 42% mtDNA deletion 
(not significant) (Figure 5.2E) and a significant decrease in TMRM intensity within cell bodies of 
neurons harbouring a 42% mtDNA deletion was observed in comparison to the low mtDNA 











Figure 5.2. Mitochondrial membrane potential analysis in large scale deletion IPSC and neurons.  A-B) TMRM 
intensity values taken from mitochondria within NGN2 axons (white boxes) and cell bodies (white triangles) in this 
study. C) IPSC TMRM fluorescence, demonstrates increased TMRM fluorescence in patient line harbouring 
increased (black bar) (53%) mtDNA deletion, followed by a large reduction in this intensity in patient line 
harbouring 63% heteroplasmy (Red bar) (not significant) (Russell et al., 2018, included with permission). D) TMRM 
fluorescence within NGN2 derived neurons expressing a decreased TMRM fluorescence in observed within 
patients harbouring ~53% mtDNA deletion (pink bar), compared to cell line with lower mtDNA deletion (grey bar) 
(not significant) (Included with permission from Russell et al., 2018).  E) Current study – TMRM intensity was 
decreased in axons of high heteroplasmy cell lines with 42% mtDNA deletion (not significant) (N=230 axons [low 
heteroplasmy neurons] and N=250 [high heteroplasmy neurons]). F) Significant decrease in TMRM intensity in cell 
bodies of neurons harbouring a 42% mtDNA deletion was observed in comparison to the low mtDNA deletion cell 
line (N=226 cell bodies [low heteroplasmy] and N=228 cell bodies [high heteroplasmy]). Statistical differences 




5.4.3 The differentiation of NGN2 stem cells into dopaminergic neurons – Challenges and 
Protocols  
 
Following the protocol described by Russell et al., 2018, IPSCs were successfully differentiated 
into a heterogeneous population of neurons harbouring two levels of a large scale mtDNA 
deletion: (<10%) and (<40%) mtDNA deletion respectively, since the aim of this thesis was to 
understand mitochondrial trafficking within PD. As the NGN2 neurons are a heterogeneous 
population of varying neuronal subtypes, efforts to drive differentiation of a DAergic-only 
neuronal subtype from these lines were attempted. Indeed, formation of midbrain DAergic 
neurons involves the addition of different growth factors and supplements at various stages of 
neuronal growth and differentiation (Table 5.4). Different growth factors and supplements 
were added throughout NGN2 neuronal development in accordance to the Kriks protocol (Kriks 
et al., 2011), to support DAergic neuronal differentiation (Figure 5.3).  
The 3 main factors added to proliferation media were sonic hedgehog (SHH), Purmorphamine 
and ChIR99021 (CHIR). SHH is a morphogen which promotes DAergic neuron formation along 
the dorsoventral axis.  Purmorphamine acts as a SHH agonist and therefore enhances DAergic 
neuron formation. The addition of CHIR, allows the reprogramming of embryonic stem cells via 
WNT-signalling (Table 5.4). Growth factors were taken from Kriks et al., (2011) protocol. Finally, 
doxycycline was added to the proliferation media with and without factors to drive NGN2 


















































Supplements Final Concentration Functions 
Sonic hedgehog (shh) 100ng /ml Signals for DAergic neuron formation along 
dorsoventral axis (PM) 
Purmorphamine 2μM SHH agonist (PM) 
Chir  - 99021 (CHIR) 3μM It allows reprogramming of ES cells. It has 
also shown to activate WNT-signalling and 





butyl ester (DAPT) 
10μM γ-secretase inhibitor, inhibits notch 
signalling which increases DAergic neurons 
(DM) 
Ascorbic acid 0.2mM Cell survival (DM) 
Brain derived neurotrophic 
factor (BDNF) 
20nM Survival and morphological differentiation of 
neurons (DM) 
Fibroblast Growth factor 8 
(FGF8) 
100ng/ ml Survival of DAergic neurons, also involved in 
signalling via dorsoventral axis (DM) 
Glial cell line derived 
neurotrophic factor (GDNF) 
20ng/ ml Survival and morphological differentiation of 
neurons (DM) 




The factors added to the differentiation media included, BDNF, GDNF, FGF8, DAPT, L-Ascorbic 
acid and (db)–cAMP (Table 5.4). FGF8 promotes the survival of DAergic neurons and also 
further signals along the dorsoventral axis in the brain. DAPT inhibits NOTCH signalling, which 
in turn increases DAergic neuron formation (Yamauch et al., 2009). L-Ascorbic acid further 
promotes cell survival. BDNF, GDNF and cAMP factors were all added to enhance neuronal 
maturation (Xia & Lee, 2016) (Figure 5.3).  
 
Tyrosine hydroxylase (TH) catalyses the conversion of L-tyrosine to L-3,4-
dihydroxyphenylalanine (L-DOPA), using molecular oxygen (O2) (Daubner et al., 2012). As L-
DOPA is a precursor for DA, TH was selected as a marker for DAergic neurons. Once NGN2 
neurons had reached 7 days of maturation, differentiated neurons were fixed stained with 
MAP2 (Microtubule associated protein 2) to identify neuronal processes, and Hoechst to stain 





 Figure 5.3. Conditions for DA neuron differentiation. Supplements added to proliferation and differentiation media, when differentiating neurons into DA neurons (Protocol adapted 




Neurons were grown under 4 different conditions (Figure 5.3) and differentiated for 8 days to 
generate neurons.  
 
Condition number 1, followed the standard INGN2 differentiation protocol with the addition of 
supplements (that have been reported by Kriks et al., 2011) to enhance DA neuron formation. 
Condition number 2 followed the standard protocol by Russell et al., 2018, without the addition 
of any factors. Condition 3 entailed a protocol that does not involve the addition of doxycycline 
during proliferation and all growth supplements during differentiation. Condition 4 comprises 
the same protocol as condition 3 with the addition of doxycycline.  
 
TH staining was used to observe whether DAergic neurons were being generated by these 
various protocols. They showed that DAergic neurons were only formed under conditions 1 and 
2 (Figure 5.4). Furthermore, as experiments proceeded with culturing neurons under 
conditions 1 and 2, it was found that the addition of DAergic supplements (as observed in 
Condition 1) were not reproducible, due to increased neuronal death (data not shown) (N=3 
biological repeats). 
 
On the first day of neuronal progenitor cell (NPCs) culture, DAergic growth factors, SHH, 
Purmorphamine and CHIR were added and maintained over the 72 hour NPC culture. Within 
the dish, NPCs are seeded to be densely packed, in order to inhibit their spontaneous 
differentiation and enhance proliferation. The addition of these factors was found to perturb 
NPC growth, disrupt their distribution and alter cell morphology. This resulted in low yield of 
surviving and viable NPCs primed for differentiation. Growth condition 2 (Russell et al., 2018) 
was therefore selected due to the presence of DAergic neurons after differentiation, but also 






Figure 5.4. Low and high heteroplasmy DA neuron differentiation. A-B) DAergic neurons are observed in growth conditions 1 and 2 due to bright TH staining (red) and MAP2 
(green) staining C) Condition 3 - indicate no TH-positive or MAP2 staining suggesting no neurons are formed D) Condition 4 shows no generation of neurons, due to cell death. 




Furthermore, to ascertain the proportion of DAergic neurons in this NGN2 heterogeneous 
neuronal population TH-positive neurons were counted. TH-positive neurons within this 
neuronal population were compared against MAP2 and Hoescht staining. Analysis revealed that 
low (<10%) and high (43.7%) heteroplasmy neurons showed 66.78% TH-positive and 78.02% 
MAP2-positive staining and 70.27% TH-positive and 96.06% MAP2 expression respectively 
(staining normalised to nuclear staining) (Figure 5.5).   
 
It may be that the remaining percentage of cells that were undetected within this analysis could 
be glial or undifferentiated cells, not stained for in this experiment. This result indicates that 
neurons harbouring a higher level of mtDNA deletion, generated more neurons in comparison 
to the lower heteroplasmy line, as well as exhibiting increased TH expression indicative of 





Figure 5.5. TH-MAP2 expression in heteroplasmy neurons. Low heteroplasmy neurons harbour a <10 % mtDNA 
deletion. Quantification of TH and MAP2 neurons indicate that in low heteroplasmy neurons 96.06% of neurons 
are MAP2 positive, of which 70.27% of these are TH positive. High heteroplasmy neurons harbour a <43.7 % 
mtDNA deletion, of which 66.78% are MAP2 positive and 78.02% of these are TH positive. (N=2). Error bars 






5.4.4 Quantifying the expression of neuronal markers in iNGN2 derived neurons 
 
Following this quantification, immunofluorescence was conducted on these neurons to 
compare the levels of other neuronal subtypes within the generated population. In addition to 
quantifying DAergic (TH antibody staining) expression, GABAergic (Gamma-aminobutyric acid) 
(GABA antibody staining) and glutamatergic (VGLUT1 antibody staining) positive neurons were 
also counted to understand other neuronal subtype expression within a heterogeneous 
neuronal population. 
 
Quantification of 2145 cell bodies (low heteroplasmy neuronal cohort) were analysed for the 
neurotransmitter triad: TH, GABA, and VGLUT1 staining which demonstrated that 96% of 
neurons expressed TH, 88% were GLUT positive and 82% were GABAergic positive (Figure 5.6).  
Although a fully homogenous DAergic neuronal population could not be generated from these 





Figure 5.6. Quantification of neuronal differentiation. Tyrosine hydroxylase, glutamatergic and GABAergic 
quantification of low heteroplasmy NGN2 neurons. Co-localisation analysis measured as a percentage against total 
number of nuclei. Increased TH expression in NGN2 neurons (96%), followed by glutamatergic expression (88%) 
and GABAergic expression at (82%). Two technical repeats were conducted, where error bars represent Mean +/- 





As a large amount of overlap in staining was observed, the co-localisation of these antibodies 
within these neurons was quantified. This study counted the co-localisation of TH-GABA-GLUT, 
TH-GABA, TH-GLUT and GABA-GLUT staining within 499 low heteroplasmy neuronal cell bodies.  
 
Results revealed that the co-localisation of TH with these neurotransmitters within a 
heterogeneous neuronal population demonstrated large variability. The highest antibody co-
localisation within these neurons were observed in the TH-GABA-GLUT cohort (Figure 5.8), 
showing that 76.5% of cell bodies expressed TH-GABA-GLUT staining, followed by co-
localisation of TH-GABA (Figure 5.9) in 13.22% of neurons. TH-GLUT and GABA-GLUT co-
localisation was found to be 0.6 % and 2.8% respectively (Figure 5.7 and 5.8).  All counts were 
carried out as a percentage of the total number of nuclei.  
 
Therefore, once neuronal subtypes were quantified, a heterogeneous population of neurons 
was used in all future experiments. From here onwards, the differentiation protocol described 
by Russell et al., (2018) (Condition 2) was used to generated neurons harbouring a large scale 






















Figure 5.7. TH—GABA-GLUT co-localisation analyses. TH-GABA-GLUT co-localisation is 76.5%, followed 
by TH-GABA colocalisation at 13.22% of neurons. TH-GLUT and GABA-GLUT colocalisation is 0.6 % and 























































Figure 5.8. Quadruple neuronal staining of low heteroplasmy neurons. Co-localisation of TH, 
Glutamatergic and GABAergic neurons. White arrow heads indicate colocalised staining of TH-GABA-





Figure 5.9. TH-GABA localisation in low heteroplasmy neurons. Co-localisation of TH and GABAergic neurons. 




















5.5.1 Summary of results 
 
• Western blot analysis demonstrated that IPSCs harbouring a large scale mtDNA deletion 
exhibit a moderate decrease in mitochondrial complex I and IV protein expression, 
compared with isogenic control  
• Cell bodies of neurons harbouring a large scale mtDNA deletion exhibit a small but 
significant decrease in TMRM intensity indicative of perturbed mitochondrial 
membrane potential in comparison to the low mtDNA deletion cell lines 
• Differentiated neurons derived from both cell lines showed a heterogeneous neuronal 
population containing TH-expressing neurons indicative of DAergic neurons  
 
5.5.2 Large scale mtDNA deletion IPSCs exhibit a mitochondrial dysfunctional phenotype at 
protein level  
 
This study manipulated an induced pluripotent stem cell model harbouring a large scale mtDNA 
deletion (spanning 6017 base pairs from m.7777-13794). Deletions are the most common 
mtDNA mutation type observed in SNpc neurons, affected in PD.  In order to confirm the 
presence of a respiratory chain deficiency within the cell lines (required for future experiments 
[See Chapter 7]) both deletion and control IPSCs were analysed for OXPHOS protein expression 
by western blot.  
COX deficiency observed in the SNpc is caused specifically by mtDNA deletions reaching up to 
50% heteroplasmy (Bender et al., 2006, Kraytsberg et al., 2006, Reeve et al., 2009, Taylor et al., 
2003).  For this reason, an mtDNA deletion cell line was used in this study as opposed to 
inducing mitochondrial damage via a complex inhibitor i.e. Rotenone or MPTP, in order to 
maintain physiological relevance. This cell line provides as a unique paradigm to observe PD 
and advancing age, since these individuals harbour mtDNA deletions, commonly observed 
within PD patients. This model provides insight into how mitochondrial trafficking is affected 
by the mitochondrial DNA alterations present within SN neurons. 
The mtDNA deletion described in the high heteroplasmy cell line in the current study (~42%), 
removes subunits of complex I and complex IV. Therefore, a decrease was observed in 




respectively). Furthermore, having already reported a decrease in oxygen consumption rate 
(OCR) following FCCP treatment, within the high heteroplasmy cell line compared to the low 
heteroplasmy cell line, Russell et al., 2018 characterised this cell line as having reduced capacity 
to utilise oxidative respiration. This supported the findings in this study that a significant 
decrease in TMRM intensity was observed within high mtDNA deletion cell bodies compared 
to the lower mtDNA deletion cell line. This might indicate that dysfunctional mitochondria 
harbouring a lower membrane potential might remain within the cell body perhaps awaiting 
lysosomal degradation. 
 
5.5.3 Using IPSCs with mitochondrial dysfunction as a Parkinson’s disease model  
 
Whilst the generation of DAergic IPSCs from PD patient lines provides as a powerful tool to 
understand PD pathology, the traditional protocol to generate these midbrain DAergic neurons, 
requires a long differentiation time period i.e. via the Krik’s protocol (Kriks et al., 2011). This is 
because it is important to create the correct biological milieu for these DA neurons via the 
addition of DAergic growth factors.  
 
Mitochondrial dysfunction in PD can be driven by mtDNA deletions and therefore the utilisation 
of this NGN2 line containing a mitochondrial DNA deletion is hugely beneficial. Even the 
generation of a heterogeneous neuronal population would still provide valuable insight into the 
effect of these mitochondrial DNA mutations on mitochondrial transport, to support the ex vivo 
studies performed in this thesis.   
 
Several studies have utilised PD-patient IPSCs, some of which now successfully demonstrate 
disease-specific phenotypes in differentiated neurons (Nguyne et al., 2011, Siebler et al., 2011, 
Cooper et al., 2012, Jiang et al., 2012, Sanchez-Danes et al., 2012). This study therefore 
attempted to generate DAergic IPSC-derived NGN2 neurons from mitochondrial disease 
patients harbouring a large scale mtDNA deletion (Kraytsberg et al., 2006, Bender et al., 2006).  
Initial experiments were performed to differentiate neurons into a homogeneous DA 
population. It was found that though DAergic neurons were produced, though a homogeneous 




Directed neuronal growth towards a DAergic subtype were conducted using morphogens such 
as sonic hedgehog (SHH) and fibroblast growth factor-8a  (FGF8a) (Cooper et al., 2010), with 
further neuronal maturation achieved through the addition of ascorbic acid, BDNF, GDNF and 
cAMP (Schneider et al., 2007,Chambers et al., 2009, Cooper et al., 2010). The selection of which 
growth factors were added when, was determined through examination of the timings from 
the Kriks protocol (Kriks et al., 2011). This lead to SHH, CHIR and Purmorphamine being added 
during neuronal proliferation and L-ascorbic acid, FGF8, and cAMP were then added to 
promote DAergic neuronal differentiation from NPCs to neurons. Studies have shown that 
increased CHIR expression can create hindbrain neurons, and contrastingly, little CHIR can 
cause neurons to undergo a rostral-directed differentiation (Kirkeby et al., 2012). The 
concentration of supplements used within the Kriks et al., (2011) and Hartfield et al., (2014) 
protocols were replicated in this study, although a homogeneous DAergic neuronal population 
was not achieved.  
 
Unfortunately, this study could not generate a homogenous DAergic population, with the 
addition of these factors, most likely dependant on the NGN2 differentiation protocol, which 
generates neurons within 8 days from NPCs. Perhaps, as many studies report that a longer time 
period is required (to actually successfully culture these neurons), not enough time was allowed 
to generate DAergic neurons (in this study only 8 days of neuronal growth) and therefore only 
created adverse effects on the cells. Rock inhibitor prevents apoptosis and, in this study, even 
in the presence of ROCKi, NPCs did not survive, as the DA supplements caused large amounts 
of cell death (Figure 5.4).  
 
As the focus of this project was to observe the impact of mtDNA deletions in mitochondrial 
trafficking in PD, it was decided that the heterogeneous population of neurons would be 
utilised in experiments, containing a largely TH-positive population harbouring a large scale 
mtDNA deletion.  
 
5.5.4 NGN2 neuronal subtype quantification 
 
The proneural gene neurogenin 2 (NGN2), is a transcription factor crucial for neuronal 
differentiation (Fode et al., 1998), but also for the generation of neuronal subtype-specification 




NGN2 expression is crucial to mesencephalic DAergic neuron generation, showing that NGN2 
plays a role in DAergic neuron development (Thompson et al., 2006). Knockout NGN2 mice 
have demonstrated a reduction in DA neuron number in the developing ventral midbrain in 
comparison to wild type postnatal mice, which suggests that, in the VM, NGN2 is involved in 
specific mesencephalic DAergic neuronal differentiation. As over 90% of the NGN2 neuronal 
population in this study stained positive for TH, it may be possible that NGN2 actually facilitates 
DAergic neuronal development in this cell line, without the addition of DAergic supplements 
(Andersson et al., 2005).  
 
Immunofluorescent analysis of these large scale mtDNA deletion neurons revealed the co-
localised staining of TH, GABA and Glutamatergic neurons. This is interesting, in regard to our 
understanding of the nigrostriatal pathway, where DAergic and GABAergic neurons have been 
known to partake in the nigrostriatal pathway (Gonzalez-Hernandez et al., 2001). Further 
investigation into this pathway has demonstrated that a nonDAergic pathway exists within the 
substantia nigra reticula which utilises GABA (Fibiger et al., 1972, Hattori et al., 1991, Rodríguez 
& González-Hernández, 1999). Experiments revealed that rat nigrotectal neurons co-express 
TH and GAD (involved in GABA synthesis, Campbell et al., 1991) (GonzaÂlez-HernaÂndez et al., 
2001). Therefore, taken together, a particular proportion of DAergic nigrostriatal neurons 
express GABA and if differentiated NGN2 neurons favour developing mesencephalic neuronal 
subtypes, it can be hypothesised that the overlap in immunostaining could be predicted, as the 
neurophysiology of the nigrostriatal pathway comprises of this co-localisation.   
 
Whilst TH and GABA have been found to co-localise in these studies, the co-expression of 
VGLUT1 and GABA was also observed. Abundant co-expression of VGLUT1 and GABA has been 
observed in cortical and hippocampal glutamatergic synapses (Kao et al., 2004, Fattorini et al., 
2009, Zander et al., 2010), where electrophysiological experiments hypothesise that GABA is 
co-released from glutamatergic hippocampal mossy fibre terminals (MFTs) during postnatal 
development (Walker et al., 2001, Gutiérrez 2003). GABA functions as an inhibitory 
neurotransmitter and the GABAergic signalling machinery arises earlier than glutamatergic 
transmission, GABA synthesis occurs from glutamate via glutamate decarboxylase (GAD). 
During GABA synthesis, glutamate (an excitatory neurotransmitter) is converted into GABA (an 
inhibitory neurotransmitter) (Petroff, 2002, Schousboe, 2007). Therefore, the co-localisation of 




excitatory glutamatergic neurons that are still undergoing the conversion into GABAergic 
neurons. Thus, it can be concluded that the large overlap in TH-GLUT-GABA co-localisation 
observed in this study may either be a combination of two factors i) NGN2 preference towards 
mesencephalic neuronal derivation and immature GABAergic neurons and/or ii) a 
heterogenous immature neuronal population which are still undergoing neuronal maturation 







































Figure 5.10. Mesostriatal projections. There are supposedly three mesostriatal pathways. The first 
DAergic pathway originates from DAergic midbrain nuclei (blue), the second GABAergic pathway (red) is 
derived from GAD67 positive neurons in the substantia nigra pars reticula (SNR) and finally the 
DAergic/GABAergic pathway (green) which arises from DAergic neurons (GAD65 mRNA positive) in the 
substantia nigra pars compacta (SNC) and the ventral tegmental area (VTA). (Figure adapted from 









5.6 LIMITATIONS OF THIS STUDY 
• Concentrations of the growth factors added to promote DAergic neuronal growth were 
taken from the Kriks et al., protocol. It may have been that incorrect supplement 
concentrations were being administered to the NGN2 neurons, and therefore may have 
perturbed NPC differentiation. However, as this aim of this project was to observe 
mitochondrial movement in an IPSC model harbouring a mitochondrial defect, the 
following study continued to observe mitochondrial trafficking in a heterogeneous 
population of neurons, as NGN2 supports DAergic neurons.   
• The overlap in the co-localisation of these neurotransmitters, firstly rendered the 
generation of a homogenous DAergic population a practically challenging task.  
Therefore, it was decided that both heteroplasmy cell lines would be differentiated into 
a heterogeneous neuronal population for all future experiments.  
• Furthermore, this study did not measure mtDNA deletion levels after IPSC 
differentiation. Therefore, it remains undetermined whether the neuron still 
maintained an mtDNA deletion after differentiation, which may significantly affect the 
interpretation of the experimental results.  
 
5.7 CONCLUSIONS & FUTURE WORK 
 
These studies confirm decreased mitochondrial complex I and complex IV activity in the high 
heteroplasmy IPSCs in comparison to low heteroplasmy IPSCs. This model provides as a useful 
tool that provides insight to PD patients, since large scale mtDNA deletions are seen in affected 
neurons. 
Future work in this study will include: 
• Lentiviral transfection of a DA specific-GFP tag (under control of either the tyrosine 
hydroxylase or Dopamine transporter promoter) into NGN2 IPSCs to highlight dopamine 
expressing neurons within a heterogeneous population of neurons during live cell 
imaging. This tool will highlight DAergic neurons to be observed individually and 
therefore allow the analysis of mitochondrial movement within a solely DAergic 








































6.1 INTRODUCTION  
 
6.1.1 ER- mitochondria Ca2+ signalling  
 
The endoplasmic reticulum (ER) uses ATP-dependent transporters to take up Ca2+ from the 
cytoplasm into the ER lumen. As these Ca2+ stores are filled, cytosolic Ca2+ triggers the opening 
of ER Ca2+ channels letting Ca2+ ions flow back into the cytoplasm. Located near the 
mitochondria, this channel opening creates an increase in local Ca2+ concentration that drives 
Ca2+ influx into the mitochondrial matrix via MCUs (Szabadkai and Duchen, 2008). The high Ca2+ 
fluctuations that occur near the mitochondrion causes increased Ca2+ buffering activity, which 
leads to an inhibitory effect on Ca2+ release/influx channels and acts as a physiological regulator 
(Berridge, 2002, Pozzan and Rudolf, 2009).  
 
Resting neuronal cellular Ca2+ concentration is around 1mM, at which most intracellular Ca2+ is 
bound to cytosolic proteins and/or retained by the ER (Figure 6.1). Free cytosolic Ca2+ is 
approximately 100nM, which upon stimulation can increase to 1µm (Meldolei and Pozzan, 
1998). Within resting neurons, the total and free mitochondrial calcium (mCa2+) levels are low: 
0.1mM and 100nM (Pozzo-miller et al., 1997, Babcock and Hille, 1998). Within neuronal 
mitochondria, this leads to an increase of mCa2+ (100 – 500μM), as a direct consequence of 
increase cytosolic free Ca2+ (Cheng and Reynolds, 1998, Stork and YV, 2006). 
 
The IP3R (inositol 1,4,5-trisphosphate receptor) mediates interactions between the ER Ca2+ 
channel and the OMM; VDAC1 (Szabadkai 2006, Gomez-Suaga et al.,  2018). The close proximity 
of these two organelles at contact sites allows the formation of areas that meet the low affinity 
threshold of mCa2+ uptake mechanisms. Mitochondrial associated membranes (MAMs) assist 
with this Ca2+ handling as they are enriched with protein chaperones (Votyakova and Reynolds, 
2001) such as calnexin and calreticulin which interact with IP3Rs and SERCA2 
(Sarco/endoplasmic reticulum ER-Ca2+ transport ATPases) to regulate Ca2+ signalling (Hayashi 
et al, 2009).  
 
At the submicromolar level, the opening of the mitochondrial calcium uniporter (MCU) causes 
mCa2+ levels to increase to 0.2–3μM, if surrounding calcium levels are elevated. This triggers 




of the TCA cycle to generate more NADH+/NADPH+ (Bezprozvanny, 2009, Gibson et al., 2010). 
Increased mCa2+ also activates mitochondrial metabolism i.e. ATP supply for cellular processes 
(Halestrap, 2009). Mitochondria are highly sensitive to extracellular Ca2+, with mCa2+ levels 
determined by (i) Ca2+ influx through the mitochondrial calcium uniporter (MCU) which is 
driven by Δψm and (ii) Ca2+ efflux through the Na+/Ca2+ transporter (NCX) (Palty et al., 2010). 
When extracellular Ca2+ is increased, exceeding the micromolar threshold, the matrix Ca2+ 
buffering activity ensures that mCa2+ efflux remains constant, to efficiently control cellular Ca2+ 





Figure 6.1. ER-Mitochondrial Ca2+ handling. A) Model of ER-mitochondria Ca2+ handling.  The ER represents the 
large Ca2+ store, where basal level Ca2+ is approximately 104 times higher than that within the cytoplasm and 
mitochondria (Szabadkai and Duchen,2008). Stimuli activate the formation of the IP3 receptor (IP3R), which leads 
to Ca2+ release from the ER. This in turn triggers a [Ca2+] increase in the cytosol and [Ca2+] reduction in the ER. B) 
Ca2+ and ADP/ATP micro domains are formed at the ER-mitochondrial contact regions that permit the direct 
control of ER Ca2+ content and direct Ca2+ channelling into the mitochondria. Ca2+ release from the ER occurs 
through the IP3R, which supplies Ca2+ to mitochondria through the OMM voltage-dependent anion channel (VDAC) 
and the IMM Ca2+ uniporter (MCU). Limited mitochondrial Ca2+ loads upregulate mitochondrial ATP production 
[by supplying reducing equivalents to the electron transport chain (ETC and F1F0 ATPase), which is transported to 
the inner mitochondrial space by the concerted activity of the ATP/ADP translocase (ANT) and VDAC. The re-
accumulation of Ca2+ into the ER lumen through the sarco-endoplasmic Ca2+ ATPase (SERCA) is directly controlled 






6.1.2 ER and mitochondrial involvement in PD 
 
ER–mitochondria linked cellular processes are altered in PD, with such alterations including Ca2+ 
dysregulation, defects in axonal transport, and mitochondrial dysfunction (Winklhofer and 
Haass, 2010, Moreira et al.,  2010, Cozzolino and Carri, 2012, Surmeier et al.,  2017). Surmeier 
et al., (2017) proposed that the autonomous pace making activity in SNpc DA neurons, (which 
maintains dopamine concentrations within the striatum) is  sustained by specific voltage 
dependent L-type Cav1.3 channels, allowing Ca2+ influx that enhances cytosolic Ca2+ 
concentrations in these cells (Poupolo et al.,  2007, Guzman et al.,  2010).  
 
Lewy body associated α-syn, localises to MAMS, and the presence of Lewy bodies is 
accompanied by signs of ER stress (Ryu et al., 2002) (Figure 6.2).  This interaction has been 
further supported by studies that showed within wild-type α-syn overexpressing cells, the co-
localisation of ER and outer mitochondrial membrane protein; protein tyrosine phosphatase-
interacting protein 51 (PTPIP51) (Cali et al., 2012, Gómez-Suaga et al., 2018).  
Furthermore, overexpression of these mitochondrial markers lead to a loss of ER–mitochondria 
contacts. It was suggested that this overexpression interrupted mitochondria-ER Ca2+ exchange 
as well as ATP generation (Paillusson et al., 2017), which may cause alerted organellar dynamics 
and perhaps even cell death. It has been shown that α-syn overexpression can alter Ca2+ 
homeostasis, autophagy (Winslow et al., 2010), mitochondrial function and impair the ER 
(Mercados et al.,  2013).   
 
 
Figure 6.2. Overexpression of Wild-type and familial PD mutation carrying synuclein decreases ER–mitochondrial 
contacts. ER–mitochondria associations in SH-SY5Y cells. A) ER-mitochondrial contact observed in control SH-SY5Y 
cells, where these are reduced in B) EGFP-α-synuclein, C) EGFPα-synucleinA53T or D) EGFP-α-synucleinA30P 
expressing cells. Red arrowheads with loops indicate regions of reduced association. Scale bar is 200nM (Figure 





This α-syn-ER association may modulate several pathways that are also perturbed within PD, 
some of which include Ca2+ homeostasis, mitochondrial dynamics and mitophagy. Therefore, 
these findings may provide as useful therapeutic targets and perhaps allowing the discovery of 





Figure 6.3. ER-mitochondria signalling in PD. The interaction between mitochondria and the MAMs of ER has been 
linked with different cellular functions. Mitochondrial dysfunction and oxidative stress bring the onset of free 
radical species (red dots) as a consequence of perturbed ER-mitochondrial Ca2+ handling. This Ca2+ dyshomeostasis 
is a standalone contributor to PD pathogenesis possibly effecting pace-making activity of SNpc DA neurons. ER-
mitochondrial contacts have shown to be altered within mitochondrial dynamics, altering the mitochondrial 
motor-adaptor complexes that regulate the transport machinery. Furthermore, studies have described 





6.1.3 The NCLX transporter 
 
mCa2+ release in neurons is regulated by a Na+/ Ca2+ (NCX) exchanger (Baughman et al., 2011). 
As the maximal rate of release (via the NCX exchanger) is much lower than the maximal rate of 
uptake (via MCU), mCa2+ accumulation is observed when the cytosolic Ca2+ is high. The net effect 
of the mCa2+ pathways is that this organelle contains little calcium in resting cells but begins to 
accumulate large amounts of calcium during stimulated Ca2+ entry (such as ischemia) to release 
this calcium overload in order to recover (Palty et al., 2009). NCX exchange facilitates mCa2+ 
efflux and is crucial in the maintenance of Ca2+ homeostasis (Philipson et al., 2000). The NCKX 
protein family have a stoichiometry of 4Na+/1Ca+/1K+, divided into four groups, of which only 
NCX1–3 and NCKX1–4 are mammalian (Philipson et al., 2000). The two families share a common 
catalytic core; called alpha 1 and 2 repeating domains (identified in DAergic neurons) which 
promote their exchange activity (Nicoll et al., 1996, Philipson et al., 2000, Palty et al., 2004, 
2010). 
 
Palty et al., (2009) identified and characterised a novel NCX exchanger; NCLX, which is enriched 
in the mitochondria and localised in the cristae (Palty et al., 2009). NCLX catalyses, Na+ or Li+-
dependent Ca2+ transport, with human NCLX expression first observed at the plasma 
membrane, with further research conducted into whether NCLX is linked to the mitochondrial 
exchanger. Studies determined that mitochondrial NCLX expressed in the mouse heart and 
brain exists as in an isoform of 50 and 70kDa respectively, with an additional 100kDa form in 
the mitochondrial fraction (Palty et al., 2009). 
6.1.4 mCa2+ overload in neurons  
 
Adult DAergic neurons in the SNpc lack significant intrinsic Ca2+ buffering capacity (Grobaski et 
al.,  1997; Puopolo et al.,  2007, Surmeier, 2007) putting them at risk from mitochondrial deficits 
(Surmeier, 2007). Furthermore, mCa2+ overload renders DA neurons more susceptible to injury 
(Gandhi et al.,  2009), which is thought to occur due to an inability of the mCa2+ shuttling system 
to handle large loads of Ca2+ within the mitochondria (Chan et al.,  2007). Recent studies 
indicate that mCa2+ content is a crucial parameter in regulating mitochondrial transport (Chang 
et al., 2011). Drugs used to inhibit the MCU complex, have revealed that blocking the MCU 
complex, in the presence of high cytoplasmic Ca2+ maintains mitochondrial movement, 
indicating an important role for MCU in regulation of Ca2+ influx and its effect on mitochondrial 




Kostic et al., (2015) revealed that impairment of NCLX activity within PINK1 deficient neurons, 
is rescued by the Protein Kinase A (PKA) signalling pathway. Their study showed this rescue via 
direct phosphorylation of NCLX by PKA via Forskolin treatment (PKA agonist), which provides a 
regulatory mode of mCa2+ efflux. Forskolin treatment served as a method to restore mCa2+ efflux 
under PINK1 deficient conditions, protecting PINK1-deficient neurons from mitochondrial 
depolarisation via the opening of the permeability transition pore (mPTP) and dopamine-
induced cell death (Figure 6.4).  
 
It is therefore of high importance to understand the role of the NCLX transporter on mCa2+ efflux 
and how this effects mitochondrial movement in neurons with a respiratory chain defect. This 
study will provide insight into how dysfunctional mitochondria are moved within neurons and 
how these systems may be altered with disease in order to supply the neuron with ATP.  
 
This study consisted of in vitro analyses of mitochondrial transport within neurons 
differentiated from human induced pluripotent stem cells (IPSC), which harbor a large-scale 
mtDNA deletion (See chapter 5). Forskolin treatment was used to assess how PKA signalling 
effects mCa2+ efflux, within neurons, to understand whether stimulation of mCa2+ efflux would 
alter mitochondrial dynamics within neurons with a large level deletion similar to that observed 







Figure 6.4.  The rescue of mCa2+ homeostasis via PKA-Mediated pathway in PINK1 deficient cells. A) PINK1 
deficiency can cause mitochondrial damage through mitochondrial depolarisation, inhibiting the NCLX 
exchanger, which regulates the major Ca2+ efflux pathway in mitochondria. The consequential mCa2+ 
overload, in addition to the mitochondrial depolarisation, opens the mitochondrial permeability 
transition pore. B) PKA activates NCLX via phosphorylation at S258 residue, which rescues its activity in 
PINK1-deficient neurons and causing a recovery of mitochondrial membrane potential, improving DA 




6.2 AIMS OF THIS STUDY  
 
After having characterized mitochondrial movements with ageing and in the presence of alpha-
synuclein overexpression in a mammalian model (See Chapter 4), it was important to 
understand whether other effectors of mitochondrial transport i.e. mtDNA deletion and 
calcium modulation would play a role in a PD-like model. Importantly, this study would also 
reveal whether modulation of neuronal calcium handling might alter mitochondrial transport 
in the presence of a mitochondrial defect and whether this might offer therapeutic targets. 
 
As a mitochondrial defect is observed in high heteroplasmy IPSCs (Russell et al., 2018), this 
study aimed to understand the effect of mitochondrial dysfunction on calcium handling within 
these neurons and the impact of these changes on mitochondrial transport. Neurons were 
treated with Forskolin to observe the impact on axonal mitochondrial dynamics of increasing 
mCa2+ efflux and thus increasing the availability of free calcium. It was hypothesised that 
mitochondrial transport would be disrupted due to mitochondrial dysfunction and that 
regulating mCa2+ homeostasis within these neurons would alter these mitochondrial 
movements. An ability to be able to affect mitochondrial movements within neurons and thus 
alter their distribution within such cells may have benefit for neurodegenerative diseases.   
 
The aims of this study therefore were to; 
1. Understand mitochondrial trafficking in neurons harbouring a large-scale mtDNA deletion. 
2. Carry out a Forskolin (PKA agonist) dose response curve to determine optimal dose for 
INGN2 neurons to observe mCa2+ efflux within neurons harbouring a large scale mtDNA 
deletion 
3. Compare the effects of Forskolin treatment on <10% and ~40% mtDNA deletion 
differentiated neurons.  
4. Observe differences in mCa2+ efflux and whether this alters mitochondrial trafficking by the 









6.3 MATERIALS & METHODS 
 
6.3.1 Neuronal culture  
Large-scale mtDNA deletion containing IPSCs were differentiated into neurons according to 
the methods described in (Chapter 2 – Methods and Materials section 2.1) 
 
6.3.2 Forskolin treatment of neurons 
6.3.2.1 Forskolin dose response curve  
Stem cells were plated at a seeding density of 3x105 cells/ml in a 24 well matrigel coated 
plate. A media change (Differentiation media + Forskolin) was conducted 24 hours before 
passaging, where cells were dosed with Forskolin at 5, 10, 50 and 100µM concentrations 
(doses determined by Kostic et al., ,2015). A media change containing differentiation media 
with 5nm TMRM was conducted prior to imaging.   
 
6.3.2.2 Forskolin experiments  
Once the optimum Forskolin dose was determined, neurons were treated at 10 and 50μM, 30 
minutes before imaging. INGN2 neurons were dosed with Forskolin at two time points of 
neuronal culture firstly, as INGN2 stem cells 24 hours post passaging into differentiation media 
(Differentiation day 1) and 24 hours prior to fixation as mature neurons (Differentiation day 6). 
All INGN2 neurons were grown in glass bottom dishes (Ibidi) (seeding density 2.5x105 cells) and 
were imaged with TMRM on Day 7. The above was repeated using H-89 (PKA inhibitor), though 
cells were only dosed at Day 1 and Day 6 and imaged on Day 7.   
 
6.3.3 Forskolin western blot in neurons 
6.3.3.1 Immunoblot Analysis 
Conducted as described in Chapter 5 –Section 5.3.1. NCLX immunoblotting was performed as 
described previously (Palty et al., 2010) using the following antibodies: custom-made antibody 






6.3.4 Ca2+ imaging 
6.3.4.1 Fluo-4-am reconstitution  
Fluo-4-AM (Thermo Scientific) was reconstituted in 280µl of chloroform (Sigma Aldrich), which 
was aliquoted into 20µl volumes that were left in the dark for 30minutes to allow the 
chloroform to evaporate.  
6.3.4.2 Loading NGN2 neurons with live imaging dyes  
NGN2 neurons were seeded at a density of 300,000 cells/mL in Ibidi glass bottom dishes. On 
the 7th day of neuronal differentiation, Fluo-4-AM aliquots were thawed and re-suspended 
in 3µl of DMSO (Sigma Aldrich), 3µl of Pluronic acid (Thermo Scientific) (which facilitates the 
solubilisation of water-insoluble dyes) of Fluo-4-AM,  5 nm TMRM and 993µl Neurobasal 
differentiation media. This solution was vortexed and existing media was removed and 
replaced with the staining solution. The dishes were incubated at 37°C for 10 minutes in the 
dark, and then at room temperature for another 10 minutes, also in the dark.  
6.3.4.3 Ionomycin loading  
All videos taken were 10 minutes in length. To determine the Rmax (a maximal increase in 
intracellular calcium consequently resulting in a maximum increase in fluorescence) (Yoshida 
and Plant, 1992) of Fluo-4-AM loading, after a measuring fluorescence for 1 minute at 
baseline, 1µM of ionomycin was added to the dish to induce cytosolic Ca2+ influx, where 
fluorescence was measured for another 5-8 minutes.  Videos were captured at 1 
frame/second for 5 minutes. 
 
6.3.5 Mitochondrial movement analyses 
6.3.5.1 Fluorescent TMRM ∆Ψm Imaging - Conducted as described in Chapter 4 –Section 
3.4.4.1 
6.3.5.2 Mitochondrial movement analyses - Conducted as described in Chapter 3 –Section 3.4.4 
6.3.5.3 Mitochondrial morphology analyses  
Aspect ratio and form factor [(perimeter)2/(4π x area)] analyses were conducted on low 
heteroplasmy neurons during Forskolin dose response optimisation. These experiments 
were conducted in low heteroplasmy neurons as an initial study to observe the effect of 
Forskolin on mitochondrial dynamics (fission/fusion) in these neurons. Results generated 




Aspect ratio measures the length-based ratio between the major and minor axes of an ellipse 
is equivalent for each mitochondrion; determining how round the mitochondria are. Whereas 
the form factor measures the length and degree of branching of mitochondria. Videos taken 
were converted into a series of TIFF images in NIS elements software, from which 3 TIFFS were 
selected, which most accurately represented the neuronal structures, prior to analysis. Cell 
body mitochondria were then analysed in Image J which comprised of a series of deconvolution 
steps, where brightness and the contrast of the image were adjusted to optimal levels, and 
following this sharpening, a binary filter was applied to simplify these images using a 
deconvolution plugin Image J to even this signal. This allowed the software to identify objects 
as mitochondria or not, dependant on mitochondrial area. In this way the complexity of the 
mitochondrial network were analysed via parameters generated according to individual 
organelles and reticular composites.  
6.3.5.4 Statistical Analysis  
 
A mixed-effect regression model was undertaken by Dr Alasdair Blain (Wellcome Centre for 
Mitochondrial Research) to model the effect of calcium efflux in neurons harbouring a large-
scale mtDNA deletion. The data was decided to be plotted as logged values for visual aid only, 
due to the range in mitochondrial movement.. All data is presented as box and whisker plots 
that show the distribution of mitochondrial speed and distance values. Raw values for both 
parameters were logged after defining a moving mitochondrion as travelling above 0.005 µm/s 














6.4.1 Optimisation of Forskolin treatment in low heteroplasmy cells 
 
Phosphorylation of NCLX via PKA through Forskolin treatment (PKA agonist) provides a method 
to regulate mCa2+ efflux. Forskolin treatment has been shown to restore mCa2+ efflux under 
PINK1 deficient conditions (Kostic et al., 2015). This study investigated how PKA signalling 
effects mCa2+ efflux (via Forskolin treating) in neurons harbouring a single, large-scale mtDNA 
deletion.   
To ensure that Forskolin did not adversely affect mitochondrial function and to test for toxicity 
in these cell lines, low heteroplasmy stem cells were dosed with 0, 5, 10, 50, and 100µM of 
Forskolin, 24 hours prior to imaging, and loaded with TMRM, 30 minutes before imaging. In low 
heteroplasmy stem cells, treatment with Forskolin was not shown to have a significant effect 
on mitochondrial membrane potential, measured through TMRM intensity (Figure 6.5A). 
Since it was thought that mitochondrial morphology in cells with a mitochondrial defect would 
be affected by Forskolin treatment, assessment of mitochondrial morphology was performed 
in treated and untreated cells, using aspect ratio (AR) and form factor (FF) analysis. AR 
determines whether the length based on the ratio between the major and minor axes of an 
ellipse is equivalent for each mitochondrion; and thus, determines how round mitochondria 
are, while FF measures the length and degree of branching of the mitochondria.  AR analysis 
on dosed stem cells showed that mitochondrial sphericity was slightly increased in comparison 
to DMSO treated cells when dosed with 5 and 10µM Forskolin (not significant). While, Forskolin 
treatment at 50µM and 100µM caused a slight decrease in mitochondrial connectivity (not 
significant) (Figure 6.5B). FF analyses revealed a slight decrease in branching of mitochondria 
when dosed with Forskolin (at all concentrations) compared to untreated cells, though these 
results did not reach significance (Figure 6.5C). These data show that mitochondrial 
morphology in the low heteroplasmy IPSCs was unaffected by Forskolin doses, this study thus 
continued with the doses previously used (Kostic et al., 2015) for the remainder of the 
experiments.  
Forskolin treatment (PKA agonist) occurs via direct phosphorylation of serine residues on the 
NCLX transporter. NCLX which acts to regulate mCa2+ efflux. To ensure NGN2 neurons express 




(Figure 6.5D). NCLX expression in these neurons were observed bands at 55 and 100kDa 
(reported in brain tissue due to the various isoforms of NCLX) and/or nonspecific antibody 
binding, Palty et al.,  2004 (Figure 6.5E). These experiments used a custom-made antibody 
against NCLX (Palty et al., 2004; 1:1,000 and 1:2,000), a kind gift from Dr Marthe Ludtmann 
from the Kostic group (UCL). Though the western blot from iPS cells is not as clear as the blot 
from isolated mitochondria (Figure 6.5E), taken together with the following calcium data it 






















Figure 6.5.  Forskolin dose response and NCLX western blot. A) The effect of Forskolin treatment on 
mitochondrial membrane potential was assessed in low heteroplasmy stem cells. Forskolin treatment had no 
significant effect in low heteroplasmy stem cells.  B) Aspect ratio (AR) was found to be unaffected by various 
doses of Forskolin. C) Form factor (FF) analyses showed no significant effect on mitochondrial branching upon 
Forskolin treatment. D) Immunoblot optimisation of NCLX antibody in low heteroplasmy neurons. 20 µg protein 
was loaded for each sample (NCLX antibody (1;1000). Bands were expected at 55 and 100 kDa. Additional bands 
were detected at ~140kDa (could either suggest dimerisation and/or nonspecific antibody binding).  Alpha 
tubulin was included as a loading control. E) Immunoblot of cellular and mitochondrial fractions of HEK-293-T 
cells overexpressing mouse NCLX (10 µg) derived from brain and heart tissues. Bands were detected at 50, 70 





6.4.2 Mitochondrial movement in Forskolin treated neurons harbouring a single, large scale 
mtDNA deletion 
 
This study utilised IPS cell lines harbouring low (<1%) and high (~40%) levels of a single, large-
scale mtDNA deletion (spanning 6017 base pairs from m.7777-13794). As the level of mtDNA 
deletion was so low in the low heteroplasmy cell line, the line served as an isogenic control.  
 
Mitochondrial dysfunction in PD can be driven by mtDNA deletions (Bender et al., 2006, 
Kraystberg et al., 2006). The experiments described below aimed to understand whether 
mitochondrial movement was affected by mtDNA deletion and whether the level of 
mitochondria Ca2+ efflux (mCa2+) further altered these dynamics. Mitochondrial movement 
parameters: speed, directionality (anterograde and retrograde movement) and distance 
travelled were analysed and compared for both cell lines via imaging TMRM loaded NGN2 




Figure 6.6. Tracking mitochondrial movement after in NGN2 neurons. A) TMRM snapshots of videos taken of low 
heteroplasmy neurons loaded with 5nm TMRM (Scale bars: 100 µm). B) Kymographs generated tracking in vitro 
mitochondrial movement in low heteroplasmy neurons, which were then analysed for speed and distance values. 
C) Arrows indicating directionality in mitochondrial movement observed in kymographs: Retrograde (Red), 







6.4.2.1 Static versus moving mitochondria in neurons treated with Forskolin 
 
Similar, to the thresholds set in Chapter 4 (Ex vivo imaging of mitochondrial trafficking in 
dopaminergic neurons) mitochondrial movements in this study were segregated into two 
populations: ‘stationary’ (0-0.005μm/s) and ‘motile’ (0.005μm/s and above). For all the 
movement parameters mixed model statistics was carried out to observe whether in this study, 
significant differences were observed between cell lines (mitochondrial movement was altered 
between both heteroplasmy neurons) and Forskolin dose (differences observed between 
dosed neurons and untreated controls).   
 
Comparing the total percentage of moving mitochondria between both cell lines, lead to the 
following observations; i) Cell line with neurons exhibit more moving mitochondria (58.27% 
moving) than low heteroplasmy neurons (31.59% moving) and ii) in both cell lines, increasing 
the Forskolin dose, displayed a trend of increased mitochondrial movements (consequently 
reducing the number of mitochondria that are stationary) when compared to untreated 
controls. Furthermore, the variability in the number of mitochondria observed in this study 
does not reflect a reduction in mitochondrial mass in the treated cells, but rather the number 












Figure 6.7. Proportion of mitochondrial movement in Forskolin dosed neurons. A) Plot shows the mean percentage 
of mitochondria that are stationary (light blue) and moving (dark blue) across three experiments. B) Table showing 
the percentage of stationary versus moving mitochondria for untreated and Forskolin dosed neurons. Overall, less 
mitochondrial movement was observed in the dosed and control low heteroplasmy neurons compared to high 

















6.4.2.2 Mitochondrial Speed 
 
Via kymograph analysis this study found that in untreated cells, the mean mitochondrial speed 
was significantly lower in high heteroplasmy neurons (0.196 µm/s ± 0.121 (Log -1.950 ± 0.989), 
[N=532 moving mitochondria]) compared to the low heteroplasmy cells (0.287 µm/s ± 0.329 
(Log -2.121 ± 1.582), [N=320 moving mitochondria]) (p<0.0001) (Figure 6.8).  
When dosed with 10µM Forskolin, the ~40% mtDNA deletion neurons showed reduced 
mitochondrial speed to (0.057 µm/s ± 0.067, (Log -3.414µm/s ± 1.058) [N=270 moving 
mitochondria]) compared to their respective untreated controls (p<0.0001).  Similar reduction 
was observed in the <10% mtDNA deletion to (0.042µm/s ± 0.071 (Log -3.691 µm/s ± 0.926), 
[N=270 moving mitochondria]) (p<0.0001). Significant differences in mitochondrial speed were 
also observed between both cell lines (p<0.0001) upon Forskolin treatment, with high 
heteroplasmy neurons showing a higher mean speed (Figure 6.8).  
At 50µM Forskolin dose, the average speed of mitochondria in both cell lines were again found 
significantly decrease to (0.041µm/s ± 0.079 (Log -3.720 µm/s ± 0.922), [N=247 moving 
mitochondria]) (p<0.0001) and (0.079 µm/s ± 0.189 (Log -3.342 µm/s ± 1.161), [N=388 moving 
mitochondria]) (p<0.0001) respectively, compared to untreated controls.  Significant 
differences in mitochondrial speed were observed between the cell lines (p<0.0001) (Figure 
6.8), with high heteroplasmy neurons again showing faster, mean mitochondrial speeds.  
Overall, this indicates that in neurons harbouring a mtDNA deletion, there are significant 
reductions in the mean speed of mitochondrial movements with Forskolin treatment. 
Significant differences were also detected between the cell lines at each dose with 
















Figure 6.8. Mitochondrial speed in Forskolin dosed neurons.  Values are logged to aid visualisation. Box and whisker 
plot showing the mean (represented by the black line) and spread of data. A) Mean mitochondrial speed was 
significantly lower in high heteroplasmy cells compared to the low heteroplasmy cell line  (p<0.0001). On 10µM 
Forskolin treatment, the mean speed of mitochondria in bot cell lines were reduced compared to their respective 
untreated controls (p<0.0001). At 50µM Forskolin dose the average speed of mitochondria in both cell lines was 
also found to significantly decrease (p<0.0001) compared to untreated controls.  Significant differences in 
mitochondrial speed were also observed between the cell lines (p<0.0001). B) Statistics table for each Forskolin 
dose for each cell line in this study comparing: number of moving mitochondria of the total mitochondria and their 
mean speed (logged) and mean speed. N=3 biological repeats for all experiments.  C) The model intercept 
represents differences in the speed of mitochondrial movements between the cell lines and Forskolin doses.  
C)  Mixed model statistics for speed of mitochondrial movement in Forskolin dosed neurons 
 AIC BIC LogLik   





Standard Error DF T-Value P-Value 
Intercept -1.9432263 0.07075873 2021 -27.462709        0.0001 
Forskolin 10 µM -1.4815239 0.06292351 2021 -23.544839        0.0001 
Forskolin 50 µM -1.4483936 0.05984375 2021 -24.202923        0.0001 
Cell line -0.2651813 0.05208165 2021 -5.091645        0.0001 
Number of observations 2027     






In order to understand the how far mitochondria move within the axons of these neurons, the 
mean distance of mitochondrial movements was calculated.  
It was found that the mean distance travelled by ~40% deletion neurons displayed a mean 
distance of (30.923 μm ± 27.291 (Log 2.746 μm ± 1.412) [N=578 total mitochondria]), 
significantly higher than in <10% deletion neurons (12.547 μm ± 14.914 (Log 1.757 μm ± 1.377) 
[N=487 travelling mitochondria]) (p<0.0001) (Figure 6.9). 
When dosed with 10µM Forskolin, a significant decrease in distance travelled was seen in ~40% 
deletion neurons (16.119 µm ± 18.968 (Log 2.076 µm ± 1.260) [N=429 travelling mitochondria]) 
(p=0.0134) compared to their respective untreated controls. A significant increase in the 
distance that mitochondria travelled was observed in the  <10% deletion cell line (14.309 µm ± 
15.789 (Log 2.035 μm ± 1.197) [N=452 travelling mitochondria]). Further differences in 
mitochondrial distance were also observed between the cell lines (p<0.0001) (Figure 6.9) at this 
dose.   
Finally, upon treatment with 50µM Forskolin, the ~40% deletion neurons displayed a decrease 
in mean mitochondrial distance travelled to (18.702 µm ± 21.992 (Log 2.219 µm ± 1.287) 
[N=573 travelling mitochondria]) (p=0.0037) compared to their respective untreated controls. 
In contrast, average distance travelled of mitochondria in the <10% deletion neurons were 
found to significantly increase to (12.899 µm ± 14.658 (Log 1.871 µm ± 1.242) [N=445 travelling 
mitochondria]). Significant differences in mitochondrial distance were also observed between 
the cell lines at this concentration of Forskolin (p<0.0001) (Figure 6.9).   
Overall, with increased Forskolin concentration, mitochondrial distance travelled was 
significantly increased within the lower mtDNA deletion cell line, with a decrease in distance 
travelled observed in the ~40% deletion neurons . Significant changes in mitochondrial distance 







C) Mixed model statistics for distance of mitochondrial movement in Forskolin dosed neurons 
 AIC BIC LogLik   





Standard Error DF T-Value P-Value 
Intercept 2.4480023 0.18581297 2958 13.174550   0.0001 
Forskolin 10 µM -0.1468414 0.05937269 2958 -2.473214 0.0134 
Forskolin 50 µM -0.1661663 0.05723763 2958 -2.903095 0.0037 
Cell line -0.4695687 0.04809592 2958 -9.763172 0.0001 
Number of observations 2964     
Number of groups 3     
 
Figure 6.9. Mitochondrial distance in Forskolin dosed neurons.  Values are logged to aid visualisation. Box and 
whisker plot showing the mean (represented by the black line) and spread of data. A) Mean distance travelled by 
mitochondria in low heteroplasmy neurons was lower than what was observed in the high heteroplasmy neurons 
(p<0.0001). When dosed with 10µM Forskolin, a significant increase in the distance travelled was observed in the 
low heteroplasmy cell line, with a significant decrease in distance travelled observed in high heteroplasmy neurons  
(p=0.0134) compared to their respective untreated controls. With 50µM Forskolin, the mean distance travelled of 
mitochondria in low heteroplasmy neurons increased, in contrast to the high heteroplasmy neurons which again 
displayed a decrease in mean mitochondrial distance travelled (p=0.0037) compared to their respective untreated 
controls. Significant differences in mitochondrial distance were also observed between the cell lines at this 
concentration of Forskolin (p<0.0001). B) Statistics table for each Forskolin dose for each cell line in this study 
comparing: total number of mitochondria, total number of travelling mitochondria, their mean distance (logged) 
and mean distance. N=3 biological repeats for all experiments. C) The model intercept represents difference in 




6.4.2.4 Anterograde moving mitochondria – Speed 
 
The motile pool of mitochondria found within both lines was then analysed for directionality, 
to observe whether the presence of an mtDNA deletion can affect anterograde (+) and 
retrograde (-) mitochondrial movements.  
The percentage of anterograde moving mitochondria (those moving away from the cell body) 
within low heteroplasmy neurons was 12.14% (mean speed = 0.343 ± 0.323 [Log -1.669 µm/s 
± 1.283]). This was slightly higher than for mitochondria within high heteroplasmy neurons 
exhibiting 11.50% anterograde movement (mean speed= 0.193 µm/s ± 0.153 [Log -2.019 µm/s 
± 0.959]), though this increase did not reach significance (Figure 6.10).  
When dosed with 10µM Forskolin, in the ~40% deletion neurons, a large decrease in 
anterograde movements from 11.50% to 3.76% was observed, again followed by a decrease in 
mean speed (mean speed= 0.074 µm/s ± 0.088 [Log -2.959 µm/s ± 0.769]) compared to 
untreated controls.  In the <10% deletion cell lines anterograde movements increased from 
12.14% to 14.34%, though this was associated with a decrease in mitochondrial mean speed 
(mean speed= 0.052µm/s ± 0.045 [Log -3.258 µm/s ± 0.747]) compared to untreated controls. 
(p<0.0001) (Figure 6.10). 
With a 50µM Forskolin dose, ~40% deletion neurons demonstrated a slight increase in 
anterograde movements to 13.19%, also followed by a decrease in mitochondrial mean speed 
(mean speed= 0.077 µm/s ± 0.074 (Log -2.936 µm/s ± 0.883). The percentage of anterograde 
moving mitochondria decreased in <10% deletion cell lines to 9.90%, which was followed by a 
decrease in speed (mean speed= 0.069µm/s ± 0.118 [Log -3.201µm/s ± 0.881]) compared to 
untreated controls., both observations were significantly different when compared to 
untreated controls (p<0.0001) (Figure 6.10) 
Overall, the speed of anterograde mitochondrial transport was found to be significantly 
reduced with Forskolin treatment compared to control experiments, although these 







C) Mixed model statistics for the speed of anterograde mitochondrial movement in Forskolin dosed neurons 
 AIC BIC LogLik   
   9977.537 10013.49   -4982.768   
 Value 
 
Standard Error DF T-Value P-Value 
Intercept -1.86819     0.08600 449 -21.722    0.0001 
Forskolin 10 µM -1.38729     0.12816 449 -10.825    0.0001 
Forskolin 50 µM -1.19305     0.11137 449 -10.713    0.0001 
Cell line 0.07028     0.09996    449 0.703     0.482     
Number of observations 453     
Number of groups 3     
 
Figure 6.10. Mitochondrial speed of anterograde moving mitochondria in Forskolin dosed neurons.  Values are 
logged to aid visualisation. Box and whisker plot showing the mean (represented by the black line) and spread of 
data A) The percentage of anterograde moving mitochondria within low heteroplasmy neurons was higher than 
for mitochondria within high heteroplasmy neurons exhibiting 11.50% anterograde movement. On 10µM 
Forskolin, anterograde movements of mitochondria in low heteroplasmy neurons increased from 12.14% to 
14.34%, associated with a decrease in mitochondrial mean speed compared to untreated controls. A decrease in 
anterograde movements 11.50% to 3.76%, was observed in the high heteroplasmy neurons, followed by a 
decrease in mean speed compared to untreated controls (p<0.0001). At 50µM Forskolin dose, the percentage of 
anterograde moving mitochondria decreased in the low heteroplasmy neurons to 9.90%, which was followed by 
a decrease in speed  compared to untreated controls.  High heteroplasmy neurons demonstrated a slight increase 
in anterograde movements to 13.19%, followed by a decrease in mitochondrial mean speed, significantly different 
when compared to untreated controls (p<0.0001). B) Statistics table for each Forskolin dose for each cell line in 
this study comparing: Percentage anterograde moving mitochondria and their mean speed. N=3 biological repeats 






6.4.2.5 Anterograde moving mitochondria – Distance 
 
Following the observations of the speed of anterograde mitochondrial movements, this study 
then observed the distance travelled of these mitochondria.  
It was found that in the untreated controls, mitochondria within ~40% mtDNA deletion neurons 
displayed a slightly lower mean distance travelled (mean distance= 13.607 µm ± 12.511 [Log 
2.339µm ± 0.704) when compared to the <10% mtDNA deletion neurons (mean distance= 
18.527µm ± 18.473 [Log 2.472µm ± 1.061) (Not significant) (Figure 6.11) 
On 10µM Forskolin, the distance travelled of anterograde moving mitochondria was found to 
increase in both cell lines (low (mean distance= 24.359 µm ± 15.832 [Log 2.991 µm ± 0.684) 
and high (25.996 µm ± 18.982 [Log 2.925µm ± 0.936 ]) respectively, compared to controls 
(P<0.0001).  
Similarly, upon 50µM Forskolin dosing, the distance travelled of anterograde moving 
mitochondria was found to increase in both cell lines (low (21.571µm ± 14.284 [Log 2.816 µm 
±  0.812) and high (28.129 µm ± 19.211 [Log 3.090µm ±  0.754) mtDNA deletion neurons 
(P<0.0001) (Figure 6.11).   
Therefore, the distance travelled of anterograde moving mitochondria were found to be 
significantly increased with Forskolin treatment in neurons compared to controls, though these 
differences were not observed between the cell lines treated with the same dose. Though 
anterograde mitochondria are moving slower, they appear to be covering longer lengths; 
















C) Mixed model statistics for the distance travelled for anterograde mitochondrial movement in Forskolin 
dosed neurons 
 AIC BIC LogLik   





Standard Error DF T-Value P-Value 
Intercept 2.417180    0.071450 483 33.830   0.0001 
Forskolin 10 µM 0.565665 0.103574    483 5.461 0.0001 
Forskolin 50 µM 0.571513    0.090240    483 6.333 0.0001 
Cell line -0.004788    0.081454   483 -0.059     0.953     
Number of observations 487     
Number of groups 3     
 
Figure 6.11. Mitochondrial distance travelled of anterograde moving mitochondria in Forskolin dosed neurons.  
Values are logged to aid visualisation.Box and whisker plot showing the mean (represented by the black line) and 
spread of data A) In the untreated controls low heteroplasmy neurons displayed a slightly higher mean distance 
travelled compared to the high heteroplasmy (Not significant). On 10µM Forskolin, the distance travelled of 
anterograde moving mitochondria was found to increase in both cell lines compared to their untreated controls 
(P<0.0001).  On 50µM Forskolin dose, distance travelled of anterograde moving mitochondria was found to 
increase in both cell lines heteroplasmy neurons (P<0.0001). N=3 biological repeats for all experiments. C) Mixed 
model intercept represents differences in the distance travelled of mitochondrial movement with increased 




6.4.2.6 Retrograde moving mitochondria – Speed  
 
In the untreated control lines, the percentage of retrograde moving mitochondria was higher 
(12.04%) and those mitochondria were faster moving within the lower mtDNA cell line (mean 
speed= 0.347 µm/s ±0.342, [Log -1.612 µm/s ± 1.211]), compared to ~40% mtDNA deletion 
neurons  ; 10.84% (mean speed 0.195 µm/s ±0.174, [Log -2.081 µm/s ± 1.043]), though this did 
not reach significance (Figure 6.12). 
Retrograde mitochondrial movements decreased following 10µM Forskolin treatment, in the 
~40% mtDNA deletion neurons to 5.85% accompanied by a decrease in mean speed (mean 
speed = 0.070 µm/s   ±0.052, [Log -2.902 µm/s ±0.723]) when compared to respective 
untreated control.  In the <10% mtDNA deletion neurons, speed increased to 13.56%, also 
showing reduced mitochondrial mean speed (mean speed= 0.043 µm/s ±0.046, [Log -3.471 
µm/s ±0.722]) compared to untreated controls. (p<0.0001) (Figure 6.12) 
Lastly, following  50µM Forskolin, in the ~40% mtDNA deletion neurons an increase to 13.19% 
of mitochondria moving in a retrograde direction was observed, with reductions in speed 
(mean speed= 0.069 µm/s ±0.046, [Log -2.900 µm/s ± 0.696]) whilst the percentage and speed 
of retrograde moving mitochondria decreased in the lower deletion line to 11.29% (mean 
speed= 0.045 µm/s ±0.036, [Log -3.349 µm/s ±0.678]) (p<0.0001) (Figure 6.12) 
The mean speed of retrograde moving mitochondria was found to decrease with Forskolin 
treatment in both cell lines , though these differences were not observed between the cell lines 





C) Mixed model statistics for the speed of retrograde mitochondrial movement in Forskolin dosed neurons 
 AIC BIC LogLik   
   9977.537 10013.49   -4982.768   
 Value 
 
Standard Error DF T-Value P-Value 
Intercept -1.81424     0.08280 455 -21.912    < 2e-16 
Forskolin 10 µM -1.48972 0.11869 455 -12.552    < 2e-16 
Forskolin 50 µM -1.26622 0.10511 455 12.046    < 2e-16 
Cell line -0.00362 0.09281   455 -0.039     0.969     
Number of observations 459     
Number of groups 3     
Figure 6.12. Mean mitochondrial speed of retrograde moving mitochondria in Forskolin dosed neurons. Values 
are logged to aid visualisation. Box and whisker plot showing the mean (represented by the black line) and spread 
of data A) In the untreated control lines, the percentage of retrograde moving mitochondria was higher (12.04%) 
and those mitochondria were faster moving within the low heteroplasmy neurons compared to the high 
heteroplasmy neurons  (not significant). On 10µM Forskolin treatment, retrograde mitochondrial movement 
increased in low heteroplasmy neurons, with a reduced mitochondrial mean compared to untreated controls. In 
the high heteroplasmy neurons, a similar pattern was observed a decrease in retrograde movements, 
accompanied by a decrease in mean speed when compared to respective untreated control (p<0.0001). On 50µM 
Forskolin, the percentage and speed of retrograde moving mitochondria decreased in the low heteroplasmy, 
though in the high heteroplasmy neurons an increase in the percentage of mitochondria moving in a retrograde 
direction was observed, with reduced mean speed compared to both cohorts untreated controls (p<0.0001). B) 
Statistics table for each Forskolin dose for each cell line in this study comparing: Percentage retrograde moving 
mitochondria and their mean speed. N=3 biological repeats for all experiments. C) Mixed model intercept 





6.4.2.7 Retrograde moving mitochondria – Distance 
 
It was found that in the untreated control lines, retrograde moving mitochondria were 
travelling a slightly shorter distance  in the ~40% deletion neurons (mean distance= 10.741µm 
± 7.734, [Log 2.128 µm  ± 0.749]) compared to the <10% deletion cell line (mean distance= 
18.447 µm  ± 12.986, [Log 2.629 µm  ± 0.837 ) though this did not reach significance (Figure 
6.13). 
On 10µM Forskolin treatment, mean distance travelled increased in both cell lines  low (mean 
distance= 23.029 µm ± 15.827, [Log 2.903 µm  ± 0.728])) and high (mean distance=37.668 µm  
± 26.161, [Log 3.388 µm  ±0.726]) mtDNA deletion neurons respectively, when compared to 
untreated controls (p<0.0001) (Figure 6.13).  
Lastly, following treatment with 50µM Forskolin, increases in mitochondrial distance travelled 
were observed in both cell lines, low (mean distance=23.029 µm ±  15.827, [Log 2.882 µm  ± 
0.769]) and high (mean distance=27.312 µm  ± 20.910, [Log 3.036 µm  ±0.786]) mtDNA deletion 
neurons, compared to untreated controls  (p<0.0001) (Figure 6.13). 
Therefore, the distance travelled by retrograde moving mitochondria increased upon Forskolin 
treatment compared to controls, though these differences were not observed between the 
both cell lines treated with the same dose. Mitochondria though are moving slower, are 
covering a longer range of distance, similarly to the anterograde findings.  
This study also found that total percentage of anterograde and retrograde moving 
mitochondria did not total 100%. Mitochondria do not exhibit a uniform pattern of movement 
and therefore the remaining mitochondria classed as moving could be exhibiting a ‘dynamic 
pause’ effect, whereby they are shuffling in the same place of origin, though this study did not 














C) Mixed model statistics for the distance travelled for retrograde mitochondrial movement in Forskolin dosed neurons 
 AIC BIC LogLik   





Standard Error DF T-Value P-Value 
Intercept 2.34780     0.06666 483 35.222 0.0001 
Forskolin 10 µM 0.60804 0.09536 483 6.376 0.0001 
Forskolin 50 µM 0.58432 0.08194 483 7.131 0.0001 
Cell line 0.10614 0.07371  483 1.440 0.151 
Number of observations 504     
Number of groups 3     
 
Figure 6.13. Box and whisker distribution plot of the distance travelled of retrograde moving mitochondria in 
Forskolin dosed neurons. Values are logged to aid visualisation. Box and whisker plot showing the mean 
(represented by the black line) and spread of data. A) In the untreated control lines, retrograde moving 
mitochondria were travelling a greater distance in the low heteroplasmy neurons compared to high heteroplasmy 
neurons (not significant). Following 10µM Forskolin treatment, in both cell lines retrograde moving mitochondria 
covered a greater distance compared to untreated controls (P<0.0001).  On 50µM Forskolin, retrograde moving 
mitochondria again covered greater distances in both cell lines when compared to controls (P<0.0001).  B) 
Statistics table for each Forskolin dose for each cell line in this study comparing: Percentage retrograde moving 
mitochondria and their mean distance travelled. N=3 biological repeats for all experiments. C) Mixed model 





6.4.3 Effect of altered calcium efflux on mitochondrial movements 
 
Taken together, these results show that mitochondria harbouring a high level of mtDNA 
deletion display alterations in their speed, directionality and distance moved after Forskolin 
treatment; a reagent which allows the opening of the NCLX exchanger allowing calcium ions to 
exit the mitochondria. Thus, having analysed this mitochondrial movement the following 
experiments describe how the effect of altered mCa2+ efflux on mitochondrial movement was 
studied to confirm whether altered cytosolic calcium availability that drives the changes in 
mitochondrial movement. The theory behind these experiments was to understand whether 
neurons with a mitochondrial defect have impaired calcium handling and whether Forskolin 
was capable of restoring this to levels found in the control. Therefore, initial experiments were 
carried out to observe levels of cytoplasmic Ca2+ after Forskolin treatment within control cell 
lines.   
 
Ionomycin is a calcium ionophore (substance that can cross cellular lipid membranes), which is 
used to increase cytoplasmic Ca2+ influx through direct stimulation of cation entry across the 
cell membrane. This maximal increase in intracellular calcium consequently results in a 
maximum increase in fluorescence (Rmax) (Yoshida and Plant, 1992). To determine the Rmax 
values of Fluo-4-am (a cytosolic calcium indicator which displays and increase in signal when 
bound to Ca2+) in both cell lines, fluorescence was measured for 60 seconds at the baseline post 
1 µM ionomycin treatment, triggering cytosolic Ca2+ influx. As Ca2+ imaging has not been 
conducted in these neurons previously, initial optimisation experiments were conducted on the 
cell lines to obtain the optimum concentrations for the upcoming experiments (Figure 6.14). 
Following which around 5-10 ROIs were selected per video, of which for each dose 
approximately 20-30 ROIs were analysed to understand the alterations in Ca2+ availability in 









Figure 6.14.  Ionomycin stimulation in neurons harbouring mtDNA deletion. Both panels show snapshots of 
Forskolin treated neurons loaded with TMRM staining (TRITC channel) and Fluo-4-am (FITC). Neurons 
were stimulated with 1μM ionomycin after 20-30 seconds of imaging (ionomycin stimulation) to induce maximum 





















6.4.3.1 Fluo-4-am and TMRM experiments  
 
Neurons were dosed with Forskolin, 30-40 minutes prior to experimentation (Kostic et al., 
2015). Measurements of the Fluo-4-AM fluorescence showed that the medians significantly 
varied between all neurons (p=0.0007). Though reduced available calcium was observed in the  
untreated ~40% deletion line  compared to the untreated <10% deletion line not significant 
(p=0.4318). When dosed with 10µM Forskolin, both cell lines displayed an increase in Fluo-4-
am fluorescence (not significant, p=0.9048). In contrast, 50µM Forskolin treatment 
demonstrated a large decrease in free Ca2+ within <10% deletion when compared to untreated 
controls, which was found to be significantly different to the ~40% deletion neurons which 
showed an increase in free Ca2+ (p=0.0159) (Figure 6.15A).  
Between doses the only significant differences observed were between the untreated high level 
deletion neurons and 10µM Forskolin high level deletion neurons (p=0.0144) and 10µM and 
50µM Forskolin treated lower deletion line (p=0.0042).  
It appears that neurons of the high heteroplasmy cell line harbour more free cytosolic Ca2+ to 
as opposed to the low heteroplasmy neurons via the NCLX exchanger through Forskolin 
treatment. It may be the case that due to fewer damaged mitochondria in the low 
heteroplasmy cell line, perhaps not as much calcium is needed to be expelled through the NCLX 
exchanger, due to a decreased mCa2+ overload.  The opposite is observed in the high 
heteroplasmy cell line, which demonstrates increased calcium availability (Figure 6.15A).   
As neurons were also stained with TMRM as well as Fluo-4-AM, variations in TMRM intensity 
were observed in these neurons. An overall decrease in TMRM intensity is observed in the high 
and low heteroplasmy neurons when Forskolin treated however these did not reach 
significance.   Interestingly though, these findings match the TMRM pattern observed in the 











Figure 6.15. Fluo-4-AM and TMRM observations in Forskolin treated neurons. Changes in free Ca2+ in low (red) and 
high (blue) heteroplasmy neurons treated with Forskolin. A) Medians significantly varied between all neurons 
(p=0.0007). Reduced available calcium was observed in the high heteroplasmy neurons compared to low 
heteroplasmy neurons (not significant). On 10µM Forskolin treatment, low and high heteroplasmy cell lines show 
increased Fluo-4-am fluorescence (not significant, p=0.9048). On 50µM Forskolin treatment significantly 
differences in free Ca2+ are observed between low and high heteroplasmy neurons (p=0.0159). Further significant 
differences observed were between the untreated high heteroplasmy neurons and 10µM Forskolin high 
heteroplasmy neurons (p=0.0144) and 10µM and 50µM Forskolin low heteroplasmy neurons (p=0.0042). B) 
Changes in TMRM intensity representative of mitochondrial membrane potential. Medians were significantly 
varied between all neurons (p=0.030).  Only significant change observed between untreated low heteroplasmy 
neurons and 50µM Forskolin treated low heteroplasmy neurons (p=0.0261). Calculated using Kruskal Wallis test, 
with post-hoc Dunn’s multiple comparison to allow the testing of comparison of more than two levels. Graphs 
represented as Mean Fluo-4-AM/TMRM intensity (normalised to ionomycin) ± SEM. 5-10 ROIs were selected per 








6.5.1 Summary of Results 
 
• Static versus motile mitochondria – Mitochondria harbouring a higher mtDNA deletion 
exhibit more mitochondrial movement than the low heteroplasmy neurons. 
Mitochondrial movement increases with Forskolin treatment in both cell lines.  
 
• Speed – Though more mitochondria are moving with Forskolin treatment, the mean 
mitochondrial speed is significantly reduced with Forskolin treatment. 
 
• Distance - Slower moving mitochondria demonstrated a reduced distance in high 
heteroplasmy neurons, and an increased distance in low heteroplasmy neurons with 
Forskolin treatment in both dosing experiments and between both cell lines.  
 
• Directionality - Overall the speed of anterograde and retrograde mitochondrial 
transport was found to be significantly reduced in both cell lines with Forskolin 
treatment though distance travelled was found to be significantly increased compared 
to controls. 
 
• Ca2+ availability – Higher heteroplasmy neurons contain more free Ca2+ than low 
heteroplasmy neurons.  Forskolin (10 µM) treatment, enhances mCa2+ efflux, causing an 
almost two fold increase in free calcium availability in both cell lines; sufficient to cause 
an increase in Ca2+ availability through the opening of the NCLX exchanger as a 
consequence of their mtDNA deletion.  
 
• Membrane potential –  An overall decrease in TMRM intensity was observed with 
Forskolin treatment, whereby an increased Ca2+ availability might rescue mitochondrial 









Impaired NCLX activity within PINK1 deficient neurons, was found to be rescued by the Protein 
Kinase A (PKA) signalling pathway via phosphorylation of the serine258 NCLX residue. This rescue 
through direct phosphorylation of NCLX by PKA via Forskolin treatment [PKA agonist]), was 
described as a regulatory mode of mCa2+ efflux, restoring mCa2+ efflux under PINK1 deficient 
neurons and protecting these cells from mitochondrial depolarisation via the opening of the 
PTPs (Figure 6.4. Kostic et al., 2015). Forskolin was used in this experiment to observe whether 
varying levels of mCa2+ efflux had differential effects on mitochondrial transport. To understand 
whether mCa2+ efflux affects mitochondrial movement, two concentrations of Forskolin were 
used.  
It has been repeatedly shown that mCa2+ is crucial for mitochondrial health and survival (Palty 
et al., 2010, Kostic et al., 2015). However, it is still debated whether mitochondrial transport is 
affected by mCa2+ efflux or the lack of it. Intramitochondrial Ca2+ (through Rhod-2-AM) was not 
observed in this experiment, as this initial experiment was conducted to first understand 
whether cytosolic Ca2+ (Fluo-4-AM) was affected by mCa2+ efflux.  
The justification for these experiments were to understand whether increasing mCa2+ efflux (by 
Forskolin treatment) increased free cytoplasmic calcium within neurons. From here, this study 
then attempted to understand whether increased intraneuronal Ca2+availability within neurons 
altered in vitro mitochondrial movement, in neurons with a mitochondrial defect.  
 
6.5.2 Impact of mCa2+ efflux on mitochondrial transport within neurons harbouring an mtDNA 
defect 
 
In this study, it was found that with Forskolin treatment, mitochondria within the high 
heteroplasmy (~40%) neurons were moving at a lower mean speed and travelled an overall 
shorter distance in comparison to mitochondria in low heteroplasmy neurons. These findings 
suggest that, mitochondria within low heteroplasmy neurons, might maintain a steady pace to 
efficiently supply energy to all regions of the neuron; especially distally, and opposingly high 
heteroplasmy neuronal mitochondria might be moving too fast, and therefore must need to be 





The neuron relies upon a functional OXPHOS system which generates ATP to meet its energy 
demands (Schwarz, 2013).  As the higher heteroplasmy untreated neurons exhibit slower 
mitochondrial movements, it may indicate that the respiratory chain deficiency; present as a 
consequence of the large scale mtDNA deletion, may be triggering a defect in motility as ATP 
generation may be altered. These alterations may then prohibit mitochondrial movement. 
Furthermore, increased cytoplasmic Ca2+ was observed after 10 µM and 50 µM Forskolin 
treatment in high heteroplasmy neurons compared to controls, where similar findings were 
observed in the low heteroplasmy neurons though only at 10 µM Forskolin treatment. With 
Forskolin treatment, cytosolic Ca2+ levels may be elevated, explaining the reduced 
speed/distance of mitochondrial movement.  
Mechanistically, the increased level of intracellular calcium identified in high heteroplasmy 
neurons may be a method to counteract the impaired calcium homeostasis within neurons with 
a large-scale mtDNA deletion. Ca2+ signalling has previously been shown by Wang and Schwarz, 
(2009) to halt mitochondrial movement in an attempt to adapt and provide for the energy 
needs of the neuron. This mode of regulation occurs as Ca2+  interacts with Miro via Milton. 
Kinesin exists on both static and moving mitochondria, whereby the EF-hands of Miro regulate 
Ca2+  dependant mitochondrial arrest via binding the kinesin motors directly. This bypasses the 
step where kinesin dissociates from the mitochondria and therefore becomes ‘inactivated’ and 
being bound to Miro stops any further interactions with the microtubule (Wang and Schwarz, 
2009).  
Recently, live imaging studies have shown an inverse correlation between mitochondrial speed 
and mCa2+ levels, whereby the lower the mCa2+ content, the faster these organelles move (Chang 
et al., 2011).  In terms of the transport machinery that may be driving this process, it was 
suggested that as each mitochondrion can bind many miro1 proteins, perhaps mitochondrial 
speed might be mediated by this binding and consequently its attachment to kinesin motors. 
Therefore, once a specific mCa2+ threshold is reached, these miro1–kinesin interactions are 
interrupted, and mitochondria therefore either slow down and/or stop moving, (Chang et al., 
2011) supporting a role of mCa2+ on mitochondrial transport.  
Moreover, as available cytosolic calcium is higher in the Forskolin treated high heteroplasmy 
neurons, it may be likely that damaged mitochondria are also expelling mCa2+ at a higher rate 
(not measured in this study). Once Forskolin treated, the NCLX exchanger may be sufficiently 




al.,  2015), as a consequence of the insufficient mCa2+ homeostasis within the dysfunctional 
mitochondria in high heteroplasmy cell line, which may already be close to opening. Thus, the 
expelled cytoplasmic Ca2+ might in turn prohibit mitochondrial dynamics through the direct 
increase in cytoplasmic calcium within neurons. 
If a high mCa2+ concentration is found within mitochondria it may signal the organelle to halt its 
movement. This might be so that TCA cycle reactions are promoted to produce ATP, in order 
provide energy wherever needed. In contrast a lowered mCa2+ concentration might signal for 
mitochondrial mobility to occur (Chang et al., 2011), and thus to provide ATP supplies to meet 
the energy demands of the neuron in distal regions. It may be that this is the case in the 
Forskolin treated NGN2 neurons, as this study observes reduced mitochondrial movement 
parameters in the neurons harbouring a large scale mtDNA deletion. 
Additionally, the medium in which the NGN2s were grown in may alter mitochondrial transport. 
NGN2 IPSCs are cultured in a medium which contains glucose, where fluctuations in neuronal 
glucose concentration affect mitochondrial trafficking (Schwarz, 2013). Hence, this suggests 
that the environment in which these neurons are grown, may have an impact on mitochondrial 
movement. Repeating these experiments in a glucose-free/low glucose medium i.e. galactose, 
will force the mitochondria to use their oxidative metabolism to generate energy and will 
provide a more representative outlook into mitochondrial movement in NGN2 cultured 
neurons. 
 
6.5.3 Anterograde and retrograde mitochondrial movement in Forskolin treated neurons 
harbouring a respiratory chain deficiency  
 
This study found that Forskolin significantly altered anterograde and retrograde mitochondrial 
movement in both cell lines. These mitochondria displayed decreased mitochondrial speed but 
travelled greater distances when treated with Forskolin compared to untreated controls.  
This study identifies alterations in both anterograde and retrograde movement when treated 
with Forskolin. Though mitochondrial speed is reduced overall with Forskolin treatment, these 
mitochondria appeared to move farther, indicating that these organelles exhibit slower 
movement to conserve energy as less ATP is available. This ensures that i) anterograde moving 




retrograde moving mitochondria are manoeuvring themselves slower to ensure they reach the 
lysosomes for degradation.  
A mitochondrion rendered as dysfunctional will need to be returned to the soma for lysosomal 
degradation (Pickrell and Youle, 2015). As this occurs over a longer distance, mitochondria will 
have to move retrograde and travel further.  This study suggests that with increased Forskolin 
treatment, retrograde mitochondrial distance travelled was increased.  As these movement 
alterations are observed, how directionality is managed via motor protein association will be 
an interesting follow up study to understand the molecular mechanism of Ca2+ regulated 
mitochondrial movement.  
Furthermore, it remains unexplored in this study whether promoting retrograde mitochondrial 
movement via Forskolin treatment is actually promoting mitophagy of damaged 
mitochondria/mildly defective mitochondria, as the TMRM data was also inconclusive. Via 
forskolin treatment it may be the case that (as found in PD patients with defective mitophagy) 
mitochondria are being targeted to the lysosomes that are not actually undergoing 
degradation, but instead causing a build up of damaged mitochondria within the cell body. 
Therefore, though targeting more mitochondria to the lysosomes for degradation is an 
attractive theory, in this study it is unclear whether i) damaged mitochondria are accumulating 
in the cell body or ii) whether healthy mitochondria (due to mild phenotype of mtDNA deletion) 
are being targeted retrograde.  These mitochondria may be exacerbating the disease by forcing 
mitochondrial transport out of the axon and into the cell body. Further studies in regard to 
answering the above questions will be highly beneficial, if not testing for the detriments of 
Forskolin treatment and whether mitophagy occurs consequently may be a counterintuitive 
setup.    
As all these trafficking methods are highly energy consuming, mitochondria with a large scale 
mtDNA deletion may have to move slower in order to prevent organelle death, as they are 
required to move a long distance. How the mitochondria then regulates its dynamics and what 
mediates the switches between anterograde and retrograde transport remains a largely 
debated subject. However, these findings indicate that the the mitochondrial transport 
machinery is an intricate system constantly undergoing changes to promote cell survival, 




As a consequence of mtDNA heteroplasmy, not all mitochondria express the large- scale mtDNA 
deletion. Though quantificational studies show evidence of a ~40% deletion level (See Chapter 
5) not all mitochondria will harbour this defect and may therefore be unaffected. The ‘healthier’ 
mitochondria may be the population of mitochondria that are moving and also exhibiting 
directionality, which might explain why the percentage of anterograde moving mitochondria 
are found to decrease with Forskolin treatment travelling a longer distance in the low 
heteroplasmy neurons. These mitochondria may not be affected by their mtDNA deletion (<1%) 
and may have functioning mitochondrial transport systems that maintain mitochondrial 
dynamics, unlike the high heteroplasmy neurons.  
 
6.5.4 The interplay of mitochondrial dysfunction and calcium handling in neurons in 
Parkinson’s disease 
 
In terms of PD pathology, SN neurons contain damaged mitochondria, in particular those that 
harbour an mtDNA deletion (Grunewald et al., 2019). The findings in this study illustrate that 
regulating mCa2+ efflux through Forskolin treatment, mitochondrial transport acts as a novel 
method to preserve mitochondrial transport within a large-scale mtDNA deletion cell line. 
These defective mitochondria may be limiting their movement to cater for their genetic 
damage as a means to conserve energy.  
In an attempt to regulate mitochondrial transport this study demonstrated that mCa2+ efflux 
effects mitochondrial motility. Mitochondria appear to be moving slower i) perhaps in 
preparation to halt, as cytosolic Ca2+ is being altered and/or ii) a depolarised membrane 
potential (indicated by TMRM intensity) triggers mitochondrial damage and thus reduced 
mitochondrial transport. Forskolin-dependant mitochondrial transport may be a unique 
method to rectify the single, large scale mtDNA deletion in a dysfunctional mitochondrial 
system and mitochondrial transport. It may also be a means as to how damaged mitochondria 
can be degraded, as a direct consequence of their increased retrograde trafficking to the 
lysosome.  
Within PD, one of the reasons attributed to DAergic neuronal loss is oxidative damage caused 
by the pace making activity of L-type Ca2+ channels (Surmeier et al., 2017). If these calcium 




also defective, and also their calcium handling properties. If intraneuronal calcium is reduced, 
as a consequence of perturbed mitochondrial calcium handling, then perhaps treating DAergic 
neurons with Forskolin may allow the expulsion of mCa2+ into the cytoplasm, and thus restoring 
the neurons calcium levels. This is important, as altered cytoplasmic calcium in neurons can 
increase mitochondrial ROS generation which may be implicated in neurodegenerative 
mechanisms (Gleichmann and Mattson, 2017).  
Therefore, these findings conclude that mitochondrial calcium efflux renders itself a novel 
target to mediate mitochondrial transport within neurons. This study provides details into 
alterations of mitochondrial movement within neurons harbouring a single, large-scale mtDNA 
deletion, a common mutation found in PD and how the NCLX exchanger is a novel target for 






Figure 6.16. Possible mCa2+ efflux mediated mitochondrial transport. A) The well-described mitochondrial transport 
system which comprises the Miro/Milton – KHC complex. B) Phosphorylation of the mitochondrial NCLX exchanger 






6.6 LIMITATIONS OF THIS STUDY 
 
• Similarly, to the previous chapter, this study did not measure mtDNA deletion levels 
after IPSC differentiation, where it was assumed that the level of deletion would remain 
the same, which may affect the interpretation of the experimental results.  
• No experiments were conducted to assess the viability of the mitochondria in both cell 
lines once differentiated and treated with Forskolin. Therefore, this must be done to 
eliminate the possibility of Forskolin having a detrimental effect on mitochondrial 
health  
• Importantly, all untreated control measurements were conducted with a DMSO 
concentration in the differentiation media, similarly to the Forskolin treated neurons. 
However, a major limiting factor in this study is that a comparison to neurons 
differentiated from both cell line, without only differentiation medium and no DMSO 
were not made in this study at the same time these experiments were conducted. 
Therefore, though it is suggested the Forskolin can initiate changes in mitochondrial 
trafficking, there may also be some interplay with the DMSO having an effect.  
• Importantly, Russell et al., 2018 demonstrate mitochondrial phenotypes at above 60% 
mtDNA deletion. The literature also states that phenotypes are observed at above 60& 
mtDNA deletion. All the experiments conducted in this study were at ~40% mtDNA 
deletion, as this was largely available in the laboratory.  It can be argued that at this 
lower level of mtDNA deletion perhaps no mitochondrial phenotype will be observed. 
Therefore, it will be beneficial to repeat thee studies at a higher level of mtDNA 
deletion. 
• Following this, trying to promote mitophagy via Forskolin treatment on healthier 
mitochondria (40% mtDNA deletion)  may have adverse effects. Healthier mitochondria 
may instead be degraded as opposed to being preserved within the axon to carry out 








6.7 CONCLUSION & FUTURE WORK 
 
This study demonstrated that a significant difference is observed in mitochondrial trafficking 
between both mtDNA deletion cell lines. The effects of Forskolin were highlighted in this study 
in neurons with a large-scale mtDNA deletion, indicate that there is interplay between the rate 
of mCa2+ efflux and mitochondrial trafficking in neurons with a respiratory chain defect. This 
model provides as a useful tool that provides insight to PD patients, since large-scale mtDNA 
deletions are seen in affected neurons, as it has not yet been established what the basal 
mitochondrial trafficking parameters are within the mammalian nigrostriatal pathway for those 
with PD.  
 
• Future research in this study will observe levels of motor/adaptor complex via western 
blot within both cell lines to understand the effects of mtDNA deletion on the 
mitochondrial transport machinery.  
 
• Observe levels of mCa2+ with Rhod-2-AM dyes (increase in fluorescence when bound 
with mitochondrial calcium) and compare these findings to cytosolic Fluo-4-AM traces 
in low and heteroplasmy neurons with an mtDNA deletion. 
 
• Administer thapsigargin to inhibit ER involvement, and then then observe Forskolin 
effects on mitochondrial trafficking via Fluo-4-AM tracing.  
 
• Use FluoVolt™ Membrane Potential Kit to further delve into the mechanisms of how ER- 


































7.1 FINAL DISCUSSION 
 
PD pathology comprises the significant loss of dopaminergic neurons from the SNpc of the 
midbrain however the contribution of mitochondrial trafficking to this loss remains unclear. It 
has become clear through previous biological studies that mitochondrial movement and 
mitophagy is perturbed in PD (Spillantini et al.,  1998, Whitworth and Pallank, 2009, Youle and 
Narendra, 2011, Narendra et al., 2012, Pozo Devoto et al.,  2017). This study aimed to elucidate 
how the movements of mitochondria, dynamic organelles that exhibit anterograde and 
retrograde motion, are altered with disease and how alterations in this trafficking may occur as 
a response to disease-related mitochondrial dysfunction. 
 
7.1.1 PD models to observe mitochondrial trafficking 
 
The initial focus of this project entailed developing two disease models that encompassed PD 
pathology to observe mitochondrial movement within these axons. The study developed the 
imaging of mitochondrial movement within i) ex vivo nigrostriatal slices (Chapter 3) and ii) IPSCs 
harbouring a single, large scale mtDNA deletion (Chapter 5).  
The generation of the mito-Dendra2 - DatIRESCre mouse model provided a unique tool to 
observe mitochondrial dynamics solely within DAergic neurons of the mouse brain. These mice 
were then crossed with human wild type alpha synuclein (SNCA) expressing mice to observe 
the effects of alpha-synuclein on mitochondrial movement. This study observed mitochondrial 
movement for the first time within a mammalian nigrostriatal slice model and how these 
dynamics were altered by ageing and alpha-synuclein.   
This study aimed to understand the effects of normal ageing on mitochondrial movement as a 
comparison to what occurs within healthy aged individuals. Furthermore, since ageing is the 
primary risk factor for the development of PD, such a study would also provide useful data 
applicable to this condition.  
Alpha-synuclein mice were generated to observe the effects of overexpression of this protein 
on mitochondrial movement to understand how this may be impaired in PD, since SNCA in the 
last decade has been identified as an effector of mitochondrial movement (Prots et al.,  2013). 




factors, generated novel insight into how mitochondrial dynamics may be altered within the 
ageing population and PD patients.   
In the second model, neurons were cultured from IPSCs harbouring a single, large scale mtDNA 
deletion which provided insight into the maintenance of mitochondrial movement within a 
heterogeneous neuronal population. Though it has been shown that mtDNA deletions are the 
most common mtDNA mutation found in PD, how defects in the mitochondria genome alters 
mitochondrial motility remains unclear (Reeve et al.,  2008). The studies were carried out to 
understand how mitochondrial trafficking was modified by mitochondrial dysfunction caused 
by the same mutations detected within SN neurons in PD patients and aged individuals.  
Mitochondrial transport within neurons is maintained by motor and adaptor complexes, which 
are maintained through Ca2+ transients (Wang and Schwarz, 2009). Following initial findings 
from IPSC derived neurons, this study then observed how intramitochondrial calcium affects 
mitochondrial transport within neurons with a defective respiratory chain due to an mtDNA 
deletion as observed in PD. Through this model conclusions were drawn with regards to how 
to basal mitochondrial trafficking was affected within neurons with a mitochondrial defect and 
also how this movement could be regulated through modulation of mitochondrial calcium 
efflux.  
Both disease models successfully encompassed several aspects of PD pathology and risk factors 
that may affect mitochondrial movement. The analysis of mitochondrial movement was 
dissected into three parameters such as speed, the distance of mitochondrial movement and 
their directionality, to understand how these individual aspects of mitochondrial movement 
contribute to or may be affected by PD.   
7.1.2 The role of alpha-synuclein and mitochondrial trafficking 
With increasing evidence of alpha-synuclein localisation with mitochondria (Martin et al., 2006, 
Li et al., 2007, Devi et al.,  2008,  Kamp et al.,  2010), several studies have since suggested a role 
for alpha-synuclein in mitochondrial transport.   
This study found that within the nigrostriatal pathway, alpha-synuclein plays a role in 
mitochondrial motility by causing a reduction in overall mitochondrial speed and distance 
travelled when compared to old aged mice, however this was not aged-matched. Moreover, a 
role for alpha synuclein in the regulation of mitochondrial motility is not surprising due to the 




site. As research into alpha-synuclein–mitochondrial interactions are still ongoing, the two main 
questions that remain unanswered are i) where does alpha-synuclein bind the mitochondrion 
and ii) under which conditions does this interaction occur.  
Alpha-synuclein interactions with the mitochondrial transport system have shown that in the 
presence of increased alpha-synuclein, Miro levels also increase. This may indicate that alpha- 
synuclein directly binds key mitochondrial transport proteins such as Miro and Milton, in 
addition to the microtubule-based kinesin motors to control mitochondrial movement 
(Shaltouki et al., 2018). The upregulation of Miro was shown to further halt mitophagy and 
consequently alpha-synuclein accumulations are observed within the SN of post mortem PD 
patient tissue and alpha-synuclein mutant flies. DAergic neurons of the nigrostriatal pathway 
constantly undergo cellular stress as a result of their unique morphology and pace making 
activity. These functions are thought to diminish in PD, whereby increased Miro binding and 
inhibited mitophagy mechanisms might cause more dysfunctional mitochondria and cell death 
(Shaltouki et al., 2018). 
Therefore, it may be that alpha-synuclein  mediates mitochondrial transport via two 
mechanisms. Firstly, the tendency of alpha-synuclein to bind curved membranes such as 
mitochondria and secondly by being an instigator of mitochondrial transport within neurons 
via the motor/adaptor transport machinery itself.  
 
7.1.3 The role of mitochondrial calcium efflux on mitochondrial trafficking  
The second half of this project was conducted within an in vitro setting where the effect of 
mtDNA deletions and how this defect affects mitochondrial trafficking was investigated.  
Ca2+ mediates mitochondrial transport in neurons (Sheng, 2014). Within mitochondria, the 
mitochondrial calcium uniporter (MCU) mediates mCa2+ influx (Baughman et al., 2011; De 
Stefani et al., 2011), whilst the NCLX exchanger regulates mitochondrial efflux (the rate limiting 
step) within mitochondrial calcium handling (Kostic et al., 2015). Though the effects of mCa2+ 
influx and efflux on mitochondrial health are well explored, how these exchangers then mediate 
mitochondrial movement is not well elucidated.  
This study also focused on understanding whether expelling mCa2+ through the NCLX exchanger 




hypothesised that perhaps there may be an accumulation of Ca2+ within these damaged 
mitochondria that was not being released. It was thought that perhaps facilitating mCa2+ release 
via the NCLX exchanger may affect mitochondrial movement. Indeed, it was shown that 
regulating the NCLX exchanger reduced mitochondrial speed in both cell lines, as well as 
altering crucial mitochondrial dynamics parameters such as mitochondrial distance and 
directionality. 
What these findings bring to light is that it may not only be an external motor adaptor complex 
that plays a role in mitochondrial transport, but also intrinsic factors within the mitochondria 
that can be manipulated to mediate mitochondrial transport. It may be the case that the 
available calcium within the axons through expulsion via NCLX exchanger, may regulate 
mitochondrial starting and stopping.    
The conclusions drawn from these studies suggest that mCa2+ efflux via NCLX mediates 
mitochondrial transport in the axons of mtDNA deletion neurons, highlighting a novel role of 






Figure 7.1. Novel regulators of mitochondrial transport in Parkinson’s disease. A) The well-described 
mitochondrial transport system which comprises the Miro/Milton – KHC complex. B) Increased alpha 
synuclein expression which can cause the detachment of kinesin from microtubules limiting 
mitochondrial speed and distance travelled. C) Phosphorylation of the mitochondrial NCLX exchanger 





7.1.4 The effects of mitochondrial transport and the clearance of pathogenic mtDNA through 
mitophagy  
 
Mitochondria are synthesised within the cell body with their movement surpassing this region 
to axons. Functional axonal mitochondrial trafficking is crucial to deliver mitochondria to 
wherever required within neurons (Uittenbogaard and Chiaramello, 2016).  
It is believed that retrograde targeted mitochondria are transported towards the cell body for 
degradation, while anterograde moving mitochondria are ‘healthy’ mitochondria that are 
moved to provide energy to regions of the neurons that require the constant influx of ATP 
(Martin et al.,  1999, Hirokawa et al.,  2010). In vitro, this study found that varying heteroplasmy 
level altered mitochondrial anterograde and retrograde directionality.  
Therefore, in addition to being a provider of energy, it remains unclear how mitochondria are 
targeted for mitophagy, whereby it may be that these organelles might have a unique system 
that facilitates this clearing process. For example, an impairment in retrograde movement may 
cause the halting of damaged mitochondria within the axon i) which may prohibit damaged 
mitochondrial degradation and also ii) cause an accumulation of stationery damaged 
mitochondria within the axon which might block the movement of other incoming 
mitochondria within the axon. These detrimental transport inhibitions may then deprive the 
neurons of its ATP distribution, to regions required, triggering cell death. Moreover, it is unclear 
at what time point in a mitochondrion’s journey through the axon, the organelle becomes 
damaged. Can a healthy mitochondrion become depolarised as it is travelling within the axon, 
or is there a constant circulation of damaged mitochondria within axons that do not undergo 
degradation? This remains unknown. Therefore, it can be thought that the mitochondrial 
transport system feeds into the mitophagy machinery whereby it may be useful to generate 
therapies that identify damaged mitochondria and to help transport them to ensure neurons 
remain healthy.  
In an attempt to clear dysfunctional mitochondria through mitophagic processes Dai et al.,  
(2013) demonstrate that increasing mTOR mediated mitophagy/autophagy selects against 
damaged mitochondria with increased mutation level. This in turn decreases the mitochondrial 
mutation level over time, due to an increase in mitophagy within cybrids harbouring the 
heteroplasmic mtDNA G11778A mutation. The inhibition of the mTOR pathway caused the co-




2014). Additionally, a study conducted in Drosophila adult fly muscle with a 2,584bp mtDNA 
deletion, revealed that deleted mtDNA were found to decrease through a few mechanisms: i) 
reduced mitochondrial fusion as a consequence of decreased mitofusin levels, ii) reducing 
mitochondrial repolarisation through ATP synthase reversal reactions and iii) increasing key 
mitophagy proteins; PINK1 or Parkin (Kandul et al.,  2016) 
Mitochondrial transport occurs to enhance neuronal network connections (Mouli et al., 2009, 
Patel et a.,2013, Tam et al.,  2015). Mitophagy appears to act as a means to remove mtDNA 
mutations, it will be interesting understand whether mutation level can be rescued within 
neurons harbouring an mtDNA deletion, and whether changes are observed in mitochondrial 
directionality and mitochondrial localisation with the autophagosome. Therefore, the interplay 
of mitochondrial motility and mitophagy provide as implications for new therapies for PD and 
mitochondrial disease, and maybe other ageing disorders. 
7.1.5 Pathways for potential therapeutic targets in this study  
 
Pharmacologically targeting dysfunctional mitochondrial transport appears to be an aspect of 
mitochondrial damage that is largely unclear. Due to the caveats of understanding disease 
mechanisms that are help within an intricate pathway such as the nigrostriatal pathway; as well 
as then reliably quantifying and extracting accurate information from these studies, render 
assessment of the parameter of mitochondrial damage a challenging task. Furthermore, 
investigating perturbations in this system and then translating them into a model that is disease 
relevant is difficult.  
This study aimed to observe mitochondrial movements within two disease models, to 
understand whether mtDNA deletion and alpha-synuclein are mediators of mitochondrial 
movement. The development of these models and assays i.e. individual tracking of 
mitochondrial movement to observe membrane potential and mitochondrial morphology, will 
provide an immense amount of data with regards to why and how damaged mitochondrial are 
targeted to where they are required.  
In these studies, it was found that alpha-synuclein can effect mitochondrial trafficking (not 
aged-matched observations), and that though the mechanisms behind these effectors still need 
to be explored, it is still a novel means by which mitochondrial movement can be investigated. 




how and why mitochondria are positioned specifically within particular regions of the neuron.  
Whether pharmacologically either the addition of healthy mitochondria and/or removal of 
damaged mitochondria within these regions of dopaminergic neurons may be an advantageous 































7.2 LIMITATIONS OF THIS STUDY 
 
This study utilised mouse and iPSC models: two disease relevant models that provide invaluable 
insight into PD, however it is important to understand that no disease model is perfect and a 
few challenges arose which were combatted within these studies.  
7.2.1 Limitations of using iPSCs with a large scale mtDNA deletion 
Since the discovery of human derived iPSCs, this model has been extremely useful to 
manipulate pharmacologically to understand neurodegenerative mechanisms. In this study, 
large scale mtDNA deletion neurons were differentiated from iPSCs in order to record 
mitochondrial movement. The two major issues that arose within this iPSC model were i) the 
occasional spontaneous cell death (regardless of passage number) and ii) loss of mtDNA 
deletion over increased passage number. In both instances, new iPSCs vials at a lower passage 
number were taken and experiments were repeated.  iPSCs are also a highly sensitivity disease 
model, and very small alterations in their growth environment and/or the addition of pathways 
altering reagents can alter cell growth and viability. Therefore all experiments were conducted 
carefully.   
7.2.2 Limitations of using a mouse model  
The main use for mice as disease model is their large genetic homology, which over decades 
has allowed the comparison and analysis of disease genotypes and phenotypes from mouse to 
patients. In this particular study, several challenges were counteracted; the most prominent 
challenges residing within maintaining tissue viability. From a mouse model nigrostriatal slices 
were taken and imaged, which required a series of optimisation steps to maintain slice viability. 
Acute brains slices are a robust method to carry out in vivo studies, where this study modified 
this technique to observe ex vivo mitochondrial dynamics. As with any mouse disease model, 
especially within PD, observing a PD phenotype cannot always be replicated, and though 
alterations in mitochondrial movement were observed with alpha synuclein expression, these 







7.3 FURTHER WORK 
 
7.3.1 Ex vivo nigrostriatal slices 
Though this study hypothesises that a mitochondrial defect may occur within these mice as a 
cause of ageing and alpha-synuclein, the mechanism behind these effects remain unidentified. 
Future work in this area will involve the understanding of kinesin and dynein motors and 
contributing further evidence into understanding whether alpha-synuclein directly binds 
kinesin motors and whether this alters mitochondrial movement, as proposed in this thesis. 
This will generate some insight into alpha-synuclein mediated mitochondrial transport 
mechanisms specific to PD.  
Furthermore, it will be interesting to replicate these studies with a mouse model that 
demonstrates a mitochondrial defect such as the polymerase gamma (POLG) mouse (Hance et 
al., 2005). The advantages of this model are that the homozygous mice exhibit a phenotype 
which includes reduced life span and premature ageing with weight loss. Observing altered 
mitochondrial dynamics in this mode may shed light into how mitochondrial genetic defects 
affect mitochondria transport in PD; a similar approach to what was conducted in the iPSC 
model in this study. The POLG mouse model once crossed and aged with the mito-
Dendra/DATIRESCre mice will provide information into how ageing and mitochondrial 
dysfunction perturbs mitochondrial movement within nigrostriatal axons in PD.   
7.3.2 Neurons harbouring a single, large scale mtDNA deletion 
This study explored the effects of perturbed mitochondrial calcium signalling and how this 
affects mitochondrial movement. Unlike other organelles, it may be important to understand 
how mitochondrial trafficking may be regulated by the mitochondrion itself as opposed to 
external stimuli within the axon, due to their calcium storage properties.  
It would also be interesting to explore mitochondria- ER connections and how these are altered 
with disease. Alterations in mitochondria-ER tethering with disease and how this effect 
mitochondrial transport machinery will provide large insight into the conditions that trigger 
mitochondria- ER co-localisation in PD, and how calcium storage is managed within the pace 




7.3.3 Removing dysfunctional mitochondria – an alternative to mitophagy?  
Though mitophagy is the commonly studied clearance pathway, other degradative pathways 
have shown to eliminate particular segments of mitochondria. This study did not specifically 
delve in to mitophagic pathways in PD, however future  studies in this area wil provide 
interesting information regarding mitochondrial clearance. Recently a lot of research has been 
undertaken to study additional possible ‘clearance’ pathways in various model organisms. 
7.3.3.1 Astrocytic involvement 
 
The role of CNS glial phagocytosis is largely undergoing investigation. Within the optic nerve 
head (ONH) of wild type mice, cellular protrusions were observed within intact axons, which 
were engulfed and degraded by neighbouring astrocytes. This is an interesting phenomenon as 
the original findings indicate that astrocytic phagocytosis occurs post trauma only (al-Ali and al-
Hussain, 1996, Bechmann and Nitsch, 1997).  These axonal protrusions were found within the 
ONH and within unmyelinated retinal ganglion cell axons. Though the reason for the onset of 
these protrusions remain inconclusive it was thought it may be an additional degradative 
mechanism for retrogradely transported axonal components (Nguyen et al., 2011). 
Furthermore, the involvement of astrocytes within neuronal mitochondrial populations 
described that astrocytes might release extracellular mitochondrial particles to neurons 
following a stroke event. However it still remains unclear through the means by which the 
organelle enters the neuron and also what mitochondrial dynamics and transport mechanisms 
occur, on and after release of mitochondria from the astrocyte (Hayakawa et al.,  2016). 
7.1.5.2 Exophers 
After the identification of mitochondrial removal through the formation of axonal protrusions, 
the idea of mitochondria being able to move into adjacent cells (Lee et al., 2010, Davis et al.,  
2014) and the possible spread of damaged mitochondria via this mechanism has become an 
interesting concept. Within adult neurons from Caenorhabditis elegans, large membrane-
surrounded vesicles extrusions (4μm) referred to as exophers, were identified. Exophers were 
found to house mitochondria and that the generation of these exophers under neuronal stress 
demonstrated a healthier function when compared to stressed neurons that did not generate 
exophers. Thus, exopher production may be an alternative method by which damaged 





7.1.5.3 Mitochondrial-derived vesicles (MDVs) 
Thought to occur through the ‘budding’ of the mitochondrial membrane, mitochondrial-
derived vesicles (MDVs) formation is thought to arise as a separate function of mitochondrial 
fission. MDVs are then targeted to the cell body for lysosomal degradation via autophagy 
(Soubannier et al.,  2012, Roberts et al.,  2016). These vesicles are created basally but can be 
triggered under oxidative stress. Interestingly MDV mediated mitochondrial clearance is 
believed to occur under conditions of mild damage, as a strong depolaristion still triggers 
PINK1/Parkin-mediated mitophagy (Shlevkov and Schwarz, 2014). It was also shown that MDVs 
can be secreted as exosomes (Matheoud et al.,  2016). These findings suggest that prior to 
mitophagy, retrograde travelling mitochondria and/or dysfunctional mitochondria may partake 
in vesicle formation that assists mitophagy, and may be degraded instantly as opposed to 
having to manoeuvre themselves to the cell body.  
  
For the most part it has been assumed that mitochondria targeted for mitophagy are 
transported to the cell body. The findings in this thesis demonstrate that in fact mitochondrial 
movement is largely limited. It may be the case that mitochondria may not have to move so far 
as they might be directed towards local axonal extrusions perhaps via glial involvement and or 
exopher formation, allowing dysfunctional mitochondria to be removed instantly. This is an 
attractive theory, especially within damaged neurons such as those affected in PD, where the 
neurons possesses a method by which dysfunctional material is instantly degraded and thus 













7.4 FINAL CONCLUSION 
 
This project successfully optimised the imaging and analysis of mitochondrial movement within 
Parkinson’s disease utilising iPSC and mouse models.   
Nigrostriatal slices were taken from mitoDendra2/DATCreIRES mice that were crossed with alpha 
synuclein (SNCA) over-expressing animals to observe how ageing and SNCA affect 
mitochondrial movement. It was found that SNCA can impact mitochondrial movement, 
reducing the speed and distance travelled of mitochondria within nigrostriatal axons when 
compared to healthy aged mice. However, as these findings were not aged-matched 
experiments must be repeated to confirm this outcome.  
This study then confirmed a respiratory chain defect in iPSCs harbouring a single, large scale 
mtDNA deletion and explored the effects of mCa2+ efflux on transport. It was revealed that 
altered mCa2+ efflux alters mitochondrial speed, distance and directionality. 
This thesis reports novel findings into how SNCA and mCa2+ efflux can mediate mitochondrial 
transport within axons. These findings have illustrated a new mechanisms to observe and 
possibly regulate mitochondrial trafficking in PD, which may perhaps be useful therapeutic 
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